,date,information,related
0,2022-09-22,"Headline: Friday Sector Leaders: Healthcare, Utilities, source:Market News Video, summary: The best performing sector as of midday Friday is the Healthcare sector, losing just 1.4% - Within that group, Regeneron Pharmaceuticals, Inc. - REGN,IDXX,XLV,EXC,WEC., Headline: The Top 5 Stocks Cathie Wood Is Buying This Week, source:InvestorPlace, summary: Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.",REGN
1,2022-09-23,"Headline: Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock, source:Yahoo, summary: In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company..., Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.32% to $697.33 Friday, on what proved to be an all-around rough trading session for the stock market,..., Headline: 10 Best ETFs to Diversify Your Portfolio and Avoid Risks, source:Yahoo, summary: In this article, we discuss 10 best ETFs to diversify your portfolio and avoid risks. If you want to see more exchange traded funds in this list, click 5 Best ETFs to Diversify Your Portfolio and Avoid Risks. The importance of ETFs has redoubled in 2022 as the stock market takes a beating amid volatility, […]",REGN
2,2022-09-25,"Headline: Connect Biopharma Is A Sleeper Heading Into October Data Readout, source:SeekingAlpha, summary: Connect Biopharma expects top-line results next month for the pivotal CBP-201 atopic dermatitis (or AD) trial in Chinese adults. See why CNTB stock is a buy.",REGN
3,2022-09-26,"Headline: Can Healthcare Stocks Continue To Outperform? , source:TalkMarkets, summary: Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.",REGN
4,2022-09-27,"Headline: The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market, source:InvestorPlace, summary: Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market., Headline: Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier year may find some solace in the 4.1% drop, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) stock price has dropped 4.1% in the previous week, but insiders who...",REGN
5,2022-09-28,"Headline: Regeneron, Sanofi announce FDA approval of Dupixent, source:Thefly.com, summary: Regeneron (REGN) and Sano... REGN, SNY, Headline: Regeneron Stock Is Attempting an Upside Breakout, source:Yahoo, summary: Regeneron Pharmaceuticals  soared sharply higher earlier this month and made a ""normal"" correction as prices pulled back to unwind overbought conditions.  The On-Balance-Volume (OBV) line shows gains in September and that is a positive development.  The weekly OBV line is pointed lower and suggests that sellers of REGN are more aggressive., Headline: Dow Jones Jumps 549 Points As Treasury Yields Tumble, But Now What? Eli Lilly Leads 7 Bullish Stocks, source:Yahoo, summary: The major indexes rebounded as Treasury yields tumbled from 4% as the Bank of England resumed bond buying. Eli Lilly led stocks showing bullish action. Here's what to do now., Headline: Dupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent becomes the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among",REGN
6,2022-09-29,"Headline: REGENERON - DUPIXENT APPROVED BY FDA AS THE FIRST AND ONLY TREATMENT INDICATED FOR PRURIGO NODULARIS, source:Finnhub, summary: TARRYTOWN - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has approved Dupixent for the treatment of adult patients with prurigo... | September 29, 2022, Headline: Dow Jones Futures Fall As Treasury Yields Rebound; Eli Lilly Leads 7 Bullish Stocks, source:Yahoo, summary: Dow Jones futures fell as Treasury yields rebounded, signaling Wednesday's rally may be short-lived. Eli Lilly leads some bullish stocks., Headline: Compounders And Dividends: Building A Watchlist, source:SeekingAlpha, summary: I explain how I generate ideas and my methodology of adding companies to my watchlist. Read here to know the stocks in areas/sectors that I find interesting., Headline: Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis, source:Yahoo, summary: The FDA approved Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. With this approval, Dupixent became the first and only medicine specifically indicated to treat prurigo nodularis in the U.S. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. The FDA evaluated the Dupixent application for prurigo nodularis under Priority Review. Related: Regeneron, Headline: Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis, source:Yahoo, summary: The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis., Headline: Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates, source:Yahoo, summary: Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week., Headline: Illumina Aims to Push Genetics Beyond the Lab With $200 Genome, source:Yahoo, summary: (Bloomberg) -- Illumina Inc. says it can read a person’s entire genetic code for as little as $200 with its new sequencing machine, bringing the company within reach of its long-promised goal of the $100 genome.Most Read from BloombergMacKenzie Scott Files for Divorce From Science Teacher HusbandMeta to Cut Headcount for First Time, Slash Budgets Across TeamsStocks Plummet to 22-Month Low as Fed Hawks Circle: Markets WrapTrump Refuses to Delay Florida Deposition in Phone-Fraud Case Despite Hurri",REGN
7,2022-09-30,"Headline: Regeneron reports 'positive' results from trials of novel aflibercept 8mg, source:Thefly.com, summary: Regeneron announced the f... REGN, Headline: Cowen biotech/pharma analysts hold an analyst/industry conference call, source:Thefly.com, summary: Biotech Analysts Van Bure... REGN, BAYRY, Headline: Aflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The data were presented in a late-breaking session at the American Academy of Ophthalmology (AAO) annual meeting in Chicago and will support the s",REGN
8,2022-10-01,"Headline: Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock, source:Yahoo, summary: Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the..., Headline: 3 Biotech Stocks For Your October 2022 Watchlist, source:StockMarket, summary: Could now be a good time to add these top biotech stocks to your October 2022 watchlist?, Headline: The One-Minute Market Report - Sunday, Oct. 2, source:TalkMarkets, summary: In today's issue of the One-Minute Market Report, I examine the damage done in September and highlight the parts of the market that were hit the hardest.",REGN
9,2022-10-03,"Headline: Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio , source:TalkMarkets, summary: Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio., Headline: GLOBAL BROKER RATINGS: Goldman Sachs cuts Citi but lifts Wells Fargo, source:Alliance News, summary: No summary, Headline: REGENERON PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K), source:Finnhub, summary: Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.On October... | October 3, 2022, Headline: REGENERON - AFLIBERCEPT 8 MG POSITIVE PIVOTAL RESULTS IN DIABETIC MACULAR EDEMA AND WET AGE-RELATED MACULAR DEGENERATION PRESENTED AT AAO, source:Finnhub, summary: TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the first presentations of positive detailed results from two pivotal trials investigating novel aflibercept 8 mg with 12-and 16-week... | October 3, 2022, Headline: Regeneron Elects Dr. Craig B. Thompson to Board of Directors, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Craig B. Thompson, M.D., has been elected to the Board of Directors, effective immediately. Dr. Thompson has also been appointed to serve on the Technology Committee of the Regeneron Board. Dr. Thompson is a renowned healthcare business leader with exceptional senior executive experience and scientific expertise in multiple therapeutic areas, including oncology. Regeneron's Board of Directors has been expanded from 12 to 13 memb, Headline: Goldman Sachs Sticks to Their Buy Rating for Regeneron (REGN), source:TipRanks, summary: Goldman Sachs analyst Salveen Richter maintained a Buy rating on Regeneron (REGN &#8211; Research Report) today and set a price target of $970.00. The company&#8217..., Headline: The 1-Minute Market Report October 2, 2022, source:SeekingAlpha, summary: Asian markets continue to struggle this year, thanks in large part to the weak China market. The only asset class showing positive performance is volatility., Headline: Regeneron Pharmaceuticals : Management Change/Compensation - Form 8-K, source:Finnhub, summary: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT ... | October 3, 2022, Headline: ARKG: Too Hard To Pin Down, Too Volatile For Comfort, source:SeekingAlpha, summary: ARKG's objective is compelling and inoffensive, but their current approach to realizing it feels too vague and scattershot. Click here to read more.",REGN
10,2022-10-04,"Headline: Regenxbio price target lowered to $29 from $47 at RBC Capital, source:Thefly.com, summary: RBC Capital analyst Luca ... RGNX, REGN, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Aeglea Biotherapeutics (AGLE) and Autolus Therapeutics (AUTL), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (<a h..., Headline: Video: Nasdaq 100 Movers: REGN, ILMN, source:Market News Video, summary: In early trading on Tuesday, shares of Illumina topped the list of the day's best performing components of the Nasdaq 100 index, trading up 7.7% - Year to date, Illumina has lost about 47.0% of its value - REGN,ILMN,NFLX,ASML., Headline: If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have Now, source:Yahoo, summary: Holding on to popular or trending stocks for the long-term can make your portfolio a winner., Headline: Sanofi (SNY) Relies on Dupixent and Vaccines to Drive Growth, source:Yahoo, summary: Dupixent has become the key top-line driver for Sanofi (SNY). Sanofi possesses a leading vaccine portfolio, which has become the primary top-line driver. Its R&D pipeline is strong., Headline: Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?, source:Yahoo, summary: Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition., Headline: Regeneron (REGN) Recently Broke Out Above the 20-Day Moving Average, source:Yahoo, summary: Should investors be excited or worried when a stock crosses above the 20-day simple moving average?, Headline: 3 Revolutionary Stocks I'd Buy Right Now Without Hesitation, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ: REGN), Vertex Pharmaceuticals (NASDAQ: VRTX), and Biogen (NASDAQ: BIIB) are developing remarkable therapies that, instead of merely treating disorders, have the potential to cure them or at least make an impact that no other drug has to date.  The reason that's not a big cause for alarm is that the company's second-quarter revenue of $2.86 billion would be up 20% over the same period in 2021 if its COVID-19 therapy, REGEN-COV, was excluded from total revenue.  The company's sales of the treatment ended late last year when government contracts for the therapy ended., Headline: REGN vs. RGEN: Which Stock Is the Better Value Option?, source:Yahoo, summary: REGN vs. RGEN: Which Stock Is the Better Value Option?, Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.60% higher to $739.54 Tuesday, on what proved to be an all-around positive trading session for the stock..., Headline: Regeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.",REGN
11,2022-10-05,"Headline: JOET: Mixing Quality And Momentum, source:SeekingAlpha, summary: Virtus Terranova U.S. Quality Momentum picks large-cap companies with a ranking system based on trend, profitability, and growth. Click here to read why JOET is a hold., Headline: Regeneron Pharmaceuticals' (NASDAQ:REGN) three-year earnings growth trails the 37% YoY shareholder returns, source:Yahoo, summary: The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But in contrast you can..., Headline: Final Trades: Lamar, Wynn, Eaton & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.83% higher to $745.68 Wednesday, on what proved to be an all-around rough trading session for the stock..., Headline: Tracking William Nygren's Harris Associates Portfolio - Q2 2022 Update, source:SeekingAlpha, summary: Harris Associates' 13F portfolio value decreased from $75.90B to $62.85B this quarter. Read more to see about Harris Associates' holdings and trades for Q2 2022.",REGN
12,2022-10-06,"Headline: Best Stocks To Buy For October 2022? 2 Healthcare Stocks In Focus, source:StockMarket, summary: 2 top healthcare stocks to watch in October 2022., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.85% to $731.86 Thursday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: Buy Illumina Stock. The Biotech Is Lowering the Cost of Gene Sequencing., source:MarketWatch, summary: Illumina CEO Francis deSouza told analysts that the company can cut sequencing’s cost without crimping its 60%-plus gross margins.",REGN
13,2022-10-07,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.30% to $722.37 Friday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: 10 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital, source:Yahoo, summary: In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd’s Armistice Capital. To skip our analysis of Steven Boyd’s profile, investment strategy, and 13F holdings, you can go directly to see the 5 Best Pharmaceutical Stocks to Buy According to Steven Boyd’s Armistice Capital. […]",REGN
14,2022-10-09,"Headline: Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Stock Performance Tethered To Its Strong Fundamentals?, source:Yahoo, summary: Most readers would already be aware that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased significantly by 16...",REGN
15,2022-10-10,"Headline: 7 Biotech Stocks Set to Boom in 2023, source:InvestorPlace, summary: This article looks at seven biotech stocks that look like good options to move significantly higher in 2023, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.18% to $730.92 Monday, on what proved to be an all-around dismal trading session for the stock market,...",REGN
16,2022-10-11,"Headline: Regeneron, Sanofi present late-breaking results from Dupixent trial, source:Thefly.com, summary: Regeneron (REGN) and Sano... REGN, SNY, Headline: Dupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE). The data will be shared at United European Gastroenterology (UEG) Week 2022 and submitted to regulatory authorities around the world, starting with the U.S. Food and Drug Administration (FDA) next year. In May 2022, Dupixent 300 mg weekly, Headline: Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product, source:Yahoo, summary: Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) presented more positive data for their Dupixent product. The companies said new Dupixent data showed a significant histological remission of eosinophilic esophagitis in children 1 to 11 years old. Eosinophilic esophagitis is a chronic inflammatory disease that damages the esophagus and prevents it from working properly. In May 2022, FDA approved Dupixent 300 mg weekly for EoE in people aged 12 years and older, weighing at l, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.89% higher to $737.41 Tuesday, on what proved to be an all-around mixed trading session for the stock...",REGN
17,2022-10-12,"Headline: Regeneron announces U.S. FDA accepted for priority review the sBLA for EYLEA, source:Thefly.com, summary: Regeneron Pharmaceuticals... REGN, BAYRY, Headline: Regeneron Gets FDA Priority Review of Eylea in Retinopathy of Prematurity >REGN, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration granted priority review to its application seeking..., Headline: EYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. The target action date for the FDA decision is February 11, 2023., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.27% to $728.06 Wednesday, on what proved to be an all-around grim trading session for the stock market,...",REGN
18,2022-10-13,"Headline: 3 Red-Hot Stocks That Could Continue to Beat the Market, source:Yahoo, summary: Investors often favor that industry during tough times because its earnings are less at risk -- patients can't do without the products these companies sell.  Shares of Axsome Therapeutics (NASDAQ: AXSM), Regeneron Pharmaceuticals (NASDAQ: REGN), and Vertex Pharmaceuticals (NASDAQ: VRTX) have actually been climbing this year, and it doesn't look as if those trends will end any time soon.  Axsome Therapeutics attracted investors' attention as it moved closer to product commercialization., Headline: Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?, source:Yahoo, summary: Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 22% over the past three months. Given that the..., Headline: Regeneron's (REGN) Eylea sBLA Gets FDA's Priority Review, source:Yahoo, summary: The FDA accepts and grants priority review to Regeneron's (REGN) sBLA for Eylea injection to treat retinopathy of prematurity in preterm infants. A decision is due on Feb 11, 2023., Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 3.37% to $752.56 Thursday, on what proved to be an all-around great trading session for the stock market,...",REGN
19,2022-10-14,"Headline: Regeneron announces positive CHMP opinion for for Libtayo, source:Thefly.com, summary: Regeneron announced the E... REGN, Headline: Regeneron Gets CHMP Backing for Libtayo for Advanced Cervical Cancer >REGN, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended..., Headline: Why Cash-Rich Companies And #ETFs Are Beating The Market?, source:TalkMarkets, summary: Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest from investors lately., Headline: Libtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. The European Commission is expected to make a final decision on the application in the coming months., Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 2.19% to $736.06 Friday, on what proved to be an all-around dismal trading session for the stock market, with...",REGN
20,2022-10-16,"Headline: Top 5 3rd Quarter Trades of RO - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: What You Missed On Wall Street On Monday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. NWS, NWSA, FOX, FOXA, BAC, BP, LFG, CLR, SPLK, OPEN, NET, CLX, CHD, REGN, TSLA, TWTR, AAPL, CVS, CS, CANO, V, MA, GOEV, RBLX, APPS, NGM, KR, ACI, SCHW, TPB, BK, GNTY, ECOR",REGN
21,2022-10-17,"Headline: Decibel Therapeutics receives FDA clearance of IND for DB-OTO, source:Thefly.com, summary: Decibel Therapeutics (DBT... DBTX, REGN, Headline: Regeneron downgraded to In Line from Outperform at Evercore ISI, source:Thefly.com, summary: Evercore ISI analyst Josh... REGN, Headline: Regeneron downgraded to In Line at Evercore ISI with stock near $760 target, source:Thefly.com, summary: As previously reported, E... REGN, Headline: Immune-Onc Therapeutics Initiates Expansion Cohorts for IO-108 and Enters into Clinical Supply Agreement with Regeneron, source:Business Wire, summary: No summary, Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Cloudflare upgrade, Regeneron downgrade and Salesforce initiation among today's top calls on Wall Street NET, CLX, CHD, PLD, FRC, FCFS, REGN, FOXA, ACI, XPO, OPEN, CRM, LTHM, NOVA, SPWR, PPG, Headline: Video: Nasdaq 100 Movers: REGN, MELI, source:Market News Video, summary: In early trading on Monday, shares of MercadoLibre topped the list of the day's best performing components of the Nasdaq 100 index, trading up 9.2% - Year to date, MercadoLibre has lost about 38.7% of its value - REGN,MELI,AMGN,PDD., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. NWSA, FOXA, BAC, BP, LFG, CLR, SPLK, OPEN, NET, CLX, CHD, REGN, FRPT, PG, TSLA, TWTR, AAPL, CANO, CVS, GOEV, RBLX, APPS, NGM, KR, SCHW, TPB, BK, GNTY, ECOR, NWS, FOX, Headline: An Intrinsic Calculation For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Suggests It's 37% Undervalued, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN..., Headline: Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.01% to $735.96 Monday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer, source:Yahoo, summary: Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer., Headline: Biotech Investors Need Patience (And a Strong Stomach), source:Yahoo, summary: The sector has been tricky for investors. Regeneron Pharmaceuticals is an example, getting a downgrade to In Line from Outperform from Evercore ISI., Headline: Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed the most recent trading day at $735.96, moving -0.01% from the previous trading session., Headline: Noteworthy Tuesday Option Activity: REGN, DOW, TSCO, source:Stock Options Channel, summary: Staff article entitled Noteworthy Tuesday Option Activity: REGN, DOW, TSCO, about stock options, from Stock Options Channel.",REGN
22,2022-10-18,"Headline: H.C. Wainwright says 'Decibel could certainly be acquired as well' after Akouos, source:Thefly.com, summary: After Akouos (AKUS) annou... DBTX, AKUS, LLY, REGN, Headline: 2 Biotech Stocks You Can Buy and Hold for the Next Decade, source:Yahoo, summary: Regulators in the U.S. restricted the use of REGEN-COV because they deemed it unlikely to work against what has now become the most widespread variant in the country, omicron.  The company's two key assets, Eylea and Dupixent, continue to perform well; Regeneron shares the rights to these products with Bayer and Sanofi, respectively.  It's worth noting that Eylea's patents start expiring next year, meaning Regeneron could face generic competition soon., Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.80% to $722.71 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
23,2022-10-19,"Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.85% to $709.37 Wednesday, on what proved to be an all-around poor trading session for the stock market,...",REGN
24,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy., Headline: Top 5 3rd Quarter Trades of St - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Regeneron price target raised to $750 from $655 at Cowen, source:Thefly.com, summary: Cowen analyst Tyler Van B... REGN, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 0.49% to $705.89 Thursday, on what proved to be an all-around grim trading session for the stock market, with...",REGN
25,2022-10-21,"Headline: Regeneron granted pediatric exclusivity for EYLEA from FDA, source:Thefly.com, summary: Regeneron Pharmaceuticals... REGN, Headline: Regeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity for EYLEA® (aflibercept) Injection. This grant extends the period of U.S. market exclusivity for EYLEA by an additional six months through May 17, 2024., Headline: Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 20...",REGN
26,2022-10-23,"Headline: Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV, source:SeekingAlpha, summary: Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV. Read why investors are getting HQL at an attractive valuation., Headline: RGA Investment Advisors Q3 2022 Investment Commentary, source:SeekingAlpha, summary: For RGA Investment Advisors, the third quarter saw a continuation of the ugly trend from the first half of the year. Click here to read the full fund letter., Headline: Is it a Good Decision to Add Regeneron Pharmaceuticals (REGN) to Your Portfolio?, source:Yahoo, summary: Investment management company RGA Investment Advisors recently released its third-quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, the market continued the declining trend from the first half of 2022, and September was the worst month for the fund. But the firm believes this is a good time […]",REGN
27,2022-10-24,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 3.26% to $737.15 Monday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
28,2022-10-25,"Headline: Top 5 3rd Quarter Trades of DO - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$16m worth of stock, source:Yahoo, summary: Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the..., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.38% to $747.33 Tuesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Regeneron (REGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Regeneron (REGN) closed at $747.33, marking a +1.38% move from the previous day., Headline: Bronte Capital Amalthea Fund September 2022 Fund Letter, source:SeekingAlpha, summary: Bronte Capital Amalthea Fund gained 6.68% for September and lost 0.32% across the quarter. Click here to read the full fund letter.",REGN
29,2022-10-26,"Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.79% to $733.98 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",REGN
30,2022-10-27,"Headline: Midterm Elections 2022: 3 Stocks to Avoid Like the Plague for a 'Blue Wave', source:InvestorPlace, summary: If you see a blue wave coming get out of the oilpatch, crypto, and pharmaceuticals that are subject to price regulation., Headline: Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?, source:Yahoo, summary: Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Why Regeneron (REGN) Could Beat Earnings Estimates Again, source:Yahoo, summary: Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Is Regeneron Pharmaceuticals (REGN) an Attractive Long-Term Stock?, source:Yahoo, summary: Bronte Capital, an investment management company, released its “Amalthea Fund” third-quarter 2022 investor letter. A copy of the same can be downloaded here. The fund lost 0.32% in the third quarter compared to a 0.17% gain for the MSCI ACWI (in $A). For September, the fund gained 6.68% compared to a 3.58% loss for the MSCI […], Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.24% to $724.88 Thursday, on what proved to be an all-around mixed trading session for the stock market,...",REGN
31,2022-10-28,"Headline: UPDATE 2-Sanofi sees faster profit growth on Dupixent, flu vaccine demand, source:Yahoo, summary: French drugmaker Sanofi on Friday forecast faster earnings growth this year on strong demand for its bestselling drug Dupixent and for its flu vaccines, spurring a rise in its battered share price.  Sanofi said it now expects 2022 adjusted earnings per share to grow by about 16%, not taking into account an expected positive currency impact of between 9.5% and 10.5%.  It also reported a 26.5% rise in third-quarter business operating income, or adjusted earnings before interest and tax, to 4.5 billion euros ($4.5 billion), well ahead of an average analyst estimate of 4.17 billion., Headline: Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) has been recognized as the ""Best Biotechnology Product"" of 2022 by the Galien Foundation, which acknowledges extraordinary scientific innovations that improve the human condition. The Prix Galien USA Award was presented in a ceremony in New York City last night., Headline: Final Trades: Boeing, Amazon, Regeneron & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push Sales, source:Yahoo, summary: Sanofi (SNY) beats third-quarter estimates for earnings and sales. Dupixent and flu vaccines drive sales growth. The company raises its earnings growth guidance for 2022., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 3.57% to $750.76 Friday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
32,2022-10-29,"Headline: Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?, source:Yahoo, summary: Regeneron Pharmaceuticals' (NASDAQ:REGN) stock is up by a considerable 29% over the past three months. Given the...",REGN
33,2022-10-31,"Headline: Biogen: Super-Strong Momentum In A Defensive Sector, source:SeekingAlpha, summary: Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock., Headline: Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?, source:Yahoo, summary: Regeneron's (REGN) third-quarter earnings are likely to have got a boost from the solid performance of Eylea and Dupixent., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.27% to $748.75 Monday, on what proved to be an all-around poor trading session for the stock market, with the...",REGN
34,2022-11-01,"Headline: JPMorgan Chase hires OrbiMed Advisors executive for new life sciences venture capital unit, source:MarketWatch, summary: JPMorgan Chase & Co. undefined said Tuesday its J.P. Morgan Asset Management unit is launching a new private capital team aimed at investments in life..., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.49% to $759.91 Tuesday, on what proved to be an all-around dismal trading session for the stock market,...",REGN
35,2022-11-02,"Headline: Tyra Biosciences CFO Esther van den Boom to step down, Alan Fuhrman to succeed, source:Thefly.com, summary: Tyra Biosciences (TYRA) a... TYRA, REGN, Headline: Top 5 3rd Quarter Trades of SE - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Notable companies reporting before tomorrow's open, source:Thefly.com, summary: Notable companies reporti... COP, CI, REGN, ZTS, MRNA, MAR, FIS, DDOG, K, RCL, PENN, TPX, W, UAA, UA, PTON, COMM, PZZA, SPR, NKLA, Headline: AbCellera announces Regeneron exercises right to advance antibody candidate, source:Thefly.com, summary: AbCellera (ABCL) announce... ABCL, REGN, Headline: Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 29%?, source:Yahoo, summary: Does the November share price for Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) reflect what it's really worth..., Headline: Drug, Biotech Stocks' Q3 Earnings on Nov 3: AMGN, REGN & More, source:Yahoo, summary: Let us look at five drug and biotech companies, AMGN, REGN, ZTS, and MRNA, which are gearing up for their earnings release., Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 2.56% to $740.48 Wednesday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Regeneron price target lowered to $765 from $775 at Piper Sandler, source:Thefly.com, summary: Piper Sandler analyst Chr... REGN",REGN
36,2022-11-03,"Headline: Regeneron reports Q3 EPS $11.14, consensus $9.48, source:Thefly.com, summary: Reports Q3 revenue $2.94B... REGN, Headline: Regeneron: Q3 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Regeneron Reports Third Quarter 2022 Financial and Operating Results, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2022 and provided a business update. The full press release can be accessed on Regeneron's media and investor relations website (http://newsroom.regeneron.com)., Headline: Regeneron Pharmaceuticals Q3 tops earnings and revenue marks, source:Yahoo, summary: Regeneron Pharmaceuticals Inc. said Thursday its third-quarter net income fell 19% to $1.32 billion or $11.66 a share, from $1.63 billion or $14.33 a share, in the year-ago period. Adjusted net income fell to $11.14 a share from $15.37 a share. Revenue at the Tarrytown, N.Y., drug maker dropped 15% to $2.94 billion from $3.45 billion. Wall Street analysts expected Regeneron to earn $9.76 a share on revenue of $2.92 billion, according to a survey by FactSet. Regeneron CFO Robert Landry said the t, Headline: Regeneron's revenue falls on decline of Covid-19 product sales, source:Alliance News, summary: No summary, Headline: Regeneron (REGN) Surpasses Q3 Earnings and Revenue Estimates, source:Yahoo, summary: Regeneron (REGN) delivered earnings and revenue surprises of 14.85% and 5.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Regeneron Pharmaceuticals, Inc. (REGN) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (AAPL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 a.m., Headline: Regeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new data across its hematology pipeline will be highlighted in 17 presentations at the 2022 American Society of Hematology (ASH) Annual Meeting from December 10-13 in New Orleans, LA., Headline: Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent, source:Yahoo, summary: Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year., Headline: Stock Market Extends Losses Despite Easing Labor Costs; Qualcomm, Roku At New Lows, source:Yahoo, summary: The stock market fell Thursday despite weaker-than-expected labor costs. Qualcomm and Roku dragged stocks lower., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.24% to $738.68 Thursday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Regeneron Announces Investor Conference Presentations, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:, Headline: Regeneron Sinks Despite Massive Earnings Beat On A Notable Blockbuster Miss, source:Yahoo, summary: Regeneron Pharma topped third-quarter expectations Thursday, reporting less of a decline than expected. But REGN stock was down early.",REGN
37,2022-11-04,"Headline: Analysts Conflicted on These Healthcare Names: Humana (HUM), Myriad Genetics (MYGN) and Regeneron (REGN), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Humana (<a href..., Headline: Analysts Offer Insights on Healthcare Companies: Avadel Pharmaceuticals (AVDL), Illumina (ILMN) and Regeneron (REGN), source:TipRanks, summary: Analysts have been eager to weigh in on the Healthcare sector with new ratings on Avadel Pharmaceuticals (<span class='tr-stock-ticker' style='color:blue; font-weig..., Headline: BMO Capital Sticks to Their Buy Rating for Regeneron (REGN), source:TipRanks, summary: BMO Capital analyst Evan Seigerman maintained a Buy rating on Regeneron (REGN &#8211; Research Report) today and set a price target of $1,025.00. The company&#8217;..., Headline: Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y, source:Yahoo, summary: Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs., Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.21% higher to $740.21 Friday, on what proved to be an all-around positive trading session for the stock..., Headline: U.S. Supreme Court to hear Amgen bid to revive Repatha patents, source:Yahoo, summary: The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.  Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs., Headline: RPT-U.S. Supreme Court to hear Amgen bid to revive Repatha patents, source:Yahoo, summary: The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents.  Amgen and other drugmakers have called the case a test of their ability to earn and defend patents for important drugs., Headline: UPDATE 3-U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents., Headline: U.S. Supreme Court to hear Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: WASHINGTON (Reuters) -The U.S. Supreme Court on Friday agreed to hear Amgen Inc's bid to revive patents on its cholesterol drug Repatha that were invalidated due to a legal challenge by rivals  Regeneron Pharmaceuticals Inc and Sanofi SA.  The justices took up Amgen's appeal of the lower court ruling that threw out the Repatha patents., Headline: 7 Cash-Rich Stocks to Buy for Peace of Mind, source:Yahoo, summary: Companies of all sizes appear to be hoarding cash for the much-discussed impending recession. If we do dive into a recession, cash-rich stocks will be more than prepared for whatever slowdown comes their way. However, when investing, it’s not enough to look for businesses with cash. They should also have limited debt and strong cash flow generation in good times and bad. So, who are these companies? For this article, I selected four large-cap and three mid-cap cash-rich stocks to buy. Cash-rich, Headline: Regeneron accelerates research spending as drug pipeline grows, source:Yahoo, summary: ""Our strategy continues to focus on investing in our internal [research and development] capabilities while exploring potential collaborations that will enable us to fully realize the power of our science,"" chief executive Len Schleifer told analysts., Headline: 10 Latest Earnings That Surprised Wall Street, source:Yahoo, summary: In this article, we will take a look at the 10 latest earnings that surprised Wall Street. If you want to see more such earnings reports on the list, go directly to 5 Latest Earnings That Surprised Wall Street. All three major U.S. indices struggled to find direction on Friday following the latest jobs data […], Headline: Aflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced late-breaking presentations of updated results from two positive pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens, compared to EYLEA® (aflibercept) Injection, in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wAMD). The positive data from PHOTON and PULSAR were presented at the 55th Annual Scientific Session of The Retina Society in Pasadena, California.",REGN
38,2022-11-06,"Headline: Subdued Growth No Barrier To Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price, source:Yahoo, summary: It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of...",REGN
39,2022-11-07,"Headline: Regeneron Pharmaceuticals Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.45% to $750.93 Monday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy, source:Thefly.com, summary: Regeneron Pharmaceuticals... REGN",REGN
40,2022-11-08,"Headline: Regeneron Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations, source:Yahoo, summary: Regeneron Pharmaceuticals ( NASDAQ:REGN ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.94b (down 15..., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.14% higher to $751.95 Tuesday, on what proved to be an all-around positive trading session for the stock..., Headline: Libtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC), source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patie, Headline: AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack, source:SeekingAlpha, summary: AbCellera Biologics has multiple high-value opportunities that should become clear in the next few years. Find out why I'm confident in the long-term return potential of ABCL.",REGN
41,2022-11-09,"Headline: Regeneron price target raised to $856 from $790 at Truist, source:Thefly.com, summary: Truist analyst Robyn Karn... REGN, Headline: Regeneron (REGN) Gets FDA Nod for Libtayo's Label Expansion, source:Yahoo, summary: Regeneron (REGN) obtains FDA approval for the second advanced NSCLC indication, which expands the patient population eligible for a Libtayo-based regimen to include combination treatment with chemotherapy, irrespective of PD-L1 expression levels., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.20% to $742.95 Wednesday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on Update, source:Yahoo, summary: Earnings updates from REGN and MRNA are the key highlights from the biotech sector during the past week.",REGN
42,2022-11-10,"Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.25% to $741.08 Thursday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Society for Immunotherapy of Cancer to hold a meeting, source:Thefly.com, summary: 37th Annual Meeting SITC ... ABMD, ADPT, ALKS, AMGN, ASND, BMY, CGEN, CLRB, CRL, INKT, INCY, PHIO, INBX, XNCR, VCYT, TXG, TPST, TMO, TIL, SGEN, REGN, REPL, RHHBY, DNA, CUE, IOVA, IPSC, LH, MRK, MXCT, EXEL, FATE, GMAB",REGN
43,2022-11-11,"Headline: Regeneron, Sanofi announce CHMP recommendation for Dupixent approval, source:Thefly.com, summary: Regeneron (REGN) and Sano... REGN, SNY, Headline: Regeneron, Sanofi Get CHMP Backing for Dupixent in Prurigo Nodularis >REGN SNY, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use..., Headline: Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. The European Commission is expected to announce a final decision on the Dupixent application in the coming months. In Septembe, Headline: Regeneron, Sanofi, Bayer report positive opinions from EU regulators, source:Alliance News, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.89% to $734.45 Friday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
44,2022-11-12,"Headline: Subdued Growth No Barrier To Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price, source:Yahoo, summary: It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of..., Headline: 2 Top Biotech Stocks to Buy in November, source:Yahoo, summary: Biotech giants Regeneron Pharmaceuticals (NASDAQ: REGN) and Gilead Sciences (NASDAQ: GILD) are among them.  Eylea could lose patent protection as early as next year.  Why is Regeneron beating the market this year despite these issues?",REGN
45,2022-11-13,"Headline: Vertex: High Growth For Years Ahead, source:SeekingAlpha, summary: Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3., Headline: Regeneron Pharmaceuticals Moves Up In Market Cap Rank, Passing Altria Group, source:The Online Investor, summary: the online investor,REGN,MO,",REGN
46,2022-11-14,"Headline: Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease, source:Yahoo, summary: The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease., Headline: Kodiak: Turnaround Strategy Has Shown Life Thus Far, source:SeekingAlpha, summary: Primary endpoint of phase 3 BEACON study, using tarcocimab tedromer for the treatment of patients with macular edema due to retinal vein occlusion, was met. Read the outlook here., Headline: Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive Opinion, source:Yahoo, summary: Bayer (BAYRY) gets positive recommendation from the CHMP for label extension of ophthalmology drug Eylea for the treatment of preterm infants with retinopathy of prematurity.",REGN
47,2022-11-16,"Headline: Regeneron Pharmaceuticals, Inc. (REGN) Jefferies London Healthcare Conference - (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies London Healthcare Conference November 16, 2022 10:15 AM ET Company Participants Ryan Crowe - VP, IR Robert Landry - EVP,..., Headline: IDNA: Healthcare Dashboard For November, source:SeekingAlpha, summary: The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Read how this ties into the IDNA healthcare ETF.",REGN
48,2022-11-17,"Headline: Regeneron, CytomX Set Cancer-Therapy Collaboration >REGN CTMX, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. and CytomX Therapeutics Inc. on Thursday said they plan to create bispecific cancer therapies under a..., Headline: CytomX Therapeutics Shares Rally on Regeneron Pact, source:MarketWatch, summary: By Colin Kellaher Shares of CytomX Therapeutics Inc. jumped more than 25% Thursday after the clinical-stage biopharmaceutical company unveiled a..., Headline: CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer, source:Yahoo, summary: - Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $30 million upfront payment with the potential for up to $2 billion in research, development, regulatory and sales-based milestones - SOUTH SAN FRANCISCO, Calif. and TARRYTOWN, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ: CTMX) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to, Headline: Regeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and CytomX Therapeutics, Inc. (NASDAQ: CTMX) today announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer therapies utilizing CytomX's Probody® therapeutic platform and Regeneron's Veloci-Bi® bispecific antibody development platform., Headline: Peninsula biotech moves from layoffs to cancer-fighting deal with potential $2B payoff, source:Yahoo, summary: The deal is the company's third to help larger pharmaceutical companies power up their bispecific antibodies while getting those drugs closer to cancer cells instead of healthy tissue., Headline: CytomX Shares Jump After Cancer Therapy Pact With Pharma Major Regeneron, source:Yahoo, summary: CytomX Therapeutics Inc (NASDAQ: CTMX) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced a collaboration and licensing agreement to create conditionally-activated bispecific cancer therapies. The collaboration will utilize CytomX's Probody therapeutic platform and Regeneron's Veloci-Bi bispecific antibody development platform. Under the agreement, Regeneron and CytomX will collaborate on the discovery activities to identify and validate conditionally active bispecific antibodies. Regene, Headline: Cramer's lightning round: BioXcel Therapeutics may be home run or nothing, source:CNBC, summary: ""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.",REGN
49,2022-11-18,"Headline: Regeneron Pharmaceuticals (NASDAQ:REGN) shareholders have earned a 28% CAGR over the last three years, source:Yahoo, summary: It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes..., Headline: Compounders And Dividends: November 2022 Watch List Update, source:SeekingAlpha, summary: Since my original watch list article in September 2022, I have purchased three companies, two of which were on my September 2022 watch list. Click to read., Headline: CytomX (CTMX) Stock Surges on Oncology Deal With Regeneron, source:Yahoo, summary: CytomX (CTMX) gets a boost after its deal with Regeneron for the development of investigational next-generation bispecific immunotherapies.",REGN
50,2022-11-21,"Headline: Best Penny Stocks To Buy Now? 5 Biotech Stocks To Watch This Week, source:PennyStocks, summary: Biotech penny stocks to watch this week. Are they a buy now?",REGN
51,2022-11-22,"Headline: There's Reason For Concern Over Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price, source:Yahoo, summary: It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of..., Headline: Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemiplimab) as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy., Headline: Regeneron: Stock Priced Too High To Buy, But Keep One Eye On This Pharma, source:SeekingAlpha, summary: Regeneron Pharmaceuticals is hoping to establish itself as a major oncology player. See why I no longer see REGN stock price upside in the near term., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.39% to $749.23 Tuesday, on what proved to be an all-around positive trading session for the stock market,...",REGN
52,2022-11-23,"Headline: Regeneron: Q3 Results Show Eylea's Strength Despite Vabysmo Launch, source:SeekingAlpha, summary: Regeneron has multiple and potentially significant growth drivers in the following years. Find out why REGN stock is a Buy., Headline: Regeneron's (REGN) Libtayo Gets EC Nod for Cervical Cancer, source:Yahoo, summary: Regeneron (REGN) gets EC's approval for the label expansion of PD-1 inhibitor Libtayo for the treatment of adult patients with recurrent or metastatic cervical cancer., Headline: Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update, source:Yahoo, summary: Updates from CTMX and APLS are the key highlights from the biotech sector during the past week., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.85% to $735.36 Wednesday, on what proved to be an all-around great trading session for the stock market,...",REGN
53,2022-11-25,"Headline: Dexcom Leads 5 Stocks Near Buy Points, source:Yahoo, summary: Dexcom and other top stocks to watch this week combine strong technicals with generally solid fundamentals., Headline: Regeneron (REGN) Outperforms YTD: What's in Store for 2023?, source:Yahoo, summary: Regeneron (REGN) has had a good run in 2022 so far and the momentum should continue in 2023 as well.",REGN
54,2022-11-26,"Headline: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock suggesting impending weakness., source:Yahoo, summary: In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company..., Headline: SPGP: 'GARP' ETF Has Opposite Strategy Of ARK Funds, source:SeekingAlpha, summary: Invesco S&P 500 GARP ETF has certainly proven itself over the long term to deliver upside growth as compared to the S&P 500. Click here to find out why SPGP is a Buy.",REGN
55,2022-11-29,"Headline: Regeneron Pharmaceuticals, Inc. (REGN) 5th Annual Evercore ISI HealthCONx Conference (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) 5th Annual Evercore ISI HealthCONx Conference November 29, 2022 11:45 AM ET Company Participants Ryan Crowe - Vice President, Investor..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.73% to $736.08 Tuesday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Pfizer: COVID-19 May Never End, source:SeekingAlpha, summary: Pfizer's net income was $8,609M in Q3 2022, up 5.7% YoY. See why PFE stock could be a great healthcare sector candidate for long-term investment strategy.",REGN
56,2022-11-30,"Headline: 2 Market-Beating Stocks That Can Continue Rising in 2023, source:Yahoo, summary: A couple of stocks that have been hot buys this year are Regeneron Pharmaceuticals (NASDAQ: REGN) and T-Mobile US (NASDAQ: TMUS).  Unlike the S&P 500, which is down about 17% this year, these two stocks have generated positive returns of 15% or more.  Here's a closer look at why both of these stocks can still soar higher in 2023., Headline: Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings, source:Yahoo, summary: It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of..., Headline: Evkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Evkeeza® (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies to treat children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023., Headline: Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 34th Annual Healthcare Conference (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Piper Sandler 34th Annual Healthcare Conference Call November 30, 2022 08:00 ET Company Participants Ryan Crowe - Vice President of..., Headline: UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent, source:Yahoo, summary: The UK's Medicines and Healthcare Regulatory Agency (MHRA) warned of some new and severe eye-related side effects following the use of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) atopic dermatitis and asthma treatment Dupixent (dupilumab). Dupixent is already associated with cases of conjunctivitis and allergic conjunctivitis, dry eye, and infrequent cases of keratitis and ulcerative keratitis. The MHRA added that health professionals should look for any of these e, Headline: Regeneron's Evkeeza Under FDA Priority Review For Younger Kids With Inherited Form Of High Cholesterol, source:Yahoo, summary: The FDA has accepted Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) supplemental marketing application seeking approval for Evkeeza (evinacumab-dgnb) as an adjunct to other lipid-lowering therapies for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The FDA target action date is March 30, 2023. HoFH is an ultra-rare inherited condition that occurs when two copies of the FH-causing genes are inherited, resulting in dangerously high levels of low-density lipoprote",REGN
57,2022-12-01,"Headline: Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) Congress 2022 from December 7 to 9 in Geneva, Switzerland. Presentation highlights include first clinical results and new exploratory analyses from trials investigating LAG-3 inhibitor fianlimab and/or PD-1 inhibitor Libtayo® (cemiplimab) in non-small cell lung cancer (NSCLC), melanoma and cervica, Headline: Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority Review, source:Yahoo, summary: The FDA accepts for priority review Regeneron's (REGN) sBLA for Evkeeza for treating children aged five to 11 years with homozygous familial hypercholesterolemia. A decision is due on Mar 30, 2023., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.27% to $761.24 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",REGN
58,2022-12-02,"Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more., Headline: Stocks To Invest In Right Now? 3 Biotech Stocks To Watch, source:StockMarket, summary: Is now a good time to add these biotech stocks to your watchlsit?, Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.68% higher to $766.39 Friday, on what proved to be an all-around mixed trading session for the stock...",REGN
59,2022-12-04,"Headline: Regeneron Pharmaceuticals' (NASDAQ:REGN) three-year earnings growth trails the stellar shareholder returns, source:Yahoo, summary: It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes..., Headline: Can These 2 Stocks Crush the Market Again in 2023?, source:Yahoo, summary: The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and Biogen (NASDAQ: BIIB).  Regeneron was having an unimpressive year on the stock market until its shares soared by double-digit percentages in one day in September.  As is often the case with biotechs, Regeneron owes this move to positive clinical developments.",REGN
60,2022-12-05,"Headline: 2 Generational REIT Buying Opportunities, source:SeekingAlpha, summary: REITs are volatile and this results in a lot of opportunities to profit. Read why REITs are again priced at historically low valuations., Headline: Regeneron Pharmaceuticals Inc. stock falls Monday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.43% to $755.45 Monday, on what proved to be an all-around rough trading session for the stock market, with...",REGN
61,2022-12-06,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.06% to $747.47 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",REGN
62,2022-12-07,"Headline: Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma >REPL, source:MarketWatch, summary: By Colin Kellaher Replimune Group Inc. on Tuesday said it inked a deal to work with Swiss pharmaceutical company Roche Holding AG to advance Replimune RP2/3..., Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 2.25% to $764.27 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Cantor Fitzgerald pharma/biotech analysts hold a dinner, source:Thefly.com, summary: No summary",REGN
63,2022-12-08,"Headline: This fund beats the S&P 500 by using just 75 of its components. Here's how it works., source:MarketWatch, summary: A combination of quality and lower prices has worked well through bull and bear markets — it may be just the ticket for investors worried about a recession., Headline: Cantor Fitzgerald pharma/biotech analyst hold a luncheon, source:Thefly.com, summary: No summary, Headline: This fund beats the S&P 500 by using just 75 of its components. Here`s how it works., source:MarketWatch, summary: No summary, Headline: There's Reason For Concern Over Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price, source:Yahoo, summary: It's not a stretch to say that Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) price-to-earnings (or ""P/E"") ratio of..., Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.15% higher to $765.42 Thursday, on what proved to be an all-around positive trading session for the stock...",REGN
64,2022-12-09,"Headline: Will This Potential Approval Be a Winner for Sanofi's Shareholders?, source:Yahoo, summary: Sanofi and Regeneron's Dupixent moved closer to regulatory approval to treat another skin disease in the European Union., Headline: Our 7 Top Biotech Stock Picks for 2023, source:Yahoo, summary: If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 crisis proved that when humanity comes together, it can foster incredible advancements at breakneck speed. Moving forward, this segment will carry this momentum toward other breakthroughs. Nevertheless, even the top biotech stock picks for 2023 can’t avoid economic realities. With macro",REGN
65,2022-12-10,"Headline: Regeneron announces data from trials evaluating investigational odronextamab, source:Thefly.com, summary: No summary",REGN
66,2022-12-11,"Headline: Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These included first data from a Phase 2 cohort of patients naïve to prior CAR-T therapy (CAR-T naïve), as well as updated data from a dose expansion cohort of a Phase 1 trial in patients who had progressed on CAR-T therapy (p, Headline: Regeneron announces data on trial of odronextamab to treat R/R  FL, source:Thefly.com, summary: No summary",REGN
67,2022-12-12,"Headline: Interesting REGN Put And Call Options For December 30th, source:Stock Options Channel, summary: No summary, Headline: Regeneron announces data from Phase 2 trial of linvoseltamab, source:Thefly.com, summary: No summary, Headline: Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space, source:Yahoo, summary: Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced updated data from a Phase 1 and Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These included first data from a Phase 2 cohort of CAR-T naïve patients and updated data from a dose expansion cohort of a Phase 1 trial in patients who had progressed on CAR-T therapy. In the first look at the Phase 2 portion, Regeneron said the objective re, Headline: Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the company has been included on the Dow Jones Sustainability World Index (DJSI World) for the fourth consecutive year and on the Dow Jones Sustainability North America Index (DJSI North America) for the third year. These indices recognize Regeneron's enduring leadership in supporting its patients, colleagues, communities and planet., Headline: A Look At The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), source:Yahoo, summary: Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Regeneron..., Headline: Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial data from a pivotal Phase 2 expansion cohort evaluating investigational linvoseltamab (formerly REGN5458) at the 200 mg dose recommended for further development in patients with heavily pre-treated, relapsed/refractory (R/R) multiple myeloma. The results were part of a broader presentation of new and updated data from a Phase 1/2 trial and were shared at the 64th American Society of Hematology (ASH) Annual Meeting an, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.01% to $742.48 Monday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive first data from a cohort of a pivotal Phase 2 trial evaluating investigational odronextamab in patients with heavily pre-treated, relapsed/refractory (R/R) follicular lymphoma (FL) grades 1 to 3a. The data were presented in an oral session at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans, LA, and follow the first Phase 2 results for odronextamab in R/R diffuse large B-cell lymphom",REGN
68,2022-12-13,"Headline: Regeneron Reveals An Early Cut Data From Follicular Lymphoma Study At ASH Meeting, source:Yahoo, summary: Regeneron Pharmaceuticals Inc (NASDAQ: REGN) gave the first look at interim results from its Phase 2 study of odronextamab, a CD20xCD3 bispecific antibody in patients with relapsed/refractory follicular lymphoma. Trial investigators said 82% of 121 patients with the disease responded to Regeneron’s drug odronextamab, and 75% had a complete response. Related: Regeneron Highlights Its First Phase 2 Data To Build Case In CD20xC3 Bispecific Space. The median duration of complete response was 20.5 mo, Headline: 15 Best S&P 500 Stocks That Don’t Pay Dividends, source:Yahoo, summary: In this article, we will be taking a look at the 15 best S&P 500 stocks that don’t pay dividends. To skip our detailed analysis of these stocks and the performance of the S&P 500 so far this year, you can go directly to see the 5 Best S&P 500 Stocks That Don’t Pay Dividends. […], Headline: Regeneron (REGN) Presents Positive Data on MM and FL Drugs, source:Yahoo, summary: Regeneron (REGN) releases positive initial data on two candidates - linvoseltamab and odronextamab at ASH., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.68% higher to $747.56 Tuesday, on what proved to be an all-around positive trading session for the stock...",REGN
69,2022-12-14,"Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.33% higher to $750.00 Wednesday, on what proved to be an all-around grim trading session for the stock..., Headline: Regeneron and Sanofi note fourth EU approval for Dupixent, source:Alliance News, summary: No summary, Headline: Sanofi, Regeneron Dupixent gets approval in EU for expanded use in skin disorder, source:Seeking Alpha, summary: No summary, Headline: Regeneron, Sanofi announce EC expansion for Dupixent marketing authorization, source:Thefly.com, summary: No summary",REGN
70,2022-12-15,"Headline: Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent® (dupilumab) in the European Union to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation and its impact on quality of life is one of the highest among inflammatory skin diseases. With this approval,, Headline: SVB Securities Keeps Their Hold Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron-Sanofi's Dupixent Wins European Approval For Prurigo Nodularis, source:Yahoo, summary: The European Commission (EC) has expanded the marketing authorization of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Dupixent (dupilumab) for moderate-to-severe prurigo nodularis. Prurigo nodularis is a chronic, debilitating skin disease with underlying type 2 inflammation. With this approval, Dupixent is the first and only targeted medicine specifically indicated to treat prurigo nodularis in Europe and the U.S. Related: UK Drug Regulator Warns Of Severe Eye React, Headline: Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis, source:Yahoo, summary: The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 2.50% to $731.27 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",REGN
71,2022-12-16,"Headline: Regeneron, Sanofi: EMA`s CHMP recommends approval of Dupixent in EU, source:Thefly.com, summary: No summary, Headline: Regeneron, Sanofi Get CHMP Backing for Dupixent in Eosinophilic Esophagitis, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use..., Headline: Dupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent® (dupilumab) in the European Union (EU) to treat adults and adolescents with eosinophilic esophagitis (EoE). This positive opinion covers those who are 12 years and older, weighing at least 40 kg, and inadequately controlled by, are intolerant to or who are not can, Headline: Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$7.0m worth of stock, source:Yahoo, summary: Over the past year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a significant stake in the..., Headline: Regeneron Pharmaceuticals (REGN) Presents at 64th ASH Annual Meeting & Exposition, source:SeekingAlpha, summary: The following slide deck was published by Regeneron Pharmaceuticals, Inc., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.11% to $723.17 Friday, on what proved to be an all-around poor trading session for the stock market, with the...",REGN
72,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF.",REGN
73,2022-12-19,"Headline: Healthcare Portfolio Is Doing Well But Biotech Stocks Are Mired In Macro, source:TalkMarkets, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.29% to $721.10 Monday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis, source:Yahoo, summary: The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis., Headline: Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023. The presentation is scheduled for 9:00 a.m. Pacific Time (12:00 p.m. Eastern Time) and may be accessed from the ""Investors & Media"" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations. An archived version of the presentation will be available for at least 30 days., Headline: Tuesday Talk: Where is Santa?, source:TalkMarkets, summary: No summary",REGN
74,2022-12-20,"Headline: Intellia: Most Advanced In A Tough Field, source:SeekingAlpha, summary: Intellia announced positive biomarker data from two of its one-off gene therapies. Read why NTLA is one to watch but not one to base your retirement against., Headline: Intellia: In-Vivo Gene Editing Platform Continues To Deliver, source:SeekingAlpha, summary: Intellia has already been able to establish proof of concept in using NTLA-2002 for HAE and then NTLA-2001 for ATTR. Read our buy thesis on NTLA stock here., Headline: Top Net Payout Yields - December 2022, source:SeekingAlpha, summary: The top net payout yield stock failed to match the total return of the S&P 500 during 2H' 22 as tech stocks soared. Check out our list of stocks., Headline: Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) insiders who sold earlier this year may be offered solace in this recent price drop, source:Yahoo, summary: Even though Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) has fallen by 3.5% over the past week , insiders who sold..., Headline: IN BRIEF: Regeneron signs for USD750 million five-year credit facility, source:Alliance News, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.72% to $733.53 Tuesday, on what proved to be an all-around great trading session for the stock market,..., Headline: Regeneron`s Dupixent shows disease remission in Phase 3 esophagitis trial, source:Thefly.com, summary: No summary",REGN
75,2022-12-21,"Headline: XBI: Attractive Value In Diversified Biotech Growth, source:SeekingAlpha, summary: Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021. Click to read my analysis of the SPDR S&P Biotech ETF (XBI)., Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.36% higher to $736.19 Wednesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine has published results from a positive Phase 3 trial showing adults and adolescents treated with Dupixent® (dupilumab) 300 mg weekly experienced significant improvements in signs and symptoms of eosinophilic esophagitis (EoE), which were sustained for up to one year., Headline: Sanofi, Regeneron's Dupixent phase 3 results show disease remission, source:Alliance News, summary: No summary",REGN
76,2022-12-22,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.35% to $733.62 Thursday, on what proved to be an all-around grim trading session for the stock market,...",REGN
77,2022-12-23,"Headline: Regeneron: MHLW in Japan grants marketing, manufacturing approval for Libtayo, source:Thefly.com, summary: No summary, Headline: Regeneron`s Libtayo approved in Japan for cervical cancer, source:Seeking Alpha, summary: No summary, Headline: IN BRIEF: Regeneron says cervical cancer treatment approved in Japan, source:Alliance News, summary: No summary, Headline: Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Libtayo® (cemiplimab) as monotherapy to treat patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy., Headline: Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma, source:Yahoo, summary: Following the FDA's approval, Roche (RHHBY) Lunsumio is the first CD20xCD3 T-cell engaging bispecific antibody approved to treat follicular lymphoma., Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.94% to $726.74 Friday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
78,2022-12-24,"Headline: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders sold US$7.0m worth of stock, possibly signalling a downtrend, source:Yahoo, summary: The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...",REGN
79,2022-12-27,"Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 2.12% to $711.35 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with...",REGN
80,2022-12-28,"Headline: Race is on to develop new generation of weight-loss drugs, source:Yahoo, summary: Surging demand and tight supply for a new class of obesity drugs has sparked a race among several of the world’s largest pharmaceutical companies to develop rival medications for a market projected to be worth $50bn in annual revenues by the end of the decade.  Eli Lilly, Amgen, Pfizer and Regeneron are among the companies aiming to compete with market leader Novo Nordisk in a category which analysts say is rapidly becoming a healthcare priority and could produce several blockbuster obesity treatments this decade.  Mounjaro, a similar medication already marketed by Lilly for treating diabetes but which is expected to get a green light from regulators next year for obesity, is also scarce at least in part because of off-label use by patients with obesity., Headline: Tracking William Nygren`s Harris Associates Portfolio - Q3 2022 Update, source:Seeking Alpha, summary: No summary, Headline: Insiders who sold Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) earlier this year didn't have to weather this week's 3.4% slide, source:Yahoo, summary: Even though Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) has fallen by 3.4% over the past week , insiders who sold..., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.24% higher to $713.03 Wednesday, on what proved to be an all-around rough trading session for the stock..., Headline: Tracking William Nygren's Harris Associates Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Harris Associatesâ 13F portfolio value decreased from $62.85B to $59.68B this quarter. Click to read an update on the portfolio's trades for Q3 2022.",REGN
81,2022-12-29,"Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.16% to $721.29 Thursday, on what proved to be an all-around favorable trading session for the stock...",REGN
82,2022-12-30,"Headline: Opco reveals three biotech stocks that will outperform in 2023, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.03% higher to $721.49 Friday, on what proved to be an all-around grim trading session for the stock market,...",REGN
83,2023-01-01,"Headline: Calculating The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), source:Yahoo, summary: Does the January share price for Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) reflect what it's really worth? Today...",REGN
84,2023-01-03,"Headline: What's in Store for Regeneron Pharmaceuticals (REGN) in 2023?, source:Yahoo, summary: Regeneron Pharmaceuticals (REGN) had a good run in 2022 and the momentum should continue in 2023 on the back of growth in Eylea and Dupixent., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.14% to $720.47 Tuesday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023, source:Yahoo, summary: TARRYTOWN, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2022 financial and operating results on Friday, February 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call InformationParticipants may access the conference call live via webcast on the ’Investors and Media’ page of Reg",REGN
85,2023-01-04,"Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.84% higher to $726.49 Wednesday, on what proved to be an all-around great trading session for the stock..., Headline: CytomX Therapeutics updates business, announces 2023 relationship with Moderna, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",REGN
86,2023-01-05,"Headline: Sensei announces clinical supply agreement with Regeneron for Libtayo, source:Thefly.com, summary: No summary, Headline: Jim Cramer says he likes these 5 Nasdaq stocks for 2023, source:CNBC, summary: Cramer offered investors a list of stocks listed in the Nasdaq Composite that he believes could be winners this year., Headline: FDA Dermatologic & Ophthalmic Drugs Advisory Committee Virtual Meeting, source:Thefly.com, summary: No summary",REGN
87,2023-01-06,"Headline: 2seventy Bio announces amendment to collaboration with Regeneron, source:Thefly.com, summary: No summary, Headline: 2seventy Bio, Regeneron in Amended Collaboration >TSVT REGN, source:MarketWatch, summary: By Colin Kellaher 2seventy bio Inc. on Friday said it inked an expanded collaboration with fellow biotechnology company Regeneron Pharmaceuticals Inc.,..., Headline: 3 Growth Stocks That Could Rocket Higher in 2023, source:Yahoo, summary: If you're looking for stocks that can make dramatic gains quickly, it's hard to do any better than the biotechnology industry.  Hardly a week goes by without at least one biotech stock shooting higher or tumbling lower in response to exciting news about experimental treatments.  In 2023, all three of these drugmakers will report study results that are awfully important to their futures., Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.85% to $737.15 Friday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: CytomX (CTMX) Up 55% on Strategic Partnership With Moderna, source:Yahoo, summary: CytomX (CTMX) inks an agreement with Moderna to develop therapeutics for oncology and non-oncology conditions. The company also provides its business outlook for 2023., Headline: 5 Top Pharma Stocks of 2022 to Buy for the Long Haul, source:Yahoo, summary: Not every stock went down in 2022. Shares in some the biggest pharmaceutical companies rose in price. If you can make it in a market like 2022, imagine what can happen in 2023 for many top pharma stocks. What the best pharma stocks have in common is pricing power, patented medicines, big moats and wide margins. They’re also members of Pharmaceutical Research and Manufacturers of America, the trade group that has fought for decades to keep prices high. Pricing is the key risk for these companies.",REGN
88,2023-01-08,"Headline: 15 Most Advanced Countries in Medicine, source:Yahoo, summary: In this article, we take a look at the 15 most advanced countries in medicine. You can skip our detailed analysis of the healthcare industry and go directly to 5 Most Advanced Countries in Medicine. The recent pandemic was the best reflection of the advancements in the field of medicine. Vaccines were developed at a […]",REGN
89,2023-01-09,"Headline: These Stocks Are Moving the Most Monday: Tesla, Zillow, Regeneron, Macy’s, and More, source:MarketWatch, summary: CinCor Pharma, Albireo and Duck Creek Technologies also made big moves Monday., Headline: Stocks making the biggest moves midday: Tesla, Nvidia, Lululemon and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Healthcare Stocks See Winners and Losers on Monday, source:Yahoo, summary: Healthcare companies are pre-announcing fourth-quarter results ahead of the industry's [most important investor](https://www.wsj.com/livecoverage/stock-market-news-today-01-09-2023/card/inflation-banks-biotech-what-s-on-tap-for-this-week-SwgbGitBuQOyISoLL9Mx) conference—stocks are reacting. + Diagnostics company Exact Sciences is a Monday morning winner. The stock is up 20% after Exact, which makes the Cologuard test to detect colon cancer, said it expects to report fourth-quarter sales of $550., Headline: Health Care Down Sharply on Rate-Sensitive Sector Bias -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell sharply as traders rotated into sectors with more to gain from falling Treasury yields. Moderna said it's considering pricing its..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 7.69% to $680.49 Monday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Regeneron Stock Sinks on Disappointing Sales of Eylea Treatment, source:Yahoo, summary: Eylea is meant to treat conditions such as macular degeneration, macular edema, and diabetic retinopathy., Headline: Biotech Giant Regeneron Hit As Eylea Gives Ground To Avastin, source:Yahoo, summary: Regeneron Pharmaceuticals said sales of its linchpin Eylea drug have been negatively impacted by a short-term shift to rival drug Avastin.",REGN
90,2023-01-10,"Headline: Stocks making the biggest moves midday: Bed Bath & Beyond, Coinbase, Virgin Orbit and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Company News for Jan 10, 2023, source:Yahoo, summary: Companies In The News Are: REGN, LULU, DCT, BAX., Headline: Regeneron (REGN) Down on Ophthalmology Drug Eylea Sales Update, source:Yahoo, summary: Regeneron's (REGN) lead drug Eylea's sales decline in the fourth quarter due to a short-term shift to off-label use of Avastin., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 2.71% to $698.95 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
91,2023-01-11,"Headline: Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?, source:Yahoo, summary: With its stock down 7.1% over the past three months, it is easy to disregard Regeneron Pharmaceuticals (NASDAQ:REGN..., Headline: Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More, source:Yahoo, summary: Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week., Headline: REGN or TECH: Which Is the Better Value Stock Right Now?, source:Yahoo, summary: REGN vs. TECH: Which Stock Is the Better Value Option?, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.57% to $709.94 Wednesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics, source:SeekingAlpha, summary: Despite being founded 10 years ago, CRISPR Therapeutics could very well lose out to 3-year-old Prime Medicine. Read more to see the comparison.",REGN
92,2023-01-12,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.65% higher to $714.57 Thursday, on what proved to be an all-around great trading session for the stock..., Headline: Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed the most recent trading day at $714.57, moving +0.65% from the previous trading session.",REGN
93,2023-01-15,"Headline: Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their decent 94% return over the last five years, source:Yahoo, summary: Stock pickers are generally looking for stocks that will outperform the broader market. And in our experience, buying...",REGN
94,2023-01-16,"Headline: Why Regeneron's CEO remains bullish on Eylea drug after 11 years on the market, source:Yahoo, summary: ""What's driving the category are demographics, aging of the population, as well as [an] increase in diabetes and diabetic eye disease,"" Regeneron CEO Len Schleifer said during the 41st annual J.P. Morgan Healthcare Conference in San Francisco.",REGN
95,2023-01-17,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.83% higher to $728.11 Tuesday, on what proved to be an all-around rough trading session for the stock..., Headline: Covid Isn’t Going Away. New Drugs Are Coming., source:MarketWatch, summary: Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid.",REGN
96,2023-01-18,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.49% to $724.55 Wednesday, on what proved to be an all-around poor trading session for the stock market,...",REGN
97,2023-01-19,"Headline: Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?, source:Yahoo, summary: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says..., Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.24% to $715.57 Thursday, on what proved to be an all-around poor trading session for the stock market, with...",REGN
98,2023-01-20,"Headline: Stocks making the biggest moves premarket: Netflix, Alphabet, Nordstrom, PagerDuty and more, source:CNBC, summary: These are the stocks posting the largest moves in early trading. ",REGN
99,2023-01-23,"Headline: Regeneron (REGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed the most recent trading day at $729.91, moving +1.1% from the previous trading session.",REGN
100,2023-01-24,"Headline: Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year's Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors. The competition, now in its 82nd year, celebrates and rewards young scientists focused on a wide range of scientific topics from the space race to the AIDS epidemic to climate change. Many past winners continue to pursue innovation for",REGN
101,2023-01-25,"Headline: 12 Cheap Biotech Stocks To Buy, source:Yahoo, summary: In this article, we will be taking a look at 12 cheap biotech stocks to buy. To skip our detailed analysis of the biotech sector, you can go directly to see 5 Cheap Biotech Stocks To Buy. The biotechnology sector has been on the rise over the past three decades. Several forecasts expect the sector […]",REGN
102,2023-01-26,"Headline: 15 Most Undervalued Quality Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this article, we discuss 15 most undervalued quality stocks to buy according to hedge funds. If you want to see more stocks in this selection, 5 Most Undervalued Quality Stocks To Buy According To Hedge Funds. Quality stocks usually have little debt, steady earnings, regular growth in assets, and effective leadership. Investors can identify […]",REGN
103,2023-01-27,"Headline: Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis, source:Yahoo, summary: If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life In Europe, about 80,000 children aged 6 months to 5 years with uncontrolled severe atopic dermatitis are candidates for systemic therapy TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Rege, Headline: Sanofi/Regeneron: Dupixent wins new stage of EU regulatory approval, source:Reuters, summary: Healthcare companies Sanofi and Regeneron announced on Friday that the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as six months old with severe atopic dermatitis., Headline: UPDATE 1-Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval, source:Yahoo, summary: Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as 6 months old with severe atopic dermatitis.  The European Commission is expected to announce a final decision on the Dupixent application in coming months.  Dupixent was approved in June 2022 by the U.S. Food and Drug Administration (FDA) regulator for children in this age group., Headline: Sanofi's and Regeneron's Dupixent wins new stage of EU regulatory approval, source:Reuters, summary: Healthcare companies Sanofi and Regeneron said on Friday the European Union's medicines regulator had given a new stage of approval for their Dupixent product to treat children as young as 6 months old with severe atopic dermatitis., Headline: Regeneron, Sanofi’s Dupixent is one step closer to approval for young children in Europe, source:Yahoo, summary: MARKET PULSE Shares of Regeneron Pharmaceuticals Inc. (REGN) gained about 2.5% in premarket trading on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended approval of Dupixent, the atopic dermatitis therapy developed with Sanofi (FR:SAN) (SNY) for children as young as six months old., Headline: Possible bearish signals as Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insiders disposed of US$7.0m worth of stock, source:Yahoo, summary: In the last year, many Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders sold a substantial stake in the company..., Headline: Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?, source:Yahoo, summary: Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again, source:Yahoo, summary: Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",REGN
104,2023-01-30,"Headline: Sanofi and Regeneron's Dupixent wins new European Commission approval, source:Reuters, summary: Healthcare companies Sanofi and Regeneron said on Monday that their Dupixent product had won approval from the European Commission to treat eosinophilic esophagitis (EoE), which is a condition that damages the esophagus.",REGN
105,2023-01-31,"Headline: Regeneron Announces Investor Conference Presentations, source:Yahoo, summary: TARRYTON, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: SVB Securities Global Biopharma Conference at 9:20 a.m. ET on Tuesday, February 14, 2023Cowen 43rd Annual Health Care Conference at 12:50 p.m. ET on Monday, March 6, 2023Oppenheimer 33rd Annual Healthcare Conference at 9:20 a.m. ET on Monday, March 13, 2023Barclays Global Healthcare Conference at 9:00 a.m. ET on Wednesday, March 15, 2023 The sessions, Headline: Cowen & Co. Upgrades Regeneron Pharmaceuticals (REGN), source:Fintel, summary: nan",REGN
106,2023-02-01,"Headline: Are Investors Undervaluing Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) By 31%?, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN..., Headline: How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings, source:Yahoo, summary: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates., Headline: Top 25 Smartest Companies To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless […], Headline: The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023, source:Yahoo, summary: Thanks to the wild events of 2022, discerning investors enjoy plenty of bargains, particularly in the arena of the most undervalued Nasdaq stocks. Given the exchange’s bias toward technology players (including biotech), wagering in this space carries the advantage of relevance. Even if circumstances look shoddy right now, at some point, these enterprises have a shot at upside eventually. Now, a word of caution is in order following the utterances of the last few words above. With the most underv, Headline: Time to Buy Cigna or Regeneron Stock Before Earnings?, source:Yahoo, summary: Among the Finance and Medical sector, Cigna (CI) and Regeneron Pharmaceuticals (REGN) are both leaders in their respective industries and have had strong performances over the last year as the broader market and economy declined.",REGN
107,2023-02-02,"Headline: Why Regeneron (REGN) Might Surprise This Earnings Season, source:Yahoo, summary: Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: The 7 Most Undervalued Biotech Stocks to Buy in February 2023, source:Yahoo, summary: You don’t have to be particularly astute to recognize the importance of the most undervalued biotech stocks to buy. Fundamentally, the enterprises that undergird these names operate on the cutting edge of medical science. At the same time, the established players tend to be pricey. By picking up underappreciated names, it’s possible to secure significant upside down the line. However, anytime a discussion about the most undervalued biotech stocks to buy materializes, a question comes up: how doe, Headline: The 7 Most Undervalued Stocks to Buy in February 2023, source:Yahoo, summary: As Feb. gets underway, I’m finding under-appreciated, undervalued stocks to buy. When seeking value in the stock market the hope is that other investors will see what you see: The underappreciated value inherent in strong businesses that don’t necessarily garner a lot of attention. In turn, they follow your lead, purchase en masse, and the price of your shares rises with demand. Short-term volatility will remain for those who take this approach now. But market cyclicality will do its magic and m",REGN
108,2023-02-03,"Headline: UPDATE 4-Sanofi forecasts moderate profit growth on Dupixent demand, source:Yahoo, summary: Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis pill Aubagio and product launch costs.  Aubagio, with 2 billion euros ($2.2 billion) in sales last year, will face competition from cheaper products over the next few months after losing patent protection, Sanofi said.  Sanofi shares were down 3% at 1107 GMT, having earlier fallen as much as 5.2% to their lowest since mid-November with JP Morgan analysts saying investors had expected a better 2023 outlook and a more benign view on foreign exchange headwinds., Headline: Here's why 2seventy bio's chief executive thinks 2023 will be a 'special year', source:Yahoo, summary: The chief executive of bluebird bio's oncology-focused spinout believes that this year, it will take off as a company in its own right., Headline: Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat, source:Yahoo, summary: By Scott Kanowsky, Headline: Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results, source:Yahoo, summary: Fourth quarter 2022 revenues decreased 31% to $3.41 billion versus fourth quarter 2021; excluding REGEN-COV® and RonapreveTM(a)(b), revenues increased 14%Full year 2022 revenues decreased 24% to $12.17 billion versus full year 2021; excluding REGEN-COV and Ronapreve(a)(b), revenues increased 17%Fourth quarter 2022 EYLEA® U.S. net sales decreased 3% to $1.50 billion versus fourth quarter 2021; full year 2022 EYLEA U.S. net sales increased 8% to $6.26 billion versus 2021Fourth quarter 2022 Dupixen, Headline: CORRECTED-Regeneron quarterly profit drops 46%, source:Reuters, summary: Regeneron Pharmaceuticals Inc reported an about 46% plunge in its fourth-quarter profit on Friday, hurt by a drop in U.S. sales of its blockbuster eye drug, Eylea, and drying up of its COVID-19 antibody cocktail sales., Headline: Regeneron stock rallies after profit and revenue beat expectations by wide margins, source:Yahoo, summary: MARKET PULSE Shares of Regeneron Pharmaceuticals Inc. (REGN) rallied 1.9% toward a two-month high in premarket trading Friday, after the biotechnology company reported fourth-quarter profit and revenue that fell, as sales of its COVID-19 treatment dropped, but beat expectations by wide margins., Headline: UPDATE 2-Regeneron profit beats estimates on Dupixent strength, source:Yahoo, summary: Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea.  Eylea, which recorded total sales of $9.65 billion in 2022, has been a key growth driver for the company ever since its launch more than a decade ago.  Sales of Eylea, used to treat vision loss causing age-related macular degeneration, were impacted by temporary closing of a fund during the quarter that provides co-pay assistance to patients., Headline: Regeneron Pharmaceuticals, Inc. 2022 Q4 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Regeneron Pharmaceuticals, Inc., Headline: Regeneron Pharmaceuticals, Inc. (REGN) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Q4 2022 Earnings Conference Call February 3, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor RelationsLeonard..., Headline: Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates, source:Yahoo, summary: Regeneron (REGN) delivered earnings and revenue surprises of 29.75% and 7.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Regeneron profit beats estimates on Dupixent strength, source:Reuters, summary: Regeneron Pharmaceuticals Inc reported a better-than-expected fourth-quarter profit on Friday, as strong demand for eczema drug Dupixent helped shield a drop in U.S. sales of its blockbuster eye drug, Eylea., Headline: Regeneron’s Earnings Beat Forecasts, With No Sales of Covid-19 Treatment, source:Yahoo, summary: The pharmaceuticals company's total revenue dropped by 31% to $3.41 billion but beat the FactSet consensus of $3.13 billion., Headline: Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples, source:Yahoo, summary: Regeneron Pharma beat quarterly forecasts Friday, but its partner Sanofi posted a mixed report. Regeneron stock rose as SNY stock toppled., Headline: Regeneron (REGN) Q4 Earnings & Sales Beat, Eylea Sales Decline, source:Yahoo, summary: Regeneron (REGN) tops earnings and sales estimates for the fourth quarter. However, sales of the lead drug Eylea decline year over year., Headline: Health Care Edge Lower After Solid Earnings -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell, but not by as much as the broad market, after a solid week of earnings. Regeneron Pharmaceuticals rallied after the biotech..., Headline: Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics, source:Yahoo, summary: While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: Drug, Chip Stocks Hit 52-Week Highs As One Breaks Out Of Bullish Chart Pattern, source:Yahoo, summary: Regeneron and Analog Devices hit new highs and break out. REGN had strong fourth quarter earnings. ADI is leader in the chip industry",REGN
109,2023-02-04,"Headline: Stocks To Watch: Spotlight On Google, Disney, Regeneron Pharmaceuticals And Hesai Group IPO, source:SeekingAlpha, summary: Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week",REGN
110,2023-02-05,"Headline: Tom Gayner`s Firm Buys Brookfield Asset Management, Dumps Texas Pacific Land, source:GuruFocus, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",REGN
111,2023-02-06,"Headline: Regeneron price target raised to $756 from $670 at Baird, source:Thefly.com, summary: No summary, Headline: Top 5 4th Quarter Trades of Pacer Advisors, Inc., source:GuruFocus, summary: No summary, Headline: BMO Capital Releases a Buy Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Regeneron price target raised to $853 from $750 at Canaccord, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Genmab (GMAB) and Immunovant (IMVT), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2022 Earnings Call Transcript February 3, 2023 Operator: Welcome to the Regeneron Pharmaceuticals’ Fourth Quarter 2022 Earnings Conference Call. My name is Shannon and I will be your operator for today’s call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. Please […], Headline: Regeneron price target lowered to $787 from $789 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Regeneron (REGN) and Seagen (SGEN), source:TipRanks, summary: No summary, Headline: Bayer seeks EU approval for retinal eye disease treatment aflibercept, source:Alliance News, summary: No summary, Headline: Top 3 Healthcare Stocks for February 2023, source:Yahoo, summary: Many healthcare stocks are surging higher in 2023. Plenty of companies in the sector have seen large inflows recently. Chances are this theme can continue., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",REGN
112,2023-02-07,"Headline: Top 5 4th Quarter Trades of MCDONALD CAPITAL INVESTORS INC/CA, source:GuruFocus, summary: No summary, Headline: The 7 Best Biotech Stocks to Buy for February 2023, source:Yahoo, summary: While unpredictable compared to other sectors due to the ebb and flow of clinical trials, the best biotech stocks to buy offer investors incredible upside opportunities. Better yet, the volatility largely centers on developments of the industry itself rather than the broader economy. By that, I mean biotechnology firms may enjoy some economic insulation as their relevance supersedes variables like interest rate dynamics. Still, it doesn’t mean that the best biotech stocks to buy are immune from, Headline: Regeneron will accelerate capital spending by at least 40%, source:Yahoo, summary: Regeneron anticipates spending will increase to somewhere between $825 million and $950 million this year., Headline: Regeneron named `Catalyst Driven Idea` at Morgan Stanley ahead of COPD data, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",REGN
113,2023-02-08,"Headline: Government Contracts Trading Strategy, source:SeekingAlpha, summary: As discussions about trillion-dollar debt ceiling question intensify on Capitol Hill, we bring you one of our budget-spending-oriented trading strategies. Click here to read more., Headline: Regeneron`s Eylea injection approved by FDA for treatment of preterm infants, source:Thefly.com, summary: No summary, Headline: GLOBAL BROKER RATINGS: Bernstein cuts Deutsche Post; MS raises Amex, source:Alliance News, summary: No summary, Headline: Freedom Day Solutions, LLC Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Should Investors Worry About Regeneron Pharmaceuticals Inc`s Insider Sells?, source:GuruFocus, summary: No summary, Headline: EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA, source:Yahoo, summary: ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, EYLEA is now indicated to treat five retinal condi, Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: No summary",REGN
114,2023-02-09,"Headline: GLOBAL BROKER RATINGS: DZ Bank cuts Adyen; Kepler cuts Segro, source:Alliance News, summary: No summary, Headline: Regeneron wins FDA nod for Eylea to prevent infant blindness, source:Seeking Alpha, summary: No summary, Headline: Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update, source:Yahoo, summary: Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week., Headline: Regeneron's (REGN) Eylea Gets FDA Nod for ROP in Infants, source:Yahoo, summary: Regeneron's (REGN) Eylea gets FDA approval for the treatment of preterm infants with retinopathy of prematurity (ROP)., Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: No summary, Headline: Roche Vabysmo matches Eylea in 2 phase 3 trials for eye disorder, source:Seeking Alpha, summary: No summary",REGN
115,2023-02-10,"Headline: Pfizer Gets FDA Nod for Cibinqo in Adolescents With Atopic Dermatitis >PFE, source:MarketWatch, summary: By Colin Kellaher Pfizer Inc. on Friday said the U.S. Food and Drug Administration expanded its approval of Cibinqo to include adolescents with atopic..., Headline: Is Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Recent Performance Tethered To Its Attractive Financial Prospects?, source:Yahoo, summary: Regeneron Pharmaceuticals' (NASDAQ:REGN) stock up by 4.9% over the past month. Given that the market rewards strong...",REGN
116,2023-02-11,"Headline: 2 Biotech Stocks That Could Help Set You Up for Life, source:Yahoo, summary: Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) are each up about 20% over the past year.  The biotech companies have shown increased revenue and earnings per share (EPS) over the past three years and have burgeoning pipelines that should continue to drive growth.",REGN
117,2023-02-12,"Headline: LOOMIS SAYLES & CO L P Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood, source:InvestorPlace, summary: No summary, Headline: Ocular stock rises ~15% as eye drug implant shows promise in ongoing phase 1 trial, source:Seeking Alpha, summary: No summary, Headline: Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers, source:TalkMarkets, summary: No summary, Headline: Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers, source:TalkMarkets, summary: No summary",REGN
118,2023-02-13,"Headline: New 52-Week Highs In 2023, source:TalkMarkets, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.84% higher to $763.97 Monday, on what proved to be an all-around great trading session for the stock..., Headline: Regeneron Pharmaceuticals, Inc. (REGN) SVB Securities Global Biopharma Conference (Transcript), source:Seeking Alpha, summary: No summary",REGN
119,2023-02-14,"Headline: Regeneron: Waiting For A More Lucrative Price To Buy, source:Seeking Alpha, summary: No summary, Headline: Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 136% gain, source:Yahoo, summary: When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really..., Headline: 2 Top Healthcare Stocks Defying the Bear Market, source:Yahoo, summary: Among them are HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  With recession fears alive and well, HCA Healthcare might be an excellent stock to turn to  now.  The company is a leading hospital chain operator in the U.S., a business that is sure to remain somewhat in high demand even if a recession hits., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.28% to $754.21 Tuesday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: 9 Healthcare Stocks Where the Doubters Are on the Run, source:MarketWatch, summary: Cigna, Regeneron, Centene, and six other healthcare stocks have seen short interest drop by at least 40% recently. Fewer investors are betting against them.",REGN
120,2023-02-15,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. sank 0.24% to $752.40 Wednesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Regeneron poised to benefit from bounce-back of eye drug, source:Yahoo, summary: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) could benefit from a bounce-back in share for its drug to treat macular degeneration, according to analysts at Piper Sandler.  The analysts rate the stock overweight with an $800 price target.  Regeneron shares were down 0.2% on Wednesday but up 4.3% so far this year., Headline: 5 Least-Hurt Biotech ETFs of the Last Week, source:Yahoo, summary: Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days., Headline: Competition Coming For AbbVie's Blockbuster Humira, source:SeekingAlpha, summary: Itâs among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper âbiosimilarâ copycats. Read how price relief is on the way for Humira.",REGN
121,2023-02-16,"Headline: 3 Super Profitable S&P 500 Stocks to Buy, Other Than ExxonMobil, source:TipRanks, summary: No summary, Headline: Competition Coming For AbbVie`s Blockbuster Humira, source:Seeking Alpha, summary: No summary, Headline: IDNA: Healthcare Dashboard For February, source:SeekingAlpha, summary: Pharmaceuticals and biotechs still look attractive. We focus on iShares Genomics Immunology and Healthcare ETF. IDNA is an ETF in genomics and immunology. Click here for more., Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 2.14% to $736.33 Thursday, on what proved to be an all-around grim trading session for the stock market, with...",REGN
122,2023-02-17,"Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Bio-Rad Laboratories (BIO), Shockwave Medical (SWAV) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.69% to $748.74 Friday, on what proved to be an all-around mixed trading session for the stock market,...",REGN
123,2023-02-18,"Headline: Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?, source:Yahoo, summary: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...",REGN
124,2023-02-19,"Headline: The next big wave of patent cliffs is ahead; expect biopharma M&A to rise ��� report, source:Seeking Alpha, summary: No summary",REGN
125,2023-02-20,"Headline: 25 Most Profitable NASDAQ Stocks Today, source:Yahoo, summary: In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as […]",REGN
126,2023-02-21,"Headline: Regeneron price target raised to $860 from $800 at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Regeneron announces U.S. FDA accepted priority review for BLA for pozelimab, source:Thefly.com, summary: No summary, Headline: Regeneron Gets FDA Priority Review of Pozelimab in Chaple >REGN, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application seeking..., Headline: Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review, source:Yahoo, summary: If approved, pozelimab would be the first and only treatment for those living with CHAPLE CHAPLE is an ultra-rare hereditary immune disease that causes overactivation of the complement system, leading to potentially life-threatening abdominal and cardiovascular symptoms TARRYTOWN, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA, Headline: Regeneron’s pozelimab approved by US FDA for priority review, source:Alliance News, summary: No summary, Headline: Three-Stock Lunch: Regeneron, General Mills and DocuSign, source:CNBC, summary: Eva Ados, chief investment strategist at ERShares, joins ‘Power Lunch’ to discuss Regeneron, General Mills and DocuSign., Headline: Regeneron (REGN) Rare Disease Drug Gets FDA's Priority Review, source:Yahoo, summary: Regeneron's (REGN) application seeking approval of pozelimab for the ultra-rare hereditary immune disease CHAPLE gets Priority Review by the FDA., Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. sank 0.30% to $746.52 Tuesday, on what proved to be an all-around grim trading session for the stock market, with...",REGN
127,2023-02-22,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.21% higher to $748.08 Wednesday, on what proved to be an all-around dismal trading session for the stock...",REGN
128,2023-02-23,"Headline: Regeneron announces U.S. FDA accepted priority review for BLA for aflibercept, source:Thefly.com, summary: No summary, Headline: Regeneron`s high-dose Eylea application accepted for FDA priority review, source:Seeking Alpha, summary: No summary, Headline: Intellia, Novartis end gene editing partnership for sickle cell disease, source:Seeking Alpha, summary: No summary, Headline: Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review, source:Yahoo, summary: BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, with vast majority of patients maintaining extended dosing regimens through 48 weeks If approved, aflibercept 8 mg will be second ophthalmology medicine developed by Regeneron TARRYTOWN, N.Y., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics Lic, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.55% to $759.66 Thursday, on what proved to be an all-around favorable trading session for the stock..., Headline: Notable Friday Option Activity: REGN, ORA, FSR, source:Stock Options Channel, summary: No summary",REGN
129,2023-02-24,"Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Regeneron says CHMP adopts positive opinion on Libtayo with chemotherapy, source:Thefly.com, summary: No summary, Headline: Regeneron wins EU nod for Libtayo in PD-L1 positive lung cancer, source:Seeking Alpha, summary: No summary, Headline: Regeneron: CHMP Backs Libtayo/Chemotherapy Combo in Advanced Non-Small Cell Lung Cancer, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended..., Headline: IN BRIEF: Regeneron's Libtayo combination wins EU positive opinion, source:Alliance News, summary: No summary, Headline: Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC), source:Yahoo, summary: Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Libtayo® (cemiplimab) in combination with platinum-based chemotherapy. Specifically, the CHMP recommended the Libtayo, Headline: NEW YORK MARKET CLOSE: US stocks tumble after strong inflation data, source:Alliance News, summary: No summary, Headline: Intellia's (NTLA) Q4 Loss Matches Estimates, Revenues Up Y/Y, source:Yahoo, summary: Intellia Therapeutics (NTLA) reports loss for fourth-quarter 2022, in line with estimates., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.35% to $756.99 Friday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Pharmas, medtechs dominate list of innovation leaders thanks to patents, source:Seeking Alpha, summary: No summary",REGN
130,2023-02-25,"Headline: Regeneron: Innovation And Disruption Done Right, source:SeekingAlpha, summary: Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now., Headline: FDA PDUFA Date for Regeneron Pharma Eylea-Aflibercept is February 28, 2023, source:Thefly.com, summary: No summary",REGN
131,2023-02-26,"Headline: Replimune ends selloff after FDA response to mid-stage cancer trial, source:Seeking Alpha, summary: No summary",REGN
132,2023-02-27,"Headline: Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.11% higher to $757.79 Monday, on what proved to be an all-around positive trading session for the stock..., Headline: Top 10 Drug Companies in USA and Their China Reliance, source:Yahoo, summary: In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China […], Headline: FDA PDUFA Date for Regeneron Pharma Eylea-Aflibercept is February 28, 2023, source:Thefly.com, summary: No summary, Headline: Bayer`s Q4 sales grow on back of crop products, pharma declines; FY23 EPS to see impact, source:Seeking Alpha, summary: No summary",REGN
133,2023-02-28,"Headline: Regeneron and Sanofi`s Kevzara approved by FDA for polymyalgia rheumatica, source:Thefly.com, summary: No summary, Headline: A Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider lowered their holding by 26% earlier this year, source:Yahoo, summary: Insiders were net sellers of Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock during the past year. That is..., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.35% higher to $760.42 Tuesday, on what proved to be an all-around dismal trading session for the stock..., Headline: Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica, source:Yahoo, summary: Three times more patients treated with Kevzara achieved sustained remission compared to placebo in Phase 3 trial Kevzara now approved to treat two chronic inflammatory disorders TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Kevzara® (sarilumab) for the treatment of polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, in adul, Headline: Regeneron Pharmaceuticals Now #94 Largest Company, Surpassing Altria Group, source:The Online Investor, summary: No summary",REGN
134,2023-03-01,"Headline: Cantor Fitzgerald biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.32% to $770.44 Wednesday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Biotech Stock Roundup: MRNA Q4 Earnings, REGN's Updates, CYTK Receives Setback, source:Yahoo, summary: Earnings from Moderna (BIIB) and updates from Regeneron (REGN) are the key highlights from the biotech sector during the past week., Headline: FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles, source:Yahoo, summary: The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The approval covers adult patients who have had an inadequate response to corticosteroids or cannot tolerate corticosteroid taper. Kevzara is now approved to treat two chronic inflammatory disorders. PMR often initially presents with pain and stiffness around the neck, shoulder, and hip area, and symptoms include fa",REGN
135,2023-03-02,"Headline: REGN April 14th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.20% to $768.90 Thursday, on what proved to be an all-around favorable trading session for the stock...",REGN
136,2023-03-03,"Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.35% to $779.30 Friday, on what proved to be an all-around positive trading session for the stock market, with...",REGN
137,2023-03-04,"Headline: A Look At The Fair Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$923...",REGN
138,2023-03-05,"Headline: Unity Biotechnology: One Last Chance With UBX1325, source:SeekingAlpha, summary: Unity Biotechnology has spent its existence identifying the root causes of age-related diseases. Read more to see my full investment analysis on UBX stock., Headline: Cantor biopharma/biotech analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: What To Expect From Pfizer In The Post-COVID-19 Era, source:SeekingAlpha, summary: In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.",REGN
139,2023-03-06,"Headline: Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading, source:TalkMarkets, summary: No summary, Headline: Merck to start phase 3 of oral PCSK9 inhibitor for cholesterol following mid-stage results, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals, Inc. (REGN) Cowen 43rd Annual Health Care Conference (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Cowen 43rd Annual Health Care Conference March 6, 2023 12:50 PM ETCompany ParticipantsMarion McCourt - EVP of CommercialRyan Crowe -..., Headline: Merck's drug boosts exercise capacity in pulmonary hypertension patients, source:Yahoo, summary: Merck & Co Inc said on Monday its experimental therapy, sotatercept, helped increase exercise capacity in patients with a deadly disease that causes high pressure in blood vessels of the heart and lungs in a late-stage study.  A second experimental heart drug, MK-0616, helped reduce levels of low-density lipoprotein (LDL) cholesterol by between 41.2% at a low 6 mg dose to 60.9% at a higher 30 mg dose in a mid-stage study, the drugmaker said.  Sotatercept, which Merck gained through its $11.5 billion buyout of Acceleron Pharma, combined with background therapy helped extend the distance that patients with pulmonary arterial hypertension could walk in six minutes by 40.8 meters., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.14% higher to $780.38 Monday, on what proved to be an all-around positive trading session for the stock..., Headline: Regeneron, Sanofi announces FDA acceptance for review of Dupixent sBLA, source:Thefly.com, summary: No summary",REGN
140,2023-03-07,"Headline: FDA accepts for review Regeneron/Sanofi`s Dupixent application for inflammatory skin condition, source:Seeking Alpha, summary: No summary, Headline: Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review, source:Yahoo, summary: More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistaminesTARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) that is not, Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.84% to $773.85 Tuesday, on what proved to be an all-around rough trading session for the stock market, with...",REGN
141,2023-03-08,"Headline: Roche: Ongoing Pipeline Issues Sap Growth And Increase M&A Likelihood, source:SeekingAlpha, summary: Roche hasn't scored the sort of big wins that change investment theses or drive lasting changes in sentiment. Find out our recommendation on RHHBY stock., Headline: Sanofi (SNY), Regeneron Dupixent sBLA Accepted for FDA Review, source:Yahoo, summary: Sanofi's (SNY) sBLA seeking label expansion of drug Dupixent for chronic spontaneous urticaria accepted by the FDA, Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 3.70% to $745.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs, source:Seeking Alpha, summary: No summary",REGN
142,2023-03-09,"Headline: Regeneron price target raised to $806 from $787 at RBC Capital, source:Thefly.com, summary: No summary, Headline: 2seventy Bio: KarMMa-3 Finally Releases Positive Results, source:SeekingAlpha, summary: 2seventy Bio's strong focus on cell therapy-based combinations for solid tumors positions them as a potential leader in the immuno-oncology market. Read more here., Headline: Cantor biopharma/biotech analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: 2 Biotech Stocks You Can Buy and Hold for the Next Decade, source:Yahoo, summary: The U.S. market is highly likely to deliver attractive returns over periods of five years or more.  With that said, let's consider two biotech stocks that could deliver outsized returns in the next decade: Regeneron Pharmaceuticals (NASDAQ: REGN) and Sarepta Therapeutics (NASDAQ: SRPT).  One of the keys to success for biotech companies is the ability to develop newer medicines., Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 0.19% to $743.75 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Regeneron (REGN) Stock Moves -0.19%: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed the most recent trading day at $743.75, moving -0.19% from the previous trading session.",REGN
143,2023-03-10,"Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.44% higher to $747.00 Friday, on what proved to be an all-around rough trading session for the stock...",REGN
144,2023-03-11,"Headline: Regeneron Borrows From Big Pharma Playbook to Keep Roche, Shorts at Bay, source:Yahoo, summary: Leonard Schleifer,  the longtime  Regeneron  boss, likes to point out that, unlike many giant drug companies gaming the healthcare system with all kinds of gimmicks, his biotech focuses on true innovation.  Roche is indeed grabbing market share, reporting Vabysmo revenue of 591 million Swiss francs, equivalent to about $640 million, last year—an impressive figure for its first year on the market.",REGN
145,2023-03-13,"Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals, Inc. (REGN) Oppenheimer 33rd Annual Healthcare Conference, source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Oppenheimer 33rd Annual Healthcare Conference March 13, 2023 9:20 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.71% higher to $752.33 Monday, on what proved to be an all-around poor trading session for the stock market,...",REGN
146,2023-03-14,"Headline: Regeneron price target raised to $1,025 from $1,001 at BMO Capital, source:Thefly.com, summary: No summary, Headline: Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?, source:Yahoo, summary: It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock..., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.92% to $766.80 Tuesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Neel Moudgal, 17, of Saline, Mich., won the top $250,000 award in the 2023 Regeneron Science Talent Search, the nation's oldest and most prestigious science and math competition for high school seniors.",REGN
147,2023-03-15,"Headline: The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector, source:InvestorPlace, summary: No summary, Headline: Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Barclays Global Healthcare Conference March 15, 2023 9:00 AM ETCompany ParticipantsRyan Crowe - Vice President of Investor..., Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 0.85% to $760.30 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Regeneron (REGN) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Regeneron (REGN) closed at $760.30, marking a -0.85% move from the previous day.",REGN
148,2023-03-16,"Headline: PBE: Healthcare Dashboard For March, source:SeekingAlpha, summary: Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold., Headline: Video: Nasdaq 100 Movers: REGN, INTC, source:Market News Video, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.39% to $749.75 Thursday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Medicare Negotiation Undercuts Biotech Stocks Regeneron, Halozyme, source:Yahoo, summary: Confusion over new Centers for Medicare and Medicaid Services negotiating plans sent REGN and HALO stocks tumbling Thursday., Headline: Dow Jones Hits Session Highs; Tesla Faces New Lawsuit From Customers, Agrees To Open 7500 Charging Stations, source:Yahoo, summary: The Dow Jones Industrial Average rose throughout the session Thursday and closed near the day's highs. The blue chip index gained 1.2%, its best day since March 3. Intel was the Dow's clear leader, with a hefty 6% gain., Headline: 2 Biotech Stocks To Watch In March 2022, source:StockMarket, summary: Check out these 2 biotech stocks in the stock market today., Headline: 2 Biotech Stocks To Watch In March 2023, source:StockMarket, summary: Check out these 2 biotech stocks in the stock market today.",REGN
149,2023-03-17,"Headline: Regeneron pressure from CMS draft a buying opportunity, says Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Regeneron (REGN) Gains 9.3% in a Year: Will the Uptrend Last?, source:Yahoo, summary: Regeneron (REGN) has had a good run in the past 12 months and the momentum should continue in 2023 on the back of growth in Dupixent, as Eylea faces challenges., Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 0.28% to $747.65 Friday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: Week In Review: Livzon In-Licenses GERD Therapy In $127 Million Agreement, source:TalkMarkets, summary: No summary",REGN
150,2023-03-18,"Headline: Investing in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago would have delivered you a 133% gain, source:Yahoo, summary: The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put..., Headline: Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis, source:Yahoo, summary: More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week TARRYTOWN, N.Y. and PARIS, March 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrol, Headline: Regeneron, Sanofi present results from Dupixent clinical trial, source:Thefly.com, summary: No summary, Headline: Easing COVID pandemic sees many pharmas seeking alternate revenue streams, source:Seeking Alpha, summary: No summary",REGN
151,2023-03-19,"Headline: IN BRIEF: Regeneron and Sanofi share positive data for Dupixent, source:Alliance News, summary: No summary",REGN
152,2023-03-20,"Headline: Regeneron price target lowered to $802 from $806 at RBC Capital, source:Thefly.com, summary: No summary, Headline: IN BRIEF: Sanofi, Regeneron's Dupixent wins another EU approval, source:Alliance News, summary: No summary",REGN
153,2023-03-21,"Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: No summary, Headline: Regeneron, Sanofi announce EC approval of Dupixent, source:Thefly.com, summary: No summary, Headline: Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis, source:Yahoo, summary: Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placebo Patients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant improvements at 16 weeks sustained through one year Dupixent is now a treatment option for the approximately 80,000 infants and young children living with unc, Headline: Sanofi/Regeneron say Dupixent skin treatment wins new regulatory approval in Europe, source:Reuters, summary: Healthcare companies Sanofi and Regeneron announced on Tuesday that their Dupixent product, which treats the skin disease atopic dermatitis, had won a new regulatory approval from the European Commission., Headline: Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids, source:Yahoo, summary: Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe., Headline: Regeneron (REGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed the most recent trading day at $759.76, moving +0.07% from the previous trading session., Headline: 7 Value Stocks Worth Buying at These 52-Week Highs, source:InvestorPlace, summary: No summary",REGN
154,2023-03-22,"Headline: Regeneron announces FDA approval of Evkeeza for young children, source:Thefly.com, summary: No summary, Headline: Regeneron gets FDA approval for expanded use of high cholesterol drug Evkeeza in kids, source:Seeking Alpha, summary: No summary, Headline: Regeneron: FDA Extends Evkeeza Approval to Children Ages 5 to 11 >REGN, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. on Wednesday said the U.S. Food and Drug Administration extended the approval of its Evkeeza cholesterol..., Headline: FDA Approves First-in-class Evkeeza® (evinacumab-dgnb) for Young Children with Ultra-rare Form of High Cholesterol, source:Yahoo, summary: Approval extends Evkeeza to children aged 5 to 11 with homozygous familial hypercholesterolemia (HoFH), an inherited condition characterized by extremely high low-density lipoprotein cholesterol (LDL-C) 48% reduction in LDL-C from baseline at week 24 when Evkeeza was added to other lipid-lowering therapies in the pivotal trial TARRYTOWN, N.Y., March 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has extended, Headline: Regeneron gets US FDA nod for expanded use of cholesterol drug in children, source:Reuters, summary: Regeneron Pharmaceuticals Inc said on Wednesday the U.S. health regulator has approved expanded use of its drug to treat high cholesterol in children aged 5 to 11. (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli), Headline: UPDATE 3-US FDA expands use of Regeneron's cholesterol drug in young children, source:Yahoo, summary: Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol.  The drug, Evkeeza, was approved in February 2021 as an additional treatment with other lipid-lowering therapies for patients aged 12 years and above with homozygous familial hypercholesterolemia (HoFH).  It causes elevated levels of low-density lipoprotein (LDL) cholesterol and types of premature cardiovascular diseases., Headline: US FDA expands use of Regeneron's cholesterol drug in young children, source:Reuters, summary: Regeneron Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration had approved the expanded use of its drug in children aged 5 to 11 years to treat an ultra-rare disease that causes high cholesterol., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.11% to $751.30 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Regeneron (REGN) Gets Label Extension for Cholesterol Drug, source:Yahoo, summary: Regeneron (REGN) gets FDA approval for Evkeeza to treat children aged 5 to 11 with homozygous familial hypercholesterolemia., Headline: IN BRIEF: Sanofi, Regeneron's Dupixent shows promise for COPD in trial, source:Alliance News, summary: No summary, Headline: What You Missed On Wall Street On Thursday, source:Thefly.com, summary: No summary",REGN
155,2023-03-23,"Headline: Regeneron, Sanofi report Dupixent trial meets primary and secondary endpoints, source:Thefly.com, summary: No summary, Headline: Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial, source:Yahoo, summary: First and only biologic to demonstrate clinically meaningful and statistically significant reduction (30%) in exacerbations compared to placebo First and only biologic to show rapid and significant improvement in lung function (160 mL in FEV1) compared to placebo (77 mL in FEV1) First and only biologic to demonstrate significant improvements in quality of life and respiratory symptoms COPD is the third leading cause of death worldwide with no new treatment approaches approved in more than a deca, Headline: Sanofi and Regeneron's Dupixent meets endpoints in clinical trial, source:Yahoo, summary: Healthcare firms Sanofi and Regeneron said their Dupixent product, which treats the skin disease atopic dermatitis, has met primary and all secondary endpoints in a trial to treat chronic obstructive pulmonary disease (COPD).  Dupixent showed a 30% reduction in moderate or severe acute exacerbations of COPD, a respiratory disease that damages the lungs and causes progressive lung function decline, in the Phase 3 trial, while also showing improvements in lung function, quality of life and COPD respiratory symptoms, the companies said on Thursday., Headline: Sanofi Shares Rise After Dupixent Trial Hits Targets, Adding to Drug Potential, source:MarketWatch, summary: By Adria Calatayud Shares in Sanofi SA rose Thursday after the French pharmaceutical company and Regeneron Pharmaceuticals Inc. said their jointly developed..., Headline: UPDATE 3-Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data, source:Yahoo, summary: Sanofi's asthma and eczema drug Dupixent met all targets in a trial to treat ""smoker's lung"", giving a major boost to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.  In a late stage trial Dupixent, jointly developed with Regeneron, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline.  Sanofi and Regeneron said in a statement on Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and COPD respiratory symptoms., Headline: Regeneron Shares Rise Premarket on Dupixent COPD Study Success >REGN, source:MarketWatch, summary: By Colin Kellaher Shares of Regeneron Pharmaceuticals Inc. rose sharply in premarket trading Thursday after the biotechnology company and partner Sanofi SA..., Headline: The Fed pivot is near, and yield curve inversion has likely peaked. That`s usually bad news for stocks, this Fidelity strategist says., source:MarketWatch, summary: No summary, Headline: S&P 500 Futures Rise in Premarket Trading; Coinbase Global, Apellis Pharmaceuticals Lag, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (REGN) was up 6.7% in pre-market trading, and (DOOO) was up 5.0%. (ACN), (SMAR), and (FDS) were all posting..., Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC), source:TipRanks, summary: No summary, Headline: Regeneron, Sanofi say Dupixent works in COPD, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied about 7% in premarket trading on Thursday after the company said a pivotal Phase 3 clinical trial showed..., Headline: Coinbase’s stock tumbles after SEC warning, Regeneron shares rally, and other stocks on the move, source:MarketWatch, summary: Coinbase, Chewy, Regeneron, Accenture and First Republic were some of the most active shares on Thursday., Headline: Sanofi rises as analysts eye results from smoker's lung drug trial, source:Yahoo, summary: By Scott Kanowsky, Headline: Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data, source:Reuters, summary: Sanofi's asthma drug Dupixent met all targets in a trial to treat ""smoker's lung"", potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller., Headline: Early notable gainers among liquid option names on March 23rd, source:Thefly.com, summary: No summary, Headline: Regeneron upgraded to Market Perform from Underperform at Raymond James, source:Thefly.com, summary: No summary, Headline: Raymond James ups Regeneron to Market Perform as few downside catalysts remain, source:Thefly.com, summary: No summary, Headline: REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data, source:InvestorPlace, summary: No summary, Headline: Why Are Stocks Up Today?, source:InvestorPlace, summary: No summary, Headline: Regeneron up 7% following Dupixent data, Raymond James upgrade, source:Seeking Alpha, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Sanofi, Regeneron’s Drug Succeeds in High-Stakes Lung Trial, source:Yahoo, summary: (Bloomberg) -- Sanofi’s prescription drug Dupixent helped patients with a chronic lung disorder breathe better and regain lung function, opening a new avenue of growth for the blockbuster medicine. Most Read from BloombergJack Dorsey’s Block Vows to Fight Back After Hindenburg Says It’s Short the StockShort Seller Hindenburg Says ‘Another Big One’ Coming SoonUS Fears a War-Weary World May Embrace China’s Ukraine Peace BidJPMorgan Sold $10 Million in Jewels Left in Bank Safe Deposit Box, Suit Cla, Headline: Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today, source:Yahoo, summary: Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Phase 3 trial of Dupixent (dupilumab) for uncontrolled chronic obstructive pulmonary disease (COPD) met its primary and secondary endpoints. Dupixent exhibited a 30% reduction in moderate or severe acute exacerbations compared to the placebo. The Phase 3 trial involving 939 current or former smokers also showed impro, Headline: Stocks making the biggest moves midday: Netflix, Block, Snap, KB Home and more, source:CNBC, summary: Block fell after Hindenburg Research unveiled its latest short position on the stock. KB Home popped on earnings. , Headline: Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?, source:Yahoo, summary: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says..., Headline: Sanofi, Regeneron shares pop more than 6% after data shows asthma drug Dupixent may also treat COPD, source:CNBC, summary: Sanofi and Regeneron unveiled data on their jointly developed drug for a difficult-to-treat chronic lung disorder that analysts say ""exceeded expectations."", Headline: Why Shares of Regeneron Are Rising Thursday, source:Yahoo, summary: Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) were up as much as 8.2% on Thursday morning after the biotech company announced positive news on Thursday for a phase 3 trial for Dupixent (dupilumab) to treat patients with chronic obstructive pulmonary disease (COPD).  Regeneron's shares are up more than 18% this year, and the stock has a 52-week low of $538.01 and a 52-week high of $812.69.  Regeneron partnered with Sanofi (NASDAQ: SNY) on the phase 3 trial and said it met all primary and secondary endpoints compared to a placebo on patients with uncontrolled COPD and evidence of type 2 inflammation., Headline: KB Home, Worthington rise; MillerKnoll, Trupanion fall, source:Associated Press, The, summary: No summary, Headline: Pharma delivers, for others, source:Reuters, summary: (The author is a Reuters Breakingviews columnist. The opinions expressed are their own.), Headline: Health Care Down as Sanofi, Regeneron Rise -- Health Care Roundup, source:MarketWatch, summary: Health-care companies fell, but not by as much as the broad market, amid optimism about drug developments. Regeneron shares rallied after the biotech concern..., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 6.77% to $802.16 Thursday, on what proved to be an all-around favorable trading session for the stock..., Headline: Sanofi's (SNY) Dupixent Meets Goal in Pivotal COPD Study, source:Yahoo, summary: Sanofi (SNY) and partner Regeneron's (REGN) Dupixent led to a 30% decline in exacerbations per a late-stage pivotal study on chronic obstructive pulmonary disease., Headline: ADRs End Mostly Higher, Tencent and Sanofi Trade Actively, source:MarketWatch, summary: By Sabela Ojea International stocks trading in New York closed mostly higher on Thursday. The S&P/BNY Mellon index of American depositary receipts rose 0.5%..., Headline: Options Action: Regeneron in reverse?, source:CNBC, summary: Optimize Advisors' Mike Khouw looks at bearish options bets on Regeneron. With CNBC's Melissa Lee and the Fast Money traders, Karen Finerman, Tim Seymour, Guy Adami and Dan Nathan., Headline: Regeneron's Dupixent shows promise as COPD treatment, source:CNBC, summary: CNBC's Meg Tirrell joins 'Closing Bell' to report that Regeneron's drug Dupixent has shown promise in treating COPD during phase 3 results., Headline: Regeneron Breaks Out On Home Run In 'Smoker's Lung' As Sanofi Soars, source:Yahoo, summary: Sanofi and Regeneron's asthma drug Dupixent succeeded in a study of patients with ""smoker's lung,"" leading SNY and REGN stocks to rocket., Headline: Regeneron May Win Big with New Drug, source:TipRanks, summary: No summary, Headline: What You Missed On Wall Street On Friday, source:Thefly.com, summary: No summary",REGN
156,2023-03-24,"Headline: Regeneron upgraded to Buy from Hold at Jefferies, source:Thefly.com, summary: No summary, Headline: Regeneron upgraded to Buy on COPD opportunity at Jefferies, source:Thefly.com, summary: No summary, Headline: Regeneron price target raised to $915 from $815 at Barclays, source:Thefly.com, summary: No summary, Headline: Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Morgan Stanley Reaffirms Their Buy Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron price target raised to $800 from $756 at Baird, source:Thefly.com, summary: No summary, Headline: Regeneron price target raised to $915 from $860 at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Regeneron (REGN) Soars 6.8%: Is Further Upside Left in the Stock?, source:Yahoo, summary: Regeneron (REGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road., Headline: Regeneron draws more bullish views from analysts after Dupixent COPD data, source:Seeking Alpha, summary: No summary, Headline: GLOBAL BROKER RATINGS: Jefferies says 'buy' Regeneron and 'hold' UBS, source:Alliance News, summary: No summary, Headline: Regeneron price target raised to $1,040 from $1,025 at BMO Capital, source:Thefly.com, summary: No summary, Headline: First Republic, Deutsche Bank, Chevon, Block fall premarket; Regeneron rises, source:Yahoo, summary: By Peter Nurse, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: 5 analyst picks of the day: Nike upped on Q3 beat | Pro Recap, source:Yahoo, summary: Barclays upgraded  Nike  (NYSE:NKE) to Overweight from Equalweight and raised its price target to $154.00 from $110.00 on its belief in a high probability of margin upside.  The company reported its Q3 earnings results on Tuesday, which, according to Barclays, demonstrated the company’s “broad-based brand strength in spite of a weakening consumer macro backdrop.”  Q3 EPS came in at $0.79, better than the consensus estimate of $0.55., Headline: ETFs in Focus on Sanofi and Regeneron's COPD Drug Data, source:Yahoo, summary: Shares of drugmakers Sanofi and Regeneron surged more than 6% on Mar 23 on COPD drug data., Headline: Pharma Stock Roundup: SNY's COPD Study Meets Goal, ABBV Parkinson's Drug Gets CRL, source:Yahoo, summary: Sanofi's (SNY) Dupixent succeeds in a pivotal study for COPD. FDA gives CRL to AbbVie's (ABBV) Parkinson's disease therapy, ABBV-951, Headline: Stocks making the biggest moves midday: Block, Deutsche Bank, GameStop, Activision and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Regeneron’s Asthma Drug Results Were ‘Stellar.’ Analyst Sees a Sales Bonanza., source:Yahoo, summary: The company and its partner Sanofi presented data from a trial of the drug as a treatment for chronic obstructive pulmonary disease., Headline: Wall Street Has High Hopes for These 2 Nasdaq Stocks, source:Yahoo, summary: The stock market started out on an uncertain note on Friday, initially falling but cutting its losses in the first hour of the trading day.  Two that they recently focused on were Regeneron Pharmaceuticals (NASDAQ: REGN) and Cracker Barrel Old Country Store (NASDAQ: CBRL).  Although the duo are in very different industries and don't necessarily have much in common other than being listed on the Nasdaq, positive assessments from stock analysts indicate optimism about the prospects for their respective businesses., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 2.22% to $820.00 Friday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Biotech Growth Stock Soars To New Highs On Lung Disease Breakthrough, source:Yahoo, summary: Growth stock Regeneron Pharmaceuticals broke out in strong volume from a flat base and 800.58 entry this week.  News of the first breakthrough in a decade for a leading cause of death drove the biotech to new highs.  On Thursday, phase 3 clinical trials showed successful results for Regeneron's Dupixent in treating chronic obstructive pulmonary disease (COPD)., Headline: Regeneron's (REGN) Dupixent Meets Pivotal COPD Study Goal, Up 7%, source:Yahoo, summary: Regeneron's (REGN) share price rose after it reported data from a late-stage study showing that treatment with Dupixent led to a 30% decline in chronic obstructive pulmonary disease exacerbations., Headline: Raymond James Upgrades Regeneron Pharmaceuticals (REGN), source:Fintel, summary: nan, Headline: Jefferies Upgrades Regeneron Pharmaceuticals (REGN), source:Fintel, summary: nan",REGN
157,2023-03-25,"Headline: Regeneron Pharmaceuticals Boosted By COPD Data, source:Seeking Alpha, summary: No summary, Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify., Headline: Regeneron and Sanofi Look for Billions From COPD Drug, source:Yahoo, summary: The companies said Dupixent showed positive results in a late-stage study of current or former smokers with the killer disease.",REGN
158,2023-03-26,"Headline: FDA PDUFA Date for Regeneron Evkeeza (evinacumab) March 30, 2023, source:Thefly.com, summary: No summary",REGN
159,2023-03-27,"Headline: Regeneron upgraded to Outperform from Market Perform at SVB Securities, source:Thefly.com, summary: No summary, Headline: SVB Securities upgrades Regeneron to Outperform, sees positive drivers ahead, source:Thefly.com, summary: No summary, Headline: REGN Crosses Above Average Analyst Target, source:ETF Channel, summary: No summary, Headline: Unity Biotech sheds 48% after mid-stage setback for wet AMD candidate, source:Seeking Alpha, summary: No summary, Headline: Amgen bid to revive cholesterol drug patents comes to U.S. Supreme Court, source:Yahoo, summary: The U.S. Supreme Court on Monday is set to hear a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc., Headline: Regeneron Pharmaceuticals Takes Over #146 Spot From Arthur J. Gallagher, source:ETF Channel, summary: No summary, Headline: The Zacks Analyst Blog Highlights Sanofi, Regeneron, AbbVie, Roche and Eli Lilly, source:Yahoo, summary: Sanofi, Regeneron, AbbVie, Roche and Eli Lilly are included in this Analyst Blog., Headline: Video: S&P 500 Analyst Moves: REGN, source:Market News Video, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Final Trades: Regeneron, Hess & Bank of America, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: UPDATE 1-U.S. Supreme Court hears Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: The U.S. Supreme Court on Monday began hearing a bid by Amgen Inc to revive patents on its cholesterol-lowering drug Repatha in a legal effort that rival Sanofi SA called a ""blatant attempt"" to squeeze competitors out of the market.  Amgen is appealing a lower court's ruling that invalidated two of its patents on Repatha, a drug that can reduce risk of heart attack and stroke in people with heart disease, after a legal fight with French drugmaker Sanofi and its partner Regeneron Pharmaceuticals Inc., Headline: Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.05% higher to $820.41 Monday, on what proved to be an all-around great trading session for the stock..., Headline: UNITY Biotechnology's Wet AMD Candidate Flunks On Non-Inferiority Threshold Compared To Regeneron's Drug, source:Yahoo, summary: UNITY Biotechnology Inc (NASDAQ: UBX) announced results from Part A of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy. UBX1325 treatment generally maintained visual acuity for six months, with most patients not requiring anti-VEGF rescue. Patients in the every 8-week Rengeron Pharmaceuticals Inc (NASDAQ: REGN) Eylea (aflibercept) arm had an early and unexpected gain of 3, Headline: SVB Leerink Upgrades Regeneron Pharmaceuticals (REGN), source:Fintel, summary: nan, Headline: Amgen-Sanofi patent case divides makers of antibody drugs, source:Yahoo, summary: Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.  In the dispute with Sanofi and partner Regeneron, whose cholesterol-lowering monoclonal antibody drug Praluent works in a similar way as Repatha, Amgen wants the court to rule on how much information it and others need to disclose when describing inventions in patents.",REGN
160,2023-03-28,"Headline: RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals, Sonoma Biotherapeutics announce collaboration, source:Thefly.com, summary: No summary, Headline: Immuneering appoints Harold Brakewood as CBO, source:Thefly.com, summary: No summary, Headline: Regeneron to pay Sonoma $75M upfront in pact to develop autoimmune disease drugs, source:Seeking Alpha, summary: No summary, Headline: Regeneron resumed with a Buy at Erste Group, source:Thefly.com, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases, source:Yahoo, summary: SOUTH SAN FRANCISCO, Calif. & TARRYTOWN, N.Y., March 28, 2023--Sonoma Biotherapeutics and Regeneron Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases, Headline: Regeneron and Sonoma Biotherapeutics Announce Collaboration to Discover, Develop and Commercialize Treg Cell Therapies for Autoimmune Diseases, source:Yahoo, summary: Sonoma Biotherapeutics to receive $75 million upfront, inclusive of $45 million cash and $30 million equity investment; potential for an additional $45 million development milestone paymentTARRYTOWN, N.Y., and SOUTH SAN FRANCISCO, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sonoma Biotherapeutics, Inc. today announced a collaboration to apply their scientific and clinical expertise and respective technology platforms to the discovery, development, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.80% higher to $826.97 Tuesday, on what proved to be an all-around poor trading session for the stock..., Headline: Unity (UNX) Down on Disappointing Results From Wet AMD Study, source:Yahoo, summary: Unity's (UBX) phase II ENVISION study on UBX1325 fails to meet the non-inferiority threshold compared to aflibercept through 24 weeks in the wet AMD study.",REGN
161,2023-03-29,"Headline: Amgen, AstraZeneca`s asthma therapy Tezspire gets UK`s NICE backing, source:Seeking Alpha, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Intra-Cellular Therapies (ITCI) and uniQure (QURE), source:TipRanks, summary: No summary, Headline: Regeneron price target raised to $650 from $605 at BofA, source:Thefly.com, summary: No summary, Headline: Regeneron announces EC approved Libtayo in combination with chemotherapy, source:Thefly.com, summary: No summary, Headline: Regeneron Libtayo gets expanded approval in EU for lung cancer subtype, source:Seeking Alpha, summary: No summary, Headline: Kodiak Q4 update had `a few nice surprises,` says Capital One, source:Thefly.com, summary: No summary, Headline: Libtayo® (cemiplimab) in Combination with Chemotherapy Approved by European Commission for the First-line Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC), source:Yahoo, summary: Libtayo-based combination demonstrated superior survival outcomes compared to chemotherapy alone in Phase 3 trial designed to include patients with varied disease presentations seen in everyday clinical practice Approval marks second first-line indication in NSCLC and fifth indication for Libtayo in the European Union (EU) TARRYTOWN, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo® (cemipli, Headline: Regeneron Shares Rally on Heavy Demand and Strong Fundamentals, source:Yahoo, summary: Regeneron Pharmaceuticals (REGN) has been a bright spot in the market lately., Headline: Biotech Stock Roundup: VKTX, BMEA, ITCI Soar on Study Data, INCY Faces Setback, source:Yahoo, summary: Pipelines updates from Viking Therapeutics (VKTX) and Intra-Cellular (ITCI) are the key highlights for the biotech sector., Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.92% to $819.35 Wednesday, on what proved to be an all-around positive trading session for the stock..., Headline: FDA PDUFA Date for Regeneron Evkeeza (evinacumab) March 30, 2023, source:Thefly.com, summary: No summary",REGN
162,2023-03-30,"Headline: Regeneron in research agreement with Xeris Biopharma, source:Seeking Alpha, summary: No summary, Headline: Regeneron price target raised to $940 from $925 at Jefferies, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.96% to $811.50 Thursday, on what proved to be an all-around great trading session for the stock market, with...",REGN
163,2023-03-31,"Headline: Regeneron price target raised to $950 from $900 at JPMorgan, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.25% to $821.67 Friday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Regeneron (REGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed at $821.67 in the latest trading session, marking a +1.25% move from the prior day.",REGN
164,2023-04-03,"Headline: Capital One remains bullish on RPT193 as Rapt initiates Phase 2a Asthma study, source:Thefly.com, summary: No summary, Headline: Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags, source:TalkMarkets, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.55% higher to $826.19 Monday, on what proved to be an all-around positive trading session for the stock..., Headline: Regeneron to Report First Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2023, source:Yahoo, summary: TARRYTOWN, N.Y., April 03, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2023 financial and operating results on Thursday, May 4, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ‘Investors and Media’ page of Regeneron’s website",REGN
165,2023-04-04,"Headline: $6 billion in college scholarships are awarded each year. Here's what you need to know about applying, source:CNBC, summary: Winning a scholarship can help students graduate with less student debt. Here's what you need to know about the awards. , Headline: One Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) insider reduced their stake by 26% in the previous year, source:Yahoo, summary: Looking at Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) insider transactions over the last year, we can see that..., Headline: Why Investors Need to Take Advantage of These 2 Medical Stocks Now, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. sank 0.50% to $822.09 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",REGN
166,2023-04-05,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $825.22 Wednesday, on what proved to be an all-around mixed trading session for the stock...",REGN
167,2023-04-06,"Headline: 2 Top Growth Stocks That Could Soar This Spring, source:Yahoo, summary: Exciting news on the way for both of these companies could send their stock prices screaming higher., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.43% higher to $828.73 Thursday, on what proved to be an all-around favorable trading session for the stock...",REGN
168,2023-04-07,"Headline: Analysts Conflicted on These Healthcare Names: Alnylam Pharma (ALNY), Amgen (AMGN) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?, source:Yahoo, summary: Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",REGN
169,2023-04-08,"Headline: A Look At The Intrinsic Value Of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), source:Yahoo, summary: Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,032 based on 2 Stage Free Cash Flow to...",REGN
170,2023-04-09,"Headline: Investing $1,000 In These 2 Top Stocks Would Be a Great Move, source:Yahoo, summary: For those with $1,000 that isn't being saved for emergencies, here are two excellent stocks to buy today: HCA Healthcare (NYSE: HCA) and Regeneron (NASDAQ: REGN).  HCA Healthcare is a leading hospital chain in the U.S. It makes money based on occupancy rates in its 182 hospitals (among other facilities) and based on the services physicians order for their patients.  For instance, occupancy levels in HCA Healthcare's hospitals would soar along with the number of cases of COVID-19 and then drop back down, sometimes rendering year-over-year comparisons difficult.",REGN
171,2023-04-10,"Headline: Regeneron Pharmaceuticals Q1 one-off charges to be ~$56M, source:Seeking Alpha, summary: No summary, Headline: GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market, source:Seeking Alpha, summary: No summary, Headline: GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market, source:SeekingAlpha, summary: GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here., Headline: U.S. launches $5B program to speed up development of next-gen COVID vaccines, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.60% to $823.76 Monday, on what proved to be an all-around positive trading session for the stock market,...",REGN
172,2023-04-11,"Headline: IN BRIEF: Regeneron expects USD56 million hit in first quarter, source:Alliance News, summary: No summary, Headline: 12 Best Covid Treatment Stocks to Buy Today, source:Yahoo, summary: In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […], Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.50% to $819.64 Tuesday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Regeneron Announces Investor Conference Presentations, source:Yahoo, summary: TARRYTOWN, N.Y., April 11, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: BofA Securities 2023 Health Care Conference at 1:40 p.m. PT (4:40 p.m. ET) on Tuesday, May 9, 20232023 RBC Capital Markets Global Healthcare Conference at 9:30 a.m. ET on Tuesday, May 16, 2023 The sessions may be accessed from the ""Investors & Media"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of t, Headline: Why Healthcare Stocks Are A Prescription For Investors In Q2 2023, source:SeekingAlpha, summary: The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.",REGN
173,2023-04-12,"Headline: S&P 500 will see 11% upside from the current levels - Piper Sandler`s Craig Johnson, source:Seeking Alpha, summary: No summary, Headline: Regeneron price target lowered to $880 from $883 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.10% higher to $820.43 Wednesday, on what proved to be an all-around poor trading session for the stock...",REGN
174,2023-04-13,"Headline: Regeneron: New Highs Following Dupixent`s COPD Data, source:Seeking Alpha, summary: No summary, Headline: Regeneron: New Highs Following Dupixent's COPD Data, source:SeekingAlpha, summary: Regeneron shares jumped to new all-time highs following the successful phase 3 results of Dupixent in COPD. See why I think REGN stock is well-positioned to grow., Headline: Intellia up 12% as Canaccord starts with Buy citing gene editing approach, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.21% to $830.35 Thursday, on what proved to be an all-around favorable trading session for the stock...",REGN
175,2023-04-14,"Headline: Ghana 1st in world to approve new malaria vaccine by Oxford, source:Seeking Alpha, summary: No summary, Headline: Are Strong Financial Prospects The Force That Is Driving The Momentum In Regeneron Pharmaceuticals, Inc.'s NASDAQ:REGN) Stock?, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ:REGN) has had a great run on the share market with its stock up by a significant 15..., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.12% to $829.33 Friday, on what proved to be an all-around poor trading session for the stock market, with...",REGN
176,2023-04-16,"Headline: Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air, source:Seeking Alpha, summary: No summary",REGN
177,2023-04-17,"Headline: Regeneron aflibercept, EYLEA Injection to be featured at ARVO 2023 meeting, source:Thefly.com, summary: No summary, Headline: Regeneron announces retirement of board chair, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Chairman P. Roy Vagelos to Retire, source:MarketWatch, summary: By Colin Kellaher Regeneron Pharmaceuticals Inc. on Monday said its longtime chairman, P. Roy Vagelos, plans to retire in June. The Tarrytown, N.Y.,..., Headline: IN BRIEF: Regeneron Chair to retire; CEO and CSO to become co-chairs, source:Alliance News, summary: No summary, Headline: Aflibercept 8 mg and EYLEA® (aflibercept) Injection Presentations at ARVO Provide New Insights into the Treatment of Serious Retinal Diseases, source:Yahoo, summary: New subgroup data and further analyses of the aflibercept 8 mg clinical trial program to highlight durability results of extended dosing intervals, patient characteristics, and efficacy and safety in wet age-related macular degeneration and diabetic macular edema 18 presentations reinforce Regeneron’s commitment to patients with serious retinal diseases TARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and its collaborator Bayer today announced th, Headline: Regeneron Announces Retirement of Board Chair, Dr. P. Roy Vagelos, Accomplished Physician-Businessman and Industry Luminary, source:Yahoo, summary: Dr. Leonard S. Schleifer and Dr. George D. Yancopoulos to become Co-Chairs of the Board and Christine A. Poon to be named Lead Independent DirectorTARRYTOWN, N.Y., April 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that P. Roy Vagelos, M.D., will retire from his role as Chair of the Company’s Board of Directors and will not stand for reelection at the Company’s 2023 Annual Meeting of Shareholders. Dr. Vagelos has served as Chair since January 1995 a, Headline: Regeneron Set to Reach New Heights: $1,000 in Sight?, source:Yahoo, summary: Biotechnology company Regeneron Pharmaceuticals has posted strong stock gains since June but further gains look likely in the weeks and months ahead. Let's check out the charts. In the daily bar chart of REGN, below, I see a positive-looking picture., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.16% to $819.74 Monday, on what proved to be an all-around positive trading session for the stock market,...",REGN
178,2023-04-18,"Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their splendid 159% return over the last five years, source:Yahoo, summary: The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.43% to $808.01 Tuesday, on what proved to be an all-around mixed trading session for the stock market,..., Headline: Healthcare Shares Fall; J&J Boosts Earnings Outlook -- Healthcare Roundup, source:MarketWatch, summary: Healthcare companies sank as investors rotated into stocks with more to gain from a strong economy. Johnson &amp; Johnson raised its full-year sales and..., Headline: Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), UnitedHealth (UNH) and Sarepta Therapeutics (SRPT), source:TipRanks, summary: No summary",REGN
179,2023-04-19,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.11% higher to $808.86 Wednesday, on what proved to be an all-around rough trading session for the stock...",REGN
180,2023-04-20,"Headline: Regeneron price target raised to $885 from $875 at TD Cowen, source:Thefly.com, summary: No summary, Headline: Sensei gains FDA IND clearance for solid tumors candidate, source:Seeking Alpha, summary: No summary, Headline: Jefferies Reaffirms Their Buy Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: The Greatest 7 Blue-Chip Stocks to Buy for Your Portfolio, source:Yahoo, summary: While the debate will certainly rage over which ideas legitimately rank as the greatest blue-chip stocks to buy of all time, for right now, certain enterprises stand out for a combination of their relevance and resilience. As well, a select few large-capitalization companies may be too undervalued and beaten down for their own good. Therefore, speculators may enjoy significant upside. To generate this list, I turned to the investment resource Gurufocus, specifically its screener function. Here,, Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.33% to $798.10 Thursday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: TD Cowen Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation, source:Fintel, summary: nan",REGN
181,2023-04-21,"Headline: Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: Intellia Therapeutics: Signs Of Possible Life, source:SeekingAlpha, summary: nan, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.33% higher to $800.73 Friday, on what proved to be an all-around favorable trading session for the stock..., Headline: Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Regeneron (REGN) closed at $800.73, marking a +0.33% move from the previous day.",REGN
182,2023-04-24,"Headline: Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?, source:Yahoo, summary: Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously..., Headline: 4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates, source:Yahoo, summary: We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.46% to $797.04 Monday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Unity Touts Positive Data From Diabetic Macular Edema Study, Plans Head-To-Head Study With Regeneron's Eylea, source:Yahoo, summary: UNITY Biotechnology Inc (NASDAQ: UBX) announced results from the long-term follow-up of the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). Patients taking UBX1325 saw a mean change in best-corrected visual acuity of +6.2 ETDRS letters from baseline, a statistically significant result (p=0.0037). At 48 weeks, Unity also noted a difference of +5.6 ETDRS letters compared to sham-treated patients, but that part of the result was not statistically significant (p=0.1198",REGN
183,2023-04-25,"Headline: 3 Biotech Stocks To Watch Today, source:StockMarket, summary: Biotech stocks for your late-April 2023 watchlist., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.94% to $789.58 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with...",REGN
184,2023-04-26,"Headline: Partial clinical hold placed on Alnylam, Regeneron RNAi Alzheimer`s candidate, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Akebia Therapeutics (AKBA) and Panbela Therapeutics (PBLA), source:TipRanks, summary: No summary, Headline: Democratic senators introduce bill to enhance CMS drug price negotiations, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.47% to $778.00 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, source:Yahoo, summary: - Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging Clinical Safety and Tolerability Profile Observed with Single Dosing to Date - - Results Provide First Demonstration of Gene Silencing by RNAi Therapeutics in the Human Brain Using Alnylam's Proprietary C16 Platform - TARRYTOWN, N.Y. and CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals,, Headline: Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy, source:Yahoo, summary: CAMBRIDGE, Mass. & TARRYTOWN, N.Y., April 26, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).",REGN
185,2023-04-27,"Headline: Sanofi Q1 profit climbs on Dupixent as drug on track for ���10B this year, source:Seeking Alpha, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Edwards Lifesciences (EW), Humana (HUM), source:TipRanks, summary: No summary, Headline: Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?, source:Yahoo, summary: Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.84% to $792.29 Thursday, on what proved to be an all-around positive trading session for the stock..., Headline: Alnylam - Regeneron Partnered Alzheimer's Candidate's Initial Data Sounds Promising, Analyst Says, source:Yahoo, summary: Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) and its partner Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced preliminary data from their Phase I study of their experimental drug dubbed ALN-APP. ALN-APP is an investigational RNAi therapeutic targeting amyloid precursor protein (APP, a brain protein) in development for Alzheimer's disease and cerebral amyloid angiopathy (CAA). Patients treated with single-dose ALN-APP experienced dose-dependent, rapid and sustained reduction in cerebrospinal, Headline: Regeneron (REGN) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Regeneron (REGN) closed at $792.29, marking a +1.84% move from the previous day.",REGN
186,2023-04-28,"Headline: Stock Charts Strategy, May 1-5: Fed Policy, April Payrolls, Apple Earnings, source:Yahoo, summary: Fed policy and April payrolls may influence the stock market, but earnings will have Apple, Vertex and Albemarle stock charts in focus., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.20% to $801.79 Friday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
187,2023-05-01,"Headline: Analysts Offer Insights on Healthcare Companies: TG Therapeutics (TGTX), PTC Therapeutics (PTCT) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Small & Mid Cap Life Science Stock Portfolio: Some Good Picks In A Stalled Sector, source:TalkMarkets, summary: No summary, Headline: Is a Beat on the Cards for Regeneron's (REGN) Q1 Earnings?, source:Yahoo, summary: Regeneron's (REGN) first-quarter earnings are likely to have gotten a boost from the solid performance of Dupixent., Headline: EF Hutton Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.61% higher to $806.72 Monday, on what proved to be an all-around grim trading session for the stock market,...",REGN
188,2023-05-02,"Headline: Regeneron to highlight new, updates data at ASCO, source:Thefly.com, summary: No summary, Headline: Regeneron to Highlight New and Updated Clinical Data at ASCO Showcasing Breadth of Cancer Research, source:Yahoo, summary: Oral presentations include interim results from pivotal trial of linvoseltamab (BCMAxCD3) in relapsed/refractory multiple myeloma and three cohorts of fianlimab (LAG-3 inhibitor) combined with Libtayo® (cemiplimab-rwlc) in advanced melanoma Ten total presentations to cover clinical research across six solid tumors and blood cancers TARRYTOWN, N.Y., May 02, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the presentation of new and updated data from its div, Headline: These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: LGND vs. REGN: Which Stock Is the Better Value Option?, source:Yahoo, summary: LGND vs. REGN: Which Stock Is the Better Value Option?, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.03% to $798.45 Tuesday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: Regeneron looks to strong Dupixent, Eylea sales in Q1 report, source:Seeking Alpha, summary: No summary",REGN
189,2023-05-03,"Headline: Regeneron price target raised to $1,050 from $856 at Truist, source:Thefly.com, summary: No summary, Headline: Why Earnings Season Could Be Great for Regeneron (REGN), source:Yahoo, summary: Regeneron (REGN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season., Headline: Regeneron Pharmaceuticals Q1 2023 Earnings Preview, source:Seeking Alpha, summary: No summary, Headline: Drug, Biotech Stocks' Q1 Earnings on May 4: REGN, ZTS & More, source:Yahoo, summary: Let us look at four big drug and biotech companies, REGN, ZTS, MRNA and NVO, which are gearing up for their earnings release., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.59% higher to $803.17 Wednesday, on what proved to be an all-around dismal trading session for the stock..., Headline: GLOBAL BRIEFING: China's manufacturing weakens; Fed enacts 25bp hike, source:Alliance News, summary: No summary",REGN
190,2023-05-04,"Headline: Regeneron reports Q1 adjusted EPS $10.09, consensus $9.56, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Non-GAAP EPS of $10.09 beats by $0.53, revenue of $3.16B beats by $160M, source:Seeking Alpha, summary: No summary, Headline: Regeneron stock dips amid decline in Eylea sales despite Q1 beat, source:Seeking Alpha, summary: No summary, Headline: Regeneron: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Regeneron Posts Higher 1Q Sales, Boosted by Sanofi Work, source:MarketWatch, summary: By Will Feuer Regeneron Pharmaceuticals posted higher first-quarter sales, lifted by its collaboration with Sanofi. The Tarrytown, N.Y.-based company..., Headline: Regeneron tops Q1 estimates but lowers margin guidance, sending stock lower, source:MarketWatch, summary: Regeneron Pharmaceuticals Inc. ‘s stock slid 4% premarket Thursday, after the company topped estimates for first-quarter earnings but lowered margin guidance..., Headline: Truist Securities Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Regeneron Reports First Quarter 2023 Financial and Operating Results, source:Yahoo, summary: First quarter 2023 revenues increased 7% to $3.16 billion versus first quarter 2022First quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus first quarter 2022First quarter 2023 EYLEA® U.S. net sales were $1.43 billionFirst quarter 2023 GAAP diluted EPS of $7.17 and non-GAAP diluted EPS(a) of $10.09; includes unfavorable $0.42 impact from acquired IPR&D chargeEuropean Commission approved Dupixent for atopic dermatitis in children aged 6 months to 5, Headline: Goldman Sachs Keeps Their Buy Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: CORRECTED-Regeneron beats quarterly profit estimates , source:Reuters, summary: Regeneron Pharmaceuticals Inc beat Wall Street estimates for first-quarter profit on Thursday, driven by strong demand for eczema treatment Dupixent., Headline: Regeneron (REGN) Q1 Earnings and Revenues Top Estimates, source:Yahoo, summary: Regeneron (REGN) delivered earnings and revenue surprises of 9.08% and 8.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Intellia jumps 13% after Q1 updates, source:Seeking Alpha, summary: No summary, Headline: Here's What Key Metrics Tell Us About Regeneron (REGN) Q1 Earnings, source:Yahoo, summary: While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended March 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values., Headline: Regeneron's Eylea drug sales hit by competition from 'new kid in town', source:Reuters, summary: Regeneron Pharmaceuticals Inc's first-quarter sales of blockbuster eye drug Eylea came in below Wall Street targets on Thursday as competition heated up, dragging the company's shares more than 5% lower in early trade., Headline: Regeneron Pharmaceuticals Inc. (REGN) Q1 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Q1 2023 Results Conference Call May 4, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Investor RelationsLeonard Schleifer - Chief..., Headline: Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline, source:Yahoo, summary: Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 6.14% to $753.88 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Why Regeneron Pharmaceuticals Stock Is Tanking Today, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ: REGN), a large-cap biotechnology company, is under heavy pressure today.  Specifically, the biotech's stock was down by an unsightly 6.5% on heavy volume as of 12:19 p.m. ET Thursday afternoon.  Regeneron's shares are moving southward in response to lower-than-expected sales of its flagship eye-care treatment, Eylea, during the first quarter of 2023., Headline: Why Regeneron Pharmaceuticals Shares Are Trading Lower Today, source:Yahoo, summary: Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned adjusted EPS of $10.09, down 12% Y/Y, beating the $9.60 Street estimate. Revenues decreased 6% Y/Y to $3.16 billion, down from $3.41 billion in Q4 FY22, beating the consensus of $3.00 billion. Revenues from REGEN-COV, covid-19 antibody cocktail, reached $613.2 million, down 4% Y/Y. In the first quarter of 2023, Dupixent global net sales (recorded by Sanofi) increased 37% to $2.49 billion versus the first quarter of 2022. Eylea U.S. net sales de, Headline: Regeneron Sacrifices A Breakout As Competition Hammers At Its Biggest Moneymaker, source:Yahoo, summary: The struggles continued for Regeneron's blockbuster eye disease treatment, Eylea, in the first quarter — leading REGN stock to dive Thursday., Headline: Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call, source:Yahoo, summary: Q1 2023 Regeneron Pharmaceuticals Inc Earnings Call",REGN
191,2023-05-05,"Headline: Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Regeneron (REGN) and Puma Biotechnology (PBYI), source:TipRanks, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Ultragenyx Pharmaceutical (RARE) and Surface Oncology (SURF), source:TipRanks, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Regeneron price target lowered to $895 from $976 at SVB Securities, source:Thefly.com, summary: No summary, Headline: Regeneron price target raised to $927 from $880 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Insider Lowered Holding By 26% During Last Year \, source:Yahoo, summary: From what we can see, insiders were net sellers in Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) during the past 12..., Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.09% to $762.10 Friday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan",REGN
192,2023-05-08,"Headline: Regeneron price target lowered to $935 from $960 at Guggenheim, source:Thefly.com, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Karuna Therapeutics (KRTX) and Pennant Group (PNTG), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.31% to $752.12 Monday, on what proved to be an all-around mixed trading session for the stock market, with...",REGN
193,2023-05-09,"Headline: Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 29% Discount?, source:Yahoo, summary: Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,053 based on 2 Stage Free Cash Flow to..., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.37% higher to $754.88 Tuesday, on what proved to be an all-around dismal trading session for the stock..., Headline: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2023 Earnings Call Transcript May 4, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.09, expectations were $9.56. Operator: Welcome to the Regeneron Pharmaceuticals First Quarter 2023 Earnings Conference Call. My name is Josh, and I will be your operator for today’s call. At this time, all participants […], Headline: 15 Biggest Immunotherapy Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […], Headline: Notable Wednesday Option Activity: REGN, YETI, RNG, source:Stock Options Channel, summary: No summary, Headline: Q1 2023 Xeris Biopharma Holdings Inc Earnings Call, source:Yahoo, summary: Q1 2023 Xeris Biopharma Holdings Inc Earnings Call",REGN
194,2023-05-10,"Headline: Alvotech, Polifarma ink pact to sell potential Eylea biosimilar in Turkey, source:Seeking Alpha, summary: No summary, Headline: 2 Cathie Wood Stocks That Can Get You Through Any Recession, source:Yahoo, summary: Economists at the U.S. Federal Reserve recently uttered the dreaded ""R"" word. They are now predicting a recession will come later this year. Investors have been bracing for this possibility for a while now, so it shouldn't come as too much of a surprise., Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.70% to $749.59 Wednesday, on what proved to be an all-around mixed trading session for the stock market,...",REGN
195,2023-05-11,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. sank 0.54% to $745.57 Thursday, on what proved to be an all-around rough trading session for the stock market, with...",REGN
196,2023-05-12,"Headline: Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.16% to $744.35 Friday, on what proved to be an all-around poor trading session for the stock market, with the...",REGN
197,2023-05-13,"Headline: Regeneron Pharmaceuticals, Inc. (REGN) Bank of America Global Healthcare Conference Call Transcript, source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Bank of America Global Healthcare Conference Call May 9, 2023 4:40 PM ETCompany ParticipantsRyan Crowe - VP, IRRobert Landry - EVP,...",REGN
198,2023-05-15,"Headline: CEO Pay Packages Fell Sharply in 2022 as the Stock Market Sank, source:Yahoo, summary: The annual WSJ analysis of compensation for CEOs in the S&P 500 reveals that the median pay held steady. But in a first, companies are also disclosing how much those pay packages rose or fell in the year., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.89% higher to $750.96 Monday, on what proved to be an all-around great trading session for the stock...",REGN
199,2023-05-16,"Headline: Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Viking Therapeutics (VKTX) and UpHealth (UPH), source:TipRanks, summary: No summary, Headline: What To Expect From GSK In 2023, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ:REGN) has had a rough month with its share price down 9.4%. However, stock prices are..., Headline: Regeneron Pharmaceuticals, Inc. (REGN) 2023 RBC Capital Markets Global Healthcare Conference Transcript, source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 9:30 AM ETCompany ParticipantsAris Baras â Senior Vice President,..., Headline: RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.16% to $742.28 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Regeneron CEO backs regulators attempt to block Amgen deal, FT reports, source:Thefly.com, summary: No summary",REGN
200,2023-05-17,"Headline: Regeneron boss backs attempt to block $28bn Amgen acquisition, source:Yahoo, summary: The Regeneron chief executive has backed an attempt by US regulators to block Amgen’s $28bn acquisition of Horizon Therapeutics as he accused some pharmaceutical companies of abusing their market power to prevent competition.  Leonard Schleifer said he supported the US Federal Trade Commission’s decision to tackle a “new area” after the agency made its first attempt to block a pharma deal in over a decade by filing a novel lawsuit against the Amgen transaction.  Drugmakers pay rebates to ensure their treatment is placed on the lists of drugs covered by insurance companies., Headline: Regeneron CEO supports FTC suit against Amgen acquisition of Horizon - FT, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.99% higher to $749.63 Wednesday, on what proved to be an all-around positive trading session for the stock..., Headline: The 7 Growth Stocks You Need to Own Now for Maximum Returns, source:Yahoo, summary: Although recent headwinds like stubbornly high inflation and the banking sector crisis knocked the wind out of several publicly traded enterprises, a select number of hardened survivors potentially represent growth stocks to buy now. Using Gurufocus, all the companies below feature (on a per-share basis) five-year and ten-year growth rates of 20% and 15%, respectively. However, companies that rank among the growth stocks to own may have already run their course; that is to say, there might not b",REGN
201,2023-05-18,"Headline: Anticompetitive Behavior At United Therapeutics, Regeneron, And The FTC, source:SeekingAlpha, summary: Much of what the FTC attacks isnât anticompetitive, itâs competitive. Click here to find out more on HZNP and LQDA., Headline: Regeneron `applauds` Supreme Court`s striking down Amgen`s patent claims, source:Thefly.com, summary: No summary, Headline: Sanofi `pleased` with Supreme Court`s ruling on Amgen`s asserted patent claims, source:Thefly.com, summary: No summary, Headline: Ocular Therapeutix: I Still Don`t See The Need, source:Seeking Alpha, summary: No summary, Headline: Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen, source:MarketWatch, summary: By Denny Jacob Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court opinion affirms a lower court opinion that held Amgen's asserted U.S. PCSK9..., Headline: Ocular Therapeutix: I Still Don't See The Need, source:SeekingAlpha, summary: Ocular Therapeutix is up since my last article. I am neutral to bearish because I don't see the molecule making a space for itself. Click here for more on OCUL., Headline: UPDATE 1-U.S. Supreme Court rules against Amgen bid to revive cholesterol drug patents, source:Yahoo, summary: The U.S. Supreme Court on Thursday ruled against Amgen Inc in its bid to revive patents on its cholesterol-lowering drug Repatha over a legal challenge by French rival Sanofi SA.  The nine justices unanimously upheld a lower court's ruling that had invalidated Amgen's patents on the grounds that the Thousand Oaks, California-based drugmaker had failed to provide a roadmap for recreating the full scope of its claimed innovation.  Amgen has waged a years-long court battle to restore two of its patents on Repatha, a drug that can reduce the risk of heart attack and stroke in people with heart disease, stemming from a legal fight with Sanofi and its partner Regeneron Pharmaceuticals Inc., Headline: Regeneron Applauds Supreme Court’s Unanimous Opinion Striking Down Amgen’s PCSK9 Patent Claims and Supporting Scientific Innovation, source:Yahoo, summary: Decision ends nearly decade-long patent dispute related to Regeneron-invented Praluent® (alirocumab) TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) applauds the United States Supreme Court’s unanimous opinion1 ending a nearly decade-long patent dispute related to the Regeneron-invented PCSK9 inhibitor, Praluent® (alirocumab). The decision affirms the United States Court of Appeals for the Federal Circuit’s opinion, which held that Amgen’s asserte, Headline: Sanofi Wins Supreme Court Patent Dispute With Amgen, source:Yahoo, summary: The court said Amgen patents relating to its cholesterol drug Repatha shouldn’t have been granted by the patent office, handing a victory to rival pharmaceutical firm Sanofi., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.29% to $747.48 Thursday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Regeneron Announces Investor Conference Presentations, source:Yahoo, summary: TARRYTOWN, N.Y., May 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 4th Annual Oncology Innovation Summit at 12:30 p.m. ET on Tuesday, May 30, 2023Jefferies Healthcare Conference at 8:30 a.m. ET on Wednesday, June 7, 2023 Goldman Sachs 44th Annual Global Healthcare Conference at 8:40 a.m. PT (11:40 a.m. ET) on Wednesday, June 14, 2023 The sessions may be accessed from the ""Investors & Media"" page of Regeneron, Headline: Amgen (NASDAQ:AMGN) Loses Patent Battle to Sanofi, Regeneron, source:TipRanks, summary: No summary, Headline: Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference, source:Seeking Alpha, summary: No summary",REGN
202,2023-05-19,"Headline: Regeneron Q1 Eylea miss `not about share, says Piper Sandler, source:Thefly.com, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Moderna (MRNA), Regeneron (REGN), source:TipRanks, summary: No summary, Headline: High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023, source:Yahoo, summary: $75,000 Top Award Goes to 17-year-old Kaitlyn Wang for breakthrough innovation to accelerate exoplanet discovery in the largest international STEM competition for teensTARRYTOWN, N.Y. and WASHINGTON, D.C., May 19, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world’s large, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.55% to $759.05 Friday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: Regeneron (REGN) Faces Challenges as Eylea Sales Decline, source:Yahoo, summary: Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line., Headline: High School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. and Society for Science (the Society) announced that Kaitlyn Wang, 17, of San José, CA, won the $75,000 top award in the 2023 Regeneron International Science and Engineering Fair (Regeneron ISEF), the world's largest global pre-college science and engineering competition, for a project that explored planets that orbit very close around their suns. Other top prizes went to projects in the fields of computational biology, animal sciences and neurobiology.",REGN
203,2023-05-20,"Headline: Regeneron Pharmaceuticals' (NASDAQ:REGN) investors will be pleased with their solid 158% return over the last five years, source:Yahoo, summary: When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, if you buy shares..., Headline: Regeneron, Sanofi present Dupixent late-breaking Phase 3 COPD results, source:Thefly.com, summary: No summary",REGN
204,2023-05-21,"Headline: Dupixent® (dupilumab) Late-breaking Phase 3 COPD Results Presented at ATS and Simultaneously Published in the New England Journal of Medicine, source:Yahoo, summary: Dupixent is the first and only investigational biologic for COPD that has demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo Dupixent is the first and only investigational biologic for COPD that has significantly improved lung function at 12 and 52 weeks, with numerical improvements seen as early as 2 weeks Dupixent significantly improved quality of life, with numerical improvements as early as 4 weeks after initiating treatment, and respira",REGN
205,2023-05-22,"Headline: Here's How Much $100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth Today, source:Benzinga, summary: No summary, Headline: Sanofi: smoker's lung drug benefit was swift and sustained in trial, source:Reuters, summary: The benefits of Sanofi and Regeneron's anti-inflammatory drug Dupixent set in quickly during a trial to treat ""smoker's lung"" and lasted for the duration of the 1-year study, French drugmaker Sanofi said late on Sunday., Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Bank of America Securities Keeps Their Sell Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: A Good Week For The Market But A Pause In The Biotech Rally, source:TalkMarkets, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.99% to $751.50 Monday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: Sanofi-Regeneron Highlight Dupixent Data, Say Drug Benefit Was Swift, Sustained, source:Yahoo, summary: Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) presented results from a Phase 3 study of Dupixent (dupilumab) in adults currently on maximal standard-of-care inhaled therapy (triple therapy) with uncontrolled chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation. Dupixent demonstrated a significant reduction in moderate or severe acute exacerbations by 30% compared to placebo, meeting the primary endpoint. Dupixent significantly improved lung",REGN
206,2023-05-23,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.39% to $748.56 Tuesday, on what proved to be an all-around rough trading session for the stock market,...",REGN
207,2023-05-24,"Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.49% to $737.40 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...",REGN
208,2023-05-25,"Headline: Regeneron reports 'positive' data from Fianlimab-Libtayo combo trial, source:Thefly.com, summary: No summary, Headline: Regeneron says updated Linvoseltamab data demonstrates durable responses, source:Thefly.com, summary: No summary, Headline: 14 Best Biotech Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […], Headline: Regeneron Pharmaceuticals (REGN) Shares Cross Below 200 DMA, source:Market News Video, summary: No summary, Headline: Biopharmaceutical Sector Revisited: Investor Interest Subdued, Valuations Attractive, source:SeekingAlpha, summary: The dramatic correction seems to have bottomed in June 2022, and the Biopharma ETFs have rallied since then. See if it is a good time to enter into this sector., Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.68% to $725.00 Thursday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: Fianlimab (LAG-3 inhibitor) Combined with Libtayo® (cemiplimab) Shows Clinically Meaningful and Durable Tumor Responses Across Key Advanced Melanoma Patient Populations, source:Yahoo, summary: Data demonstrate objective response rates from 56% to 63% across three independent cohorts of advanced melanoma patients – about double the rate historically seen with anti-PD-1 alone in similar settings – per trial results to be presented in an oral session at ASCO Clinically meaningful responses observed in post hoc analyses of populations of interest, including patients with poor prognosis factors, prior anti-PD-1 therapy in the adjuvant setting and varying tumor PD-L1 expression levels Pivot, Headline: Updated Linvoseltamab (BCMAxCD3) Data from Pivotal Trial Demonstrates Early, Deep and Durable Responses in Patients with Heavily Pre-treated Multiple Myeloma, source:Yahoo, summary: 71% objective response rate, with 59% of patients achieving a very good partial response or better at the recommended 200 mg dose, per new data to be shared in an oral session at ASCO Benefit also observed across prespecified subgroups, including patients with high disease burden and aggressive disease Data from this trial to form the basis of planned regulatory submissions, starting with the FDA in 2023 TARRYTOWN, N.Y., May 25, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: R, Headline: Notable Friday Option Activity: REGN, URI, KSS, source:Stock Options Channel, summary: No summary, Headline: Brandywine Global Investment Management, LLC Buys 1, Sells 4 in 1st Quarter, source:GuruFocus, summary: No summary",REGN
209,2023-05-26,"Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: No summary, Headline: TD Cowen pharma/biotech analysts hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Regeneron (REGN) Posts Upbeat Data From Multiple Myeloma Study, source:Yahoo, summary: A mid-stage study data shows that treatment with Regeneron's (REGN) experimental antibody achieved a 71% objective response rate in heavily pre-treated multiple myeloma patients.",REGN
210,2023-05-29,"Headline: Regeneron Pharmaceuticals Unusual Options Activity, source:Benzinga, summary: No summary, Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary",REGN
211,2023-05-30,"Headline: Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 4th Annual Oncology Innovation Summit (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) TD Cowen 4th Annual Oncology Innovation Summit May 30, 2023 12:30 PM ETCompany ParticipantsIzzy Lowy - SVP, Solid Organ Oncology..., Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.49% higher to $728.60 Tuesday, on what proved to be an all-around mixed trading session for the stock...",REGN
212,2023-05-31,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.96% higher to $735.56 Wednesday, on what proved to be an all-around dismal trading session for the stock...",REGN
213,2023-06-01,"Headline: Roche to divest biologics production plant in California – Reuters, source:Seeking Alpha, summary: No summary, Headline: Thursday’s Top Analyst Upgrades and Downgrades: Chevron, Coty, Twilio, Viking Therapeutics, Xylem and More, source:247WallSt, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.60% to $731.17 Thursday, on what proved to be an all-around favorable trading session for the stock..., Headline: Cantor Fitzgerald biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary",REGN
214,2023-06-02,"Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.20% to $739.95 Friday, on what proved to be an all-around positive trading session for the stock market, with...",REGN
215,2023-06-04,"Headline: Wall Street Breakfast: The Week Ahead, source:SeekingAlpha, summary: Investors head into next week with the debt ceiling crisis resolved for the near term., Headline: Regeneron Pharmaceuticals Unusual Options Activity For June 05, source:Benzinga, summary: No summary, Headline: Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays., source:MarketWatch, summary: No summary",REGN
216,2023-06-05,"Headline: Global company events calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Noteworthy Monday Option Activity: REGN, GNRC, ORCL, source:Stock Options Channel, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.39% to $750.27 Monday, on what proved to be an all-around poor trading session for the stock market, with...",REGN
217,2023-06-06,"Headline: 26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold \, source:Yahoo, summary: Insiders were net sellers of Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) stock during the past year. That is..., Headline: 3 Biotech Stocks to Sell in June Before They Crash and Burn, source:Yahoo, summary: The biotechnology sector has seen better days. From the heady days of the pandemic when companies were racing to develop a vaccine against Covid-19, the industry is now enduring a hangover as both demand and sales decline. This means there’s more than a couple biotech stocks to sell. The iShares US Pharmaceuticals ETF (NYSEARCA:IHE) that tracks the industry is down 10% over the last 12 months and major players such as Pfizer (NYSE:PFE) have seen their share price decline 25% so far in 2023. The, Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.28% to $748.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market,...",REGN
218,2023-06-07,"Headline: Regeneron Pharmaceuticals, Inc. (REGN) Jefferies Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:NASDAQ:REGN) Jefferies Global Healthcare Conference Call June 7, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.27% to $738.63 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with...",REGN
219,2023-06-08,"Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.56% to $750.12 Thursday, on what proved to be an all-around great trading session for the stock market,..., Headline: Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Regeneron (REGN) closed at $750.12, marking a +1.56% move from the previous day., Headline: GLOBAL BRIEFING: Chinese CPI stays near zero, producer prices plunge, source:Alliance News, summary: No summary, Headline: 18 Analysts Have This to Say About Regeneron Pharmaceuticals, source:Benzinga, summary: No summary",REGN
220,2023-06-09,"Headline: AstraZeneca in pact with Quell Therapeutics for Treg cell therapies, source:Seeking Alpha, summary: No summary, Headline: Regeneron price target raised to $816 from $811 at RBC Capital, source:Thefly.com, summary: No summary, Headline: AbbVie, Amgen among firms targeted for Medicare inflation penalties, source:Seeking Alpha, summary: No summary, Headline: Cantor Fitzgerald biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Kiniksa Pharmaceuticals: A Somewhat Complicated Story, source:SeekingAlpha, summary: Kiniksa Pharmaceuticals is a commercial stage biopharma firm. KNSA sees growth in its primary drug asset and has an intriguing pipeline. Read more here., Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. sank 0.48% to $746.52 Friday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan",REGN
221,2023-06-11,"Headline: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 29% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,045 based on 2 Stage Free Cash Flow to..., Headline: Ocular falls after 12-month data for wet AMD candidate, source:Seeking Alpha, summary: No summary",REGN
222,2023-06-12,"Headline: Jefferies Reaffirms Their Buy Rating on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Notable Tuesday Option Activity: REGN, TPC, TTD, source:Stock Options Channel, summary: No summary",REGN
223,2023-06-13,"Headline: Regeneron named 'Catalyst Driven Idea' at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: 15 Most Profitable Drugs In The World, source:Yahoo, summary: In this article, we will be taking a look at the 15 most profitable drugs in the world. If you wish to see the top ones, feel free to skip our detailed analysis of the pharma industry and head straight to the 5 Most Profitable Drugs In The World. The pharmaceutical industry has long been […], Headline: SVB Securities Remains a Buy on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rose 1.77% to $767.35 Tuesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Regeneron: Solid Investment Based On Continued EYLEA Expansion, source:SeekingAlpha, summary: Regeneron Pharmaceuticals has potential to receive FDA approval of higher dosing of 8 mg of EYLEA with FDA target action date of June 27, 2023. Click here for more on REGN., Headline: EyePoint's EYP-1901 Tipped to Transform Wet AMD Market, Analyst Predicts Potential $870M Sales by 2035, source:Benzinga, summary: No summary",REGN
224,2023-06-14,"Headline: 2 Stocks to Buy No Matter What Happens in June and Beyond, source:Yahoo, summary: The first half of the year is almost over -- and so far, 2023 has been pretty kind to investors.  Buying shares of the right companies can help investors' portfolios do the same.  With that said, let's consider two stocks worth investing in regardless of what lies ahead: Regeneron Pharmaceuticals (NASDAQ: REGN) and Microsoft (NASDAQ: MSFT)., Headline: Regeneron Pharmaceuticals Inc. (REGN) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Goldman Sachs 44th Annual Global Healthcare Conference June 14, 2023 11:40 AM ETCompany ParticipantsRyan Crowe - VP, IRBob Landry - EVP..., Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.49% higher to $771.11 Wednesday, on what proved to be an all-around mixed trading session for the stock..., Headline: Regeneron (REGN) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Regeneron (REGN) closed at $771.11 in the latest trading session, marking a +0.49% move from the prior day.",REGN
225,2023-06-15,"Headline: Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD), Healthequity (HQY) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN) and BioMarin Pharmaceutical (BMRN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly, source:Yahoo, summary: Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of..., Headline: Regeneron Pharmaceuticals Achieves #131 Analyst Rank, Surpassing PulteGroup, source:ETF Channel, summary: No summary, Headline: Video: S&P 500 Analyst Moves: REGN, source:Market News Video, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.55% to $783.07 Thursday, on what proved to be an all-around favorable trading session for the stock...",REGN
226,2023-06-16,"Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.00% to $783.05 Friday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities, source:TalkMarkets, summary: No summary",REGN
227,2023-06-18,"Headline: How to Retire Rich: Biotech Stocks Edition, source:Yahoo, summary: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",REGN
228,2023-06-19,"Headline: PBE: Healthcare Dashboard For June, source:SeekingAlpha, summary: Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.",REGN
229,2023-06-20,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.23% to $781.21 Tuesday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: Biotech And Healthcare Stocks Lagging, source:TalkMarkets, summary: No summary, Headline: Agree To Buy Regeneron Pharmaceuticals At $560, Earn 5.6% Using Options, source:Stock Options Channel, summary: No summary",REGN
230,2023-06-21,"Headline: 2 Biotech Stocks You Can Buy and Hold for the Next Decade, source:Yahoo, summary: Biotech companies use living organisms to develop their therapies, and much like some living things, biotech stocks can be notoriously volatile.  Part of that is due to the complexities of making biotech therapies.  The success rate for biotech start-ups is low, but Gilead Sciences (NASDAQ: GILD), founded 36 years ago and Regeneron Pharmaceuticals (NASDAQ: REGN), founded 35 years ago, have already stood the test of time., Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.31% to $778.77 Wednesday, on what proved to be an all-around dismal trading session for the stock market,...",REGN
231,2023-06-22,"Headline: $100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today, source:Benzinga, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.13% higher to $779.81 Thursday, on what proved to be an all-around mixed trading session for the stock...",REGN
232,2023-06-23,"Headline: Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Kezar Life Sciences (KZR), source:TipRanks, summary: No summary, Headline: Friday’s Top Analyst Upgrades and Downgrades: Alcoa, Caterpillar, Dow, Kellogg, PagSeguro, Tesla, Tripadvisor, Walmart and More, source:247WallSt, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. dropped 0.01% to $779.73 Friday, on what proved to be an all-around rough trading session for the stock market, with...",REGN
233,2023-06-26,"Headline: Large Cap Biopharma Buffeted By Big Gov, Choppy Days Ahead, source:TalkMarkets, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.60% higher to $784.38 Monday, on what proved to be an all-around poor trading session for the stock market,..., Headline: Where Regeneron Pharmaceuticals Stands With Analysts, source:Benzinga, summary: No summary, Headline: Regeneron trading halted, news pending, source:Thefly.com, summary: No summary, Headline: FDA issues CRL to Regeneron for Aflibercept 8 mg Biologics License Application, source:Thefly.com, summary: No summary, Headline: Regeneron announces top-line, two-year data for aflibercept 8 mg PHOTON trial, source:Thefly.com, summary: No summary, Headline: Regeneron to resume trading at 3:15 pm ET, source:Thefly.com, summary: No summary, Headline: Roche turns positive after Regeneron issued CRL for aflibercept 8 mg BLA, source:Thefly.com, summary: No summary, Headline: Regeneron high-dose Eylea version rejected by FDA, source:Seeking Alpha, summary: No summary, Headline: Regeneron trading resumes, source:Thefly.com, summary: No summary, Headline: Regeneron resumes, down 9% after CRL issued for aflibercept 8 mg BLA, source:Thefly.com, summary: No summary, Headline: Regeneron falls as FDA rejects high-dose Eylea (update), source:Seeking Alpha, summary: No summary, Headline: Morgan Stanley says Regeneron likely to come under pressure after surprising CRL, source:Thefly.com, summary: No summary, Headline: REGN Makes Notable Cross Below Critical Moving Average, source:Market News Video, summary: No summary",REGN
234,2023-06-27,"Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Edwards Lifesciences (EW) and Tonix Pharma (TNXP), source:TipRanks, summary: No summary, Headline: Regeneron's two-year Eylea data should look 'consistent', says RBC Capital, source:Thefly.com, summary: No summary, Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Regeneron’s high-dose Eylea not approved by FDA, source:MarketWatch, summary: Regeneron Pharmaceuticals Inc. said Tuesday that the U.S. Food and Drug Administration issued a complete response letter for the biologics license..., Headline: Regeneron Gets FDA Response Letter on Aflibercept 8 Mg Application, Says Issue Involves Third-Party Filler, source:MarketWatch, summary: By Stephen Nakrosis Regeneron Pharmaceuticals said it received a complete response letter from the Food and Drug Administration for its aflibercept 8 mg..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 8.71% to $716.09 Tuesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Regeneron Pharmaceuticals shares fall on US FDA Eylea blow, source:Alliance News, summary: No summary, Headline: Regeneron shares fall after FDA rejects high-dose eye disease treatment, source:CNBC, summary: Regeneron said the rejection was ""solely due to an ongoing review of inspection findings at a third-party filler."" , Headline: 10 Martin Shkreli Stock Picks and Their Performance, source:Yahoo, summary: In this article, we will take a look at the 10 Martin Shkreli stock picks and their performance. To see more such companies, go directly to 5 Martin Shkreli Stock Picks and Their Performance. Martin Shkreli a.k.a. “Pharma Bro” is known for a variety of reasons, many of which are tinged with notoriety. He cofounded […], Headline: FDA Issues Complete Response Letter (CRL) for Aflibercept 8 mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-party Filler, source:Yahoo, summary: No issues with clinical efficacy or safety, trial design, labeling or drug substance manufacturing were identified in the CRL No additional clinical data or trials have been requested TARRYTOWN, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for aflibercept 8 mg for the treatment of patients with wet age-r, Headline: Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in Diabetic Macular Edema, source:Yahoo, summary: 89% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals through two years Of those assigned to a 16-week dosing regimen at baseline, 83% maintained ≥16-week dosing intervals through two years Many patients met the extension criteria for even longer dosing intervals, including 43% for ≥20-week intervals and 27% for 24-week intervals Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA® (aflibercept) 2 mg Injection TARRYTOWN, NY, J, Headline: Regeneron Stock Slumps After FDA Decision Delays Blockbuster Release, source:Yahoo, summary: The Food and Drug Administration rejected its application for approval of a new, higher-dose version of eye disease treatment Eylea., Headline: Regeneron Stock Crumbles After FDA Rejects Its Next Blockbuster Contender, source:Yahoo, summary: The Food and Drug Administration rejected a high-dose version of Regeneron's eye drug Eylea on Tuesday, leading REGN stock to crumble., Headline: Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: RBC Capital Reiterates Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug, source:TipRanks, summary: No summary, Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary, Headline: Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug, source:TipRanks, summary: No summary",REGN
235,2023-06-28,"Headline: Analysts’ Top Healthcare Picks: Paycor HCM (PYCR), Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: Paycor HCM (PYCR), Regeneron (REGN) and Pharvaris (PHVS), source:TipRanks, summary: No summary, Headline: These Stocks Are Moving the Most Today: Nvidia, Micron, Joby Aviation, Carnival, and More, source:MarketWatch, summary: Nvidia slumps after a report says the U.S. is considering new restrictions on exports of AI chips to China, and Joby Aviation surges after getting a special..., Headline: Regeneron downgraded to Hold from Buy at Canaccord, source:Thefly.com, summary: No summary, Headline: Regeneron price target lowered to $888 from $915 at Barclays, source:Thefly.com, summary: No summary, Headline: Regeneron price target lowered to $875 from $915 at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Regeneron price target lowered to $760 from $800 at Baird, source:Thefly.com, summary: No summary, Headline: BMO Capital Sticks to Its Buy Rating for Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron price target lowered to $789 from $816 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Amazon.com To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Wednesday, source:Benzinga, summary: No summary, Headline: GLOBAL BROKER RATINGS: Exane raises BHP Group; HSBC likes Prosus, source:Alliance News, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Regeneron (REGN), Radnet (RDNT), source:TipRanks, summary: No summary, Headline: Regeneron cut to Neutral at Cannacord on FDA snub for high-dose Eylea, source:Seeking Alpha, summary: No summary, Headline: Regeneron price target lowered to $1,045 from $1,050 at Truist, source:Thefly.com, summary: No summary, Headline: SVB Securities Sticks to Its Buy Rating for Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Check Out What Whales Are Doing With REGN, source:Benzinga, summary: No summary, Headline: Uber downgraded, Pinterest upgraded: Wall Street's top analyst calls, source:Thefly.com, summary: No summary, Headline: Catalent says FDA made three observations in Eylea inspection, Bloomberg reports, source:Thefly.com, summary: No summary, Headline: Catalent confirmed as manufacturer of Regeneron’s high-dose Eylea rejected by FDA, source:Seeking Alpha, summary: No summary, Headline: Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2023, source:Benzinga, summary: No summary, Headline: Regeneron (REGN) Gets CRL for Aflibercept 8 mg Drug, Shares Fall, source:Yahoo, summary: Regeneron (REGN) receives a completed response letter for the application seeking approval of aflibercept 8 mg for treating several retinopathic indications. The stock falls 9% following the news., Headline: Catalent confirms being Regeneron's Eylea 8 mg third party filler, says Stephens, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals' (NASDAQ:REGN) five-year total shareholder returns outpace the underlying earnings growth, source:Yahoo, summary: While Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders are probably generally happy, the stock hasn't had..., Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: General Mills, Nvidia fall; AeroVironment, Circor rise, Wednesday, 6/28/2023, source:Associated Press, The, summary: No summary, Headline: Three-Stock Lunch: REGN, PINS & GNRC, source:CNBC, summary: Lee Munson, Portfolio Wealth Advisors president and CIO, joins 'Power Lunch' to discuss three stocks: Regeneron, Pinterest and Generac Holdings., Headline: Top Analyst Reports for Texas Instruments, Regeneron & Micron Technology, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Inc. (TXN), Regeneron Pharmaceuticals, Inc. (REGN) and Micron Technology, Inc. (MU)., Headline: Catalent Is Linked to Regeneron’s Eye-Drug Rejection in Latest Misstep, source:Yahoo, summary: (Bloomberg) -- Problems at a Catalent Inc. production facility led US regulators to deny a key drug application from Regeneron Pharmaceuticals Inc., the latest headache for one of the main manufacturing partners to the drug industry. Most Read from BloombergPutin Claims He’s Back in Control. Russia’s Elite Isn’t SureUBS Preparing to Cut Over Half of Credit Suisse WorkforceQatar Group Now Confident of Winning Manchester United RaceBiden Can Cancel Student Debt Even If Supreme Court Blocks Order,, Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 2.24% to $700.03 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: INVESTIGATION ALERT : The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, source:Finnhub, summary: The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations o..., Headline: Why Catalent Stock Flopped Today, source:Yahoo, summary: It seems Catalent (NYSE: CTLT) was apparently the reason why a key drug was refused approval by the Food and Drug Administration (FDA).  According to a media report from a leading financial news agency, this is what likely happened.  The party applying for it was biotech Regeneron Pharmaceuticals (NASDAQ: REGN), and the drug is a stronger formulation of its previously approved Eylea.",REGN
236,2023-06-29,"Headline: Thursday’s Top Analyst Upgrades and Downgrades: Amazon, Bristol-Myers Squibb, Deere, GoDaddy, Pinterest, Salesforce, Uber, Vale, Walgreens and More, source:247WallSt, summary: No summary, Headline: The Zacks Analyst Blog Highlights Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks, source:Yahoo, summary: Texas Instruments, Regeneron Pharmaceuticals, Micron Technology, FedEx and Arista Networks are included in this Analyst Blog., Headline: INVESTIGATION REMINDER : The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm, source:Finnhub, summary: The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQ: REGN) for violations o..., Headline: Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL, source:Yahoo, summary: Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issues for Catalent., Headline: Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan, Headline: Truist Securities Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Baird Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation, source:Fintel, summary: nan, Headline: RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Canaccord Genuity Downgrades Regeneron Pharmaceuticals (REGN), source:Fintel, summary: nan, Headline: Why Regeneron Pharmaceuticals Stock Dipped This Week, source:Yahoo, summary: Shares of biotech heavyweight Regeneron Pharmaceuticals (NASDAQ: REGN) lost 10% of their value over the first three and a half days of trading this week, according to data provided by S&P Global Market Intelligence.  The double-digit decline came after the company announced that the Food and Drug Administration (FDA) issued a Complete Response Letter (i.e., a rejection) for its high-dose formulation of Eylea.  Eylea, a biologic therapy for various eye disorders like wet age-related macular degeneration (wet AMD), generated approximately $6.3 billion in net U.S. sales for the drugmaker in 2022., Headline: Regeneron to Report Second Quarter 2023 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2023, source:Yahoo, summary: TARRYTOWN, N.Y., June 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2023 financial and operating results on Thursday, August 3, 2023, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s webs",REGN
237,2023-06-30,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.43% to $718.54 Friday, on what proved to be an all-around positive trading session for the stock market,...",REGN
238,2023-07-01,"Headline: Wall Street Breakfast: What Moved Markets, source:SeekingAlpha, summary: Listen on the go! A daily podcast of Wall Street Breakfast will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify.",REGN
239,2023-07-02,"Headline: Check Out What Whales Are Doing With REGN, source:Benzinga, summary: No summary",REGN
240,2023-07-03,"Headline: Looking Into Regeneron Pharmaceuticals's Recent Short Interest, source:Benzinga, summary: No summary",REGN
241,2023-07-04,"Headline: Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Regeneron (REGN) and Blueprint Medicines (BPMC), source:TipRanks, summary: No summary, Headline: Biotech Blues: Stay Balanced Through July Earnings Season, source:TalkMarkets, summary: No summary",REGN
242,2023-07-05,"Headline: Regeneron gets FDA orphan drug designation for cemdisiran, source:Thefly.com, summary: No summary, Headline: Regeneron (REGN) Loses 13% in Three Months: What Lies Ahead?, source:Yahoo, summary: Regeneron (REGN) declines 13% in the last three months due to regulatory setback for 8 mg dose strength of aflibercept and competition for lead drug., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.04% to $717.83 Wednesday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: The 3 Best Biotech Stocks to Buy In July, source:Yahoo, summary: Although it’s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B",REGN
243,2023-07-06,"Headline: INVESTIGATION ALERT : The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ, source:Finnhub, summary: NEW YORK, July 6, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:
The investigation focuses on whether the Company issued..., Headline: Meta Platforms To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday, source:Benzinga, summary: No summary, Headline: Is Regeneron's Stock in Trouble After This FDA Rejection?, source:Yahoo, summary: The company's growth rate has been slowing sharply in recent quarters, and Eylea generates the bulk of its product revenue., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.81% to $704.83 Thursday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation, source:Fintel, summary: nan",REGN
244,2023-07-07,"Headline: Regeneron: Eylea Hype Past, But '23 H2 Will Be A Gut Check, source:SeekingAlpha, summary: Regeneron's stock price has suffered a setback due to concerns over the future of Eylea, its flagship drug, as competition and potential drug pricing regulations loom. Read more here., Headline: REGN FRAUD ALERT : Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws, source:Finnhub, summary: NEW YORK, July 7, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron..., Headline: 4D Molecular Therapeutics: A Complicated Story, source:SeekingAlpha, summary: Shares of 4D Molecular Therapeutics, Inc. have more or less hovered near $20 since positive 4D-150 data in November 2022. Read more about FDMT stock here., Headline: Is Regeneron Stock a Buy After a Regulatory Blow?, source:Yahoo, summary: Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year.  Regeneron suffered this blow following a regulatory obstacle, as is often the case in the biotech industry (more on that below).  Do these developments represent an excellent opportunity to buy Regeneron's shares on the dip?, Headline: Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity, source:Benzinga, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slid 1.76% to $692.45 Friday, on what proved to be an all-around rough trading session for the stock market, with...",REGN
245,2023-07-08,"Headline: 26% Of This Regeneron Pharmaceuticals Insider's Holdings Were Sold, source:Yahoo, summary: Looking at Regeneron Pharmaceuticals, Inc.'s ( NASDAQ:REGN ) insider transactions over the last year, we can see that...",REGN
246,2023-07-10,"Headline: REGN ALERT : The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws, source:Finnhub, summary: NEW YORK, July 10, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc.   shareholders:
The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and..., Headline: Analysts Conflicted on These Healthcare Names: Pacira Pharmaceuticals (PCRX), Regeneron (REGN) and Thermo Fisher (TMO), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 1.58% to $703.36 Monday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today, source:Benzinga, summary: No summary",REGN
247,2023-07-11,"Headline: REGN NEWS : The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc., source:Finnhub, summary: NEW YORK, July 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Regeneron Pharmaceuticals, Inc.   violated federal securities laws.
CURRENT..., Headline: Regeneron 483 issues might not require reinspection, says Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan, Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.92% to $716.83 Tuesday, on what proved to be an all-around great trading session for the stock market,..., Headline: Why These 7 Stocks Are the Best Ways to Play Biotech Right Now, source:Yahoo, summary: Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors. You must conduct your own due diligence. However, as a narrative, the biotechnology industry stands at the forefront of humanitarian innovation. The space has never been more important than it is right now. From the strictly financial view of investing in biotech stocks, the underlyi",REGN
248,2023-07-12,"Headline: INVESTIGATION ALERT : The Gross Law Firm Notifies Shareholders of Regeneron Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit - (NASDAQ, source:Finnhub, summary: NEW YORK, July 12, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc.:
The investigation focuses on whether the Company issued..., Headline: Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Trading At A 33% Discount?, source:Yahoo, summary: Key Insights Using the 2 Stage Free Cash Flow to Equity, Regeneron Pharmaceuticals fair value estimate is US$1,073..., Headline: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN, source:Finnhub, summary: NEW YORK, July 12, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc.  . Such investors are advised to contact Robert S...., Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.22% higher to $718.42 Wednesday, on what proved to be an all-around great trading session for the stock...",REGN
249,2023-07-13,"Headline: REGN Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Regeneron Pharmaceuticals, Inc., source:Finnhub, summary: NEW YORK, July 13, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc.   concerning possible violations of federal..., Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: 3 Pharma Stocks That AI is Loving in July, source:InvestorPlace, summary: No summary, Headline: How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings, source:Yahoo, summary: Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP., Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.36% higher to $720.98 Thursday, on what proved to be an all-around great trading session for the stock..., Headline: 3 Pharma Stocks That AI is Loving in July, source:Yahoo, summary: When it comes to investing in pharmaceutical stocks, an intriguing area for future growth is gene editing. This is an exciting field that may provide a solution to some of our most vexing diseases, such as cancer and diabetes. And in 2023, many companies are closer than ever to a solution. So, although I know that’s not how it works, it was interesting that when ChatGPT gave me a list of pharmaceutical stocks, it included several which have partnerships with gene editing companies. It’s importan",REGN
250,2023-07-14,"Headline: REGN FRAUD ALERT : Jakubowitz Law is Investigating Regeneron Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws, source:Finnhub, summary: NEW YORK, July 14, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Regeneron..., Headline: Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report?, source:Yahoo, summary: Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.34% to $718.52 Friday, on what proved to be an all-around mixed trading session for the stock market, with...",REGN
251,2023-07-15,"Headline: Regeneron Pharmaceuticals: Overdependence On Eylea Brought To The Forefront, source:Seeking Alpha, summary: No summary",REGN
252,2023-07-16,"Headline: Eli Lilly, Merck among top pharma picks in Barclays Q2 preview, source:Seeking Alpha, summary: No summary, Headline: This Is What Whales Are Betting On Regeneron Pharmaceuticals, source:Benzinga, summary: No summary",REGN
253,2023-07-17,"Headline: Alnylam announces updated interim results from ALN-APP study, source:Thefly.com, summary: No summary, Headline: REGN ALERT : The Law Offices of Vincent Wong Investigate Regeneron Pharmaceuticals, Inc. for Potential Violations of Securities Laws, source:Finnhub, summary: NEW YORK, July 17, 2023 /PRNewswire/ -- Attention Regeneron Pharmaceuticals, Inc.   shareholders:
The Law Offices of Vincent Wong announce that an investigation has commenced into Regeneron and..., Headline: Regeneron price target lowered to $900 from $935 at Guggenheim, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.43% higher to $721.61 Monday, on what proved to be an all-around great trading session for the stock..., Headline: Regeneron Pharmaceuticals Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: No summary",REGN
254,2023-07-18,"Headline: Guggenheim Maintains Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Regeneron price target lowered to $960 from $1,040 at BMO Capital, source:Thefly.com, summary: No summary, Headline: Does Regeneron Pharmaceuticals (NASDAQ:REGN) Have A Healthy Balance Sheet?, source:Yahoo, summary: Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously..., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",REGN
255,2023-07-19,"Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",REGN
256,2023-07-20,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",REGN
257,2023-07-22,"Headline: Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?, source:Yahoo, summary: It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock...",REGN
258,2023-07-23,"Headline: Kodiak Sciences: Navigating Clinical Trials And A Competitive Landscape, source:SeekingAlpha, summary: Kodiak Sciences shows improved financial performance in Q1 2023, and it's developing treatments for prevalent retinal diseases. See why KOD stock is a Hold., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: No summary",REGN
259,2023-07-24,"Headline: The 3 Most Undervalued Biotech Stocks to Buy Now: July 2023, source:InvestorPlace, summary: No summary, Headline: Kodiak drops eye disease candidate after Phase 3 setback, source:Seeking Alpha, summary: No summary, Headline: Kodiak Sciences Plumb New Lows After Tarcocimab Failure >KOD, source:MarketWatch, summary: By Colin Kellaher Kodiak Sciences shares lost more than half of their value and hit a new all-time low Monday after the biopharmaceutical company said it was...",REGN
260,2023-07-25,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.38% higher to $729.88 Tuesday, on what proved to be an all-around positive trading session for the stock..., Headline: Weight loss drugs excluded from WHO’s 'essential' medicines list, source:Seeking Alpha, summary: No summary",REGN
261,2023-07-26,"Headline: Novo Nordisk's Obesity Drug Saxenda Not Included In WHO's Essential Drug List, source:Benzinga, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.15% higher to $730.96 Wednesday, on what proved to be an all-around mixed trading session for the stock..., Headline: If You Can Only Buy One Biotech Stock, It Better Be One of These 3 Names, source:Yahoo, summary: The biotechnology industry is simply amazing, always advancing and bringing new drugs to fight complicated and serious diseases. If you are thinking about investing in this sector, it is crucial to know the best biotech stocks that can give you great returns. In this article, I’m going to introduce you to three companies that are making waves in this field and are pioneering stocks in biotech. They are making a difference and deserve to be on your radar! Best Biotech Stocks: Regeneron (REGN) Sou, Headline: Intellia Therapeutics: The Future Is Here, source:SeekingAlpha, summary: Intellia is a pipeline-stage firm, leveraging gene-editing technology to develop therapies for rare diseases. Read why NTLA stock is a Buy.",REGN
262,2023-07-27,"Headline: Roche's 1H Earnings Decline On Lower COVID-19 Sales, CFO Says Late-Stage Pipeline Has Gaps That Needs To Be Filled, source:Benzinga, summary: No summary, Headline: Kiniksa Pharmaceuticals: Arcalyst's Growth Picks Up, source:SeekingAlpha, summary: Kiniksa delivered excellent Q2 results that put it in an even better position to deliver long-term growth. Read why I'm bullish on KNSA stock., Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. advanced 1.87% to $744.66 Thursday, on what proved to be an all-around dismal trading session for the stock market,...",REGN
263,2023-07-28,"Headline: Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), HCA Healthcare (HCA) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: BMO Capital Remains a Buy on Regeneron (REGN), source:TipRanks, summary: No summary, Headline: P/E Ratio Insights for Regeneron Pharmaceuticals, source:Benzinga, summary: No summary, Headline: Those who invested in Regeneron Pharmaceuticals (NASDAQ:REGN) five years ago are up 88%, source:Yahoo, summary: Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking..., Headline: Regeneron (REGN) to Report Q2 Earnings: What's in Store?, source:Yahoo, summary: Investors' focus is likely to be on the performance of lead drugs Eylea and Dupixent when Regeneron (REGN) reports its second-quarter 2023 results., Headline: Regeneron Pharmaceuticals Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.19% higher to $746.10 Friday, on what proved to be an all-around favorable trading session for the stock...",REGN
264,2023-07-29,"Headline: Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS, source:Yahoo, summary: 89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout the two-year period, while sustaining their vision and anatomic improvements At two years, 44% of patients met the criteria for ≥20-week dosing intervals, including 27% who were eligible for 24-week dosing intervals TARRYTOWN, N.Y., July 29, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results fro",REGN
265,2023-07-30,"Headline: Regeneron presents aflibercept 8 mg two-year results from pivotal PHOTON trial, source:Thefly.com, summary: No summary",REGN
266,2023-07-31,"Headline: Regeneron Pharma Says Fewer Aflibercept Injections Maintains Vision, Anatomic Improvements In Diabetic Macular Edema, source:Benzinga, summary: No summary, Headline: REGENERON PHARMACEUTICALS, INC. - AFLIBERCEPT 8 MG TWO-YEAR RESULTS FROM PIVOTAL PHOTON TRIAL IN DIABETIC MACULAR EDEMA PRESENTED AT ASRS, source:Finnhub, summary: TARRYTOWN - Regeneron Pharmaceuticals, Inc.  today announced the first presentation of positive two-year  results from the pivotal PHOTON trial investigating aflibercept 8 mg with 12- and 16-week..., Headline: Regeneron Pharmaceuticals Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 0.56% to $741.91 Monday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: No summary",REGN
267,2023-08-01,"Headline: Regeneron Announces the 2023 Winners of The Regeneron Prize for Creative Innovation, source:Yahoo, summary: TARRYTOWN, N.Y., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the winners of the 11th annual Regeneron Prize for Creative Innovation, a competition designed to honor exceptional talent and originality in biomedical research. Each year, Regeneron invites the nation’s top research universities to nominate up-and-coming postdoctoral fellows and graduate students to pitch their ""dream projects"" within the field of biomedical science. Applicants out, Headline: If You Invested $1000 In This Stock 20 Years Ago, You Would Have $58,000 Today, source:Benzinga, summary: No summary, Headline: Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points, source:Yahoo, summary: The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",REGN
268,2023-08-02,"Headline: Regeneron: CRL For High Dose Eylea Gives Vabysmo A Wider Opening, source:SeekingAlpha, summary: Regeneron's shares decline as the company faces market delay for Eylea, allowing Roche's Vabysmo to gain ground. Click here to read my analysis of REGN stock., Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Zimmer Biomet Holdings (ZBH), Regeneron (REGN) and Addus Homecare (ADUS), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Q2 2023 Earnings Preview, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Earnings Preview, source:Benzinga, summary: No summary, Headline: Notable companies reporting before tomorrow's open, source:Thefly.com, summary: No summary, Headline: NEW YORK MARKET CLOSE: Fitch downgrade sparks retreat on Wall Street, source:Alliance News, summary: No summary, Headline: GLOBAL BRIEFING: China's services see strong growth in July, source:Alliance News, summary: No summary, Headline: Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers, source:Benzinga, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",REGN
269,2023-08-03,"Headline: Regeneron reports Q2 adjusted EPS $10.24, consensus $9.84, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Non-GAAP EPS of $10.24 beats by $0.34, revenue of $3.16B beats by $140M, source:Seeking Alpha, summary: No summary, Headline: Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), Humana (HUM) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month, source:Benzinga, summary: No summary, Headline: Earnings Scheduled For August 3, 2023, source:Benzinga, summary: No summary, Headline: Regeneron Pharma beats quarterly profit estimates, source:Finnhub, summary: Regeneron Pharmaceuticals Inc
beat Wall Street estimates for quarterly profit on Thursday,
driven by strong demand for eczema treatment Dupixent.
              The company reported adjusted profit of..., Headline: Regeneron's stock rallies after profit, revenue rise above expectations, amid a jump in collaboration, source:MarketWatch, summary: No summary, Headline: Regeneron gains after Q2 beat; FDA action on high-dose Eylea expected in Q3, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals quarterly profit boosted by Dupixent, source:Alliance News, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: Regeneron’s stock rallies after profit, revenue rise above expectations, amid a jump in collaboration revenue, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. climbed 2.6% toward a 5-week high in premarket trading Thursday, after the biotechnology company reported..., Headline: Regeneron Pharmaceuticals : August 2023 Corporate Presentation, source:Finnhub, summary: Regeneron Corporate Presentation
        
      
      
        
          A u g u s t 2 0 2 3
        
      
      
        
          This non-promotional presentation..., Headline: Regeneron Reports Second Quarter 2023 Financial and Operating Results, source:Yahoo, summary: Second quarter 2023 revenues increased 11% to $3.16 billion versus second quarter 2022Second quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 33% to $2.79 billion versus second quarter 2022Second quarter 2023 EYLEA® U.S. net sales were $1.50 billionSecond quarter 2023 GAAP diluted EPS of $8.50 and non-GAAP diluted EPS(a) of $10.24Two-year results reported for aflibercept 8 mg from pivotal PHOTON trial demonstrated durable vision gains at extended dosing intervals in diabeti, Headline: Regeneron expects FDA decision on higher-dose Eylea this year, source:Yahoo, summary: (Reuters) -Regeneron Pharmaceuticals expects a U.S. decision on a higher-dose version of its blockbuster eye disease drug Eylea in the third quarter, much earlier than market expectations, sending its shares up 5% on Thursday.  The U.S. Food and Drug Administration declined to approve the higher-dose version in June following an inspection at third-party manufacturer Catalent.  Regeneron said it has been submitting manufacturing data required by the FDA on a rolling basis, and expects to finish the submissions by mid-August., Headline: Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates, source:Yahoo, summary: Regeneron (REGN) delivered earnings and revenue surprises of 3.23% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Regeneron Pharmaceuticals Inc: A Biotech Powerhouse with High Outperformance Potential, source:GuruFocus, summary: No summary, Headline: Replimmune down 8% on skin cancer cancer candidate data delay, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. (REGN) Q2 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Regeneron Pharmaceuticals Inc. (NASDAQ:NASDAQ:REGN) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ETCompany ParticipantsRyan Crowe - Vice President, Investor RelationsLeonard..., Headline: Regeneron (REGN) Reports Q2 Earnings: What Key Metrics Have to Say, source:Yahoo, summary: Although the revenue and EPS for Regeneron (REGN) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers., Headline: Is Regeneron Pharmaceuticals (REGN) Modestly Overvalued?, source:Yahoo, summary: Regeneron Pharmaceuticals Inc (NASDAQ:REGN) witnessed a 6.4% gain, with an Earnings Per Share (EPS) of 36.8.  This article provides a comprehensive valuation analysis of Regeneron Pharmaceuticals (NASDAQ:REGN).  Regeneron Pharmaceuticals discovers, develops, and commercializes products that combat eye disease, cardiovascular disease, cancer, and inflammation., Headline: Regeneron (REGN) Q2 Earnings & Sales Top, Eylea Sales Decline, source:Yahoo, summary: Regeneron (REGN) beats earnings and sales estimates in second-quarter 2023 fueled by Dupixent. However, sales of the lead drug, Eylea, decline yet again., Headline: The Unexpectedly Good News That Helped Regeneron Retake Its 200-Day Line, source:Yahoo, summary: Regeneron guided to a faster-than-expected approval timeline for a high dose of its eye drug Eylea on Thursday, and REGN stock jumped., Headline: Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon, source:Yahoo, summary: Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration., Headline: S&P 500 Gains and Losses Today: Stocks Fall After Weaker-Than-Expected Earnings Reports, source:Yahoo, summary: The S&P 500 fell 0.3% on Thursday, Aug. 3, 2023 after weaker-than-expected earnings reports from ecommerce, travel, and chip companies weighed on the index., Headline: Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Zimmer Biomet Holdings (ZBH) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: No summary",REGN
270,2023-08-04,"Headline: Regeneron price target raised to $950 from $900 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: BMO Capital Gives a Buy Rating to Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron halts enrollment in prostate cancer trial following two deaths, source:Seeking Alpha, summary: No summary, Headline: (REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest, source:Benzinga, summary: No summary, Headline: Oppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation, source:Fintel, summary: nan, Headline: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript August 3, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.24, expectations were $9.92. Operator: Welcome to the Regeneron Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Shannon and I will be your operator for today’s call. At this time, all participants […]",REGN
271,2023-08-05,"Headline: RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan",REGN
272,2023-08-06,"Headline: 2 Top Stocks to Buy in August and Hold Forever, source:Yahoo, summary: Technological progress sometimes renders products or entire industries completely obsolete.  With that said, let's look at two healthcare stocks with solid track records of innovation and are worth buying and holding onto for good: Regeneron (NASDAQ: REGN) and Abbott Laboratories (NYSE: ABT).  Biotech giant Regeneron has outperformed the market over the past year, partly thanks to the company's excellent financial results and prospects.",REGN
273,2023-08-07,"Headline: Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Becton Dickinson (BDX) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: GLOBAL BROKER RATINGS: Stifel likes ConvaTec; JPMorgan ups Rolls-Royce, source:Alliance News, summary: No summary, Headline: Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan, Headline: 3 AI Stocks You’ll Regret Not Buying Soon, source:InvestorPlace, summary: No summary",REGN
274,2023-08-08,"Headline: Analysts Conflicted on These Healthcare Names: Axsome Therapeutics (AXSM), Stryker (SYK) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Stifel, Guggenheim, Jefferies, Wedbush start Apogee Therapeutics at buy, source:Seeking Alpha, summary: No summary, Headline: Cantor biotech/biopharma analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",REGN
275,2023-08-09,"Headline: Regeneron to acquire Decibel Therapeutics for $4.00 per share plus CVR, source:Thefly.com, summary: No summary, Headline: Regeneron buying small cap Decibel Therapeutics for $4 a share, source:MarketWatch, summary: No summary, Headline: Regeneron to acquire gene therapy developer Decibel for $4 per share, source:Seeking Alpha, summary: No summary, Headline: Regeneron To Acquire Decibel Therapeutics, source:MarketWatch, summary: By Dean Seal Regeneron Pharmaceuticals agreed to acquire Decibel Therapeutics for $4 a share, marking a 43% premium from yesterday's closing price. The..., Headline: Decibel Therapeutics stock rallies as Regeneron moves to buy the biotech company, source:MarketWatch, summary: Decibel Therapeutics Inc. stock was up 85% in premarket trades on Wednesday after Regeneron Pharmaceuticals Inc. said it would pay $4 a share for the..., Headline: Decibel Therapeutics downgraded to Neutral from Buy at H.C. Wainwright, source:Thefly.com, summary: No summary, Headline: Regeneron to acquire Decibel Therapeutics for USD109 million, source:Alliance News, summary: No summary, Headline: Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron, source:TipRanks, summary: No summary, Headline: Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal, source:InvestorPlace, summary: No summary, Headline: Decibel Therapeutics Shares Surge on Regeneron Acquisition, source:MarketWatch, summary: By Dean Seal Shares of Decibel Therapeutics were markedly higher after the company signed a deal to be acquired by Regeneron Pharmaceuticals at a 43% premium..., Headline: Health Care Company Regeneron Pharmaceuticals Announces Acquisition of Decibel Therapeutics, source:Benzinga, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs, source:Yahoo, summary: Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial TARRYTOWN, N.Y. and BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Decibel Therapeutics, Inc. (NASDAQ: DBTX), a clinical-stage biot, Headline: Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals, source:Yahoo, summary: Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline., Headline: Regeneron to buy Boston-based hearing loss biotech for $213M, source:Yahoo, summary: The Tarrytown, New York-based drugmaker has its sights set on Decibel Therapeutics, which develops gene therapies designed to treat various forms of hearing loss., Headline: Regeneron Pharmaceuticals Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: No summary",REGN
276,2023-08-10,"Headline: Regeneron announces PULSAR trial met its primary endpoint, source:Thefly.com, summary: No summary, Headline: The 7 Best Value Stocks to Buy in August, source:InvestorPlace, summary: No summary, Headline: 3 Top Biotech Stocks Defying the Bear Market, source:Yahoo, summary: If you look at the S&P 500, which is up more than 18% this year, or the Nasdaq Composite, which is up more than 34% in 2023, it appears the markets are booming.  The iShares Biotechnology ETF is down more than 3% so far in 2023, and the SPDR S&P Biotech EFT is down more than 5%.  The two ETFs reflect negative market sentiment toward biotech stocks, in general, this year., Headline: This Is What Whales Are Betting On Regeneron Pharmaceuticals, source:Benzinga, summary: No summary, Headline: Two-year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-related Macular Degeneration, source:Yahoo, summary: 88% of all aflibercept 8 mg patients were on a ≥12-week dosing interval at the end of two years 78% of all aflibercept 8 mg patients maintained ≥12-week dosing intervals throughout the two-year study period 71% met the extension criteria for even longer dosing intervals, including 47% for ≥20-week intervals and 28% for 24-week intervals Visual gains and safety of aflibercept 8 mg remained consistent with the established profile of EYLEA® (aflibercept) 2 mg Injection TARRYTOWN, N.Y., Aug. 10, 202, Headline: Bayer: eye drug shows vision gains in 70% of patients at higher dose, source:Yahoo, summary: Bayer said on Thursday its anti-blindness treatment Eylea, jointly developed with Regeneron, has been shown to achieve vision gains in more than 70% of patients when given at a higher dose at a longer interval between injections.  Eylea, which is normally given in doses of 2 milligrams every eight weeks, was given at 8 mg at intervals of up to 24 weeks, resulting in vision gains in more than 70% patients with wet age-related macular degeneration, the company said., Headline: Regeneron's Aflibercept 8mg Shows Sustained Vision Gains At Two Years, source:Benzinga, summary: No summary, Headline: Baird downgrades Decibel to neutral to reflect Regeneron takeover, source:Seeking Alpha, summary: No summary, Headline: IN BRIEF: Regeneron reports positive trial results for aflibercept, source:Alliance News, summary: No summary, Headline: Regeneron (REGN) to Buy Decibel, Gains on Hearing Loss Therapies, source:Yahoo, summary: Regeneron (REGN) further builds upon its collaboration with Decibel by acquiring the company to expand its gene therapy programs for hearing loss., Headline: The 7 Best Value Stocks to Buy in August, source:Yahoo, summary: While several market ideas have blossomed this year, many are overpriced, which naturally draws eyes to the best value stocks to buy. Here, we’re talking about publicly traded securities that trade at a lower price relative to fundamental metrics, most commonly sales or earnings. Obviously, value investing opportunities entice market participants due to their underlying discount. As humans, we’re geared to respond positively toward bargain offers. Essentially, by targeting must-buy value stocks,, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",REGN
277,2023-08-11,"Headline: Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet, source:Benzinga, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT), Alcon (ALC) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News, source:Yahoo, summary: Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.",REGN
278,2023-08-12,"Headline: 4 big deal reports: Michael Kors parent rockets on huge buyout deal with Tapestry, source:Yahoo, summary: Here is your Pro Recap of 4 head-turning deal dispatches you may have missed this week: Deals at Capri-Tapestry, Decibel-Regeneron, Amazon in talks to potentially anchor Arm's IPO, and  Digital World Acquisition  and Trump Media & Technology Group reaffirm commitment to the merger.  Capri (NYSE:CPRI) shares rocketed more than 55% on Thursday after Tapestry (NYSE:TPR) said it agreed to buy Capri, the parent company of Michael Kors, for $57 per share in cash, as reported in real time on InvestingPro., Headline: Pharma under threat from bill to expand drug price negotiations, source:Seeking Alpha, summary: No summary",REGN
279,2023-08-13,"Headline: Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: No summary",REGN
280,2023-08-14,"Headline: Second Half Outlook For Biotech Stocks, source:SeekingAlpha, summary: Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%. Click here to read my thoughts., Headline: This Is What Whales Are Betting On Regeneron Pharmaceuticals, source:Benzinga, summary: No summary, Headline: Regeneron could see share price bounce with potential approvals, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: No summary",REGN
281,2023-08-15,"Headline: $100 Invested In This Stock 20 Years Ago Would Be Worth $5,400 Today, source:Benzinga, summary: No summary, Headline: 18 Analysts Have This to Say About Regeneron Pharmaceuticals, source:Benzinga, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: No summary",REGN
282,2023-08-16,"Headline: Cantor biotech/biopharma analysts to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: No summary",REGN
283,2023-08-17,"Headline: Regeneron receives EMA filing acceptance for treatment of R/R FL, source:Thefly.com, summary: No summary, Headline: Thursday’s Top Wall Street Analyst Upgrades and Downgrades: Chevron, GE Healthcare, Keurig Dr Pepper, News Corp, Visa and More, source:247WallSt, summary: No summary, Headline: Regeneron lymphoma therapy accepted for EU review, source:Seeking Alpha, summary: No summary, Headline: EMA accepts Regeneron's filing for odronextamab for lymphoma form, source:Alliance News, summary: No summary, Headline: Bronte Capital Amalthea Fund June 2023 Letter, source:SeekingAlpha, summary: The Amalthea fund shed 1.35% in June whereas the globally diverse MSCI ACWI (in $A) was up 2.57%. For the financial year the fund gained 14.75%, outpaced by the ACWIâs 20.78%., Headline: Odronextamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma, source:Yahoo, summary: TARRYTOWN, N.Y., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for, Headline: Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 73% Above Its Share Price, source:Yahoo, summary: Key Insights Regeneron Pharmaceuticals' estimated fair value is US$1,376 based on 2 Stage Free Cash Flow to Equity..., Headline: Regeneron wins approval for rare immune disease therapy pozelimab, source:Seeking Alpha, summary: No summary, Headline: RBC says Regeneron news intimates high-dose Eylea approval likely, source:Thefly.com, summary: No summary, Headline: Catalyst watch: Nvidia earnings, Twilio event, AMC drama and Jackson Hole jitters, source:Seeking Alpha, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",REGN
284,2023-08-18,"Headline: Regeneron high-dose Eylea gains FDA approval, source:Seeking Alpha, summary: No summary, Headline: REGENERON PHARMACEUTICALS, INC. - ODRONEXTAMAB RECEIVES EMA FILING ACCEPTANCE FOR TREATMENT OF RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA, source:Finnhub, summary: TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the European Medicines Agency has accepted for review the Marketing Authorization Application for odronextamab to treat adult..., Headline: AARP, Public Citizen file briefs in Medicare drug price negotiations case, source:Seeking Alpha, summary: No summary, Headline: Regeneron announces FDA approval of Veopoz for Chaple disease, source:Thefly.com, summary: No summary, Headline: US FDA approves Regeneron's ultra-rare blood disease drug, source:Finnhub, summary: The U.S. health regulator on Fridayapproved Regeneron Pharmaceuticals' drug to treat arare blood disease, the company said. The drug, Veopoz, is the first treatment to be approved..., Headline: Regeneron gets FDA green light on first treatment for life-threatening immune disease, source:MarketWatch, summary: Regeneron Pharmaceuticals Inc. said Friday that the U.S. Food and Drug Administration has approved its treatment for CHAPLE disease, a rare and..., Headline: Regeneron Pharmaceuticals' Veopoz Gets FDA Approval for Adults, Children, source:Finnhub, summary: By Denny Jacob Regeneron Pharmaceuticals said the Food and Drug Administration approved Veopoz to treat patients aged 1 year old and up who have CHAPLE disease. The biotechnology company..., Headline: Regeneron's (REGN) Application for Blood Cancer Drug Accepted, source:Yahoo, summary: Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU., Headline: Veopoz™ (pozelimab-bbfg) Receives FDA Approval as the First Treatment for Children and Adults with CHAPLE Disease, source:Yahoo, summary: CHAPLE is an ultra-rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms Approval represents 10th FDA-approved medicine invented by Regeneron With the approval of Veopoz, the pre-approval inspection issues related to the aflibercept 8 mg biologics license application (BLA) have been addressed FDA action on the aflibercept 8 mg BLA is expected in the next few weeks TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceutica, Headline: UPDATE 2-US FDA approves Regeneron's ultra-rare blood disease drug, source:Yahoo, summary: Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease.  The drug pozelimab, branded as Veopoz, has been approved to treat adult and pediatric patients 1 year of age and older suffering from the CHAPLE disease.  Veopoz — the first treatment to be approved by the U.S. Food and Drug Administration (FDA) for the life-threatening disease — will be sold in the United States at a list price of $34,615.38 per single-use vial, the company told Reuters in an emailed response., Headline: Regeneron Pharmaceuticals Gets FDA OK for High-Dose Eylea Eye Treatment, source:MarketWatch, summary: By Will Feuer Regeneron Pharmaceuticals said the Food and Drug Administration has approved an eight-milligram injection of its Eylea treatment for various..., Headline: US FDA approves Regeneron's 8-mg dose of eye disease drug Eylea, source:Finnhub, summary: The U.S. Food and Drug Administrationapproved the 8-mg dose of Regeneron Pharmaceuticals'eye disease drug Eylea, the company said in a statement onFriday.(Reporting by Jahnavi Nidumolu in..., Headline: US FDA approves higher dose of Regeneron's eye disease drug Eylea, source:Finnhub, summary: The U.S. Food and Drug Administrationapproved a higher dose version of Regeneron Pharmaceuticals'drug Eylea for treatment of a disease that is a leadingcause of blindness among the elderly, the..., Headline: EYLEA HD (aflibercept) Injection 8 mg Approved by FDA for Treatment of Wet Age-related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR), source:Yahoo, summary: Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment approved in wAMD and DME for immediate dosing at 8-week and up to 16-week intervals following three initial monthly doses TARRYTOWN, N.Y., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administ, Headline: Is Regeneron Pharmaceuticals Inc (REGN) Modestly Overvalued?, source:Yahoo, summary: A Comprehensive Analysis of Regeneron Pharmaceuticals' Valuation, Headline: UPDATE 2-US FDA approves higher dose of Regeneron's eye disease drug Eylea, source:Yahoo, summary: The U.S. Food and Drug Administration approved a higher dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is a leading cause of blindness among the elderly, the company said in a statement on Friday.  The drug, Eylea HD, is priced at $2,625 per single-use vial in the U.S. and is used to treat patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR), Regeneron said.  Eylea, which is jointly developed with Bayer, is normally given in doses of 2 milligrams every eight weeks., Headline: Canaccord Genuity Maintains Regeneron Pharmaceuticals (REGN) Hold Recommendation, source:Fintel, summary: nan, Headline: With two approvals in one day, Regeneron could be headed higher, source:Seeking Alpha, summary: No summary",REGN
285,2023-08-19,"Headline: Regeneron Gets Boost With FDA Approval Of High-Dose Eylea (Rating Upgrade), source:SeekingAlpha, summary: Regeneron reported strong Q2 2023 financial results, with an 11% YoY revenue surge to $3.2B, outperforming expectations. Read more about REGN stock here.",REGN
286,2023-08-20,"Headline: Lilly's market cap soared 36% in Q2, eclipsing J&J, Merck, Novo Nordisk, source:Seeking Alpha, summary: No summary, Headline: Regeneron celebrates as Eylea HD and Veopoz gain FDA approval, source:Alliance News, summary: No summary",REGN
287,2023-08-21,"Headline: Regeneron announces FDA approval of Eylea HD for three indications, source:Thefly.com, summary: No summary, Headline: Regeneron price target raised to $925 from $900 at Barclays, source:Thefly.com, summary: No summary, Headline: Analysts Are Bullish on These Healthcare Stocks: Nuvation Bio (NUVB), Finch Therapeutics Group (FNCH), source:TipRanks, summary: No summary, Headline: Palo Alto Networks shares surge after earnings, Tesla climbs and more stocks on the move, source:MarketWatch, summary: Palo Alto Networks, Napco Security, Tesla and Jet.AI were among the biggest moving stocks on Monday., Headline: Regeneron price target raised to $1,050 from $950 at Oppenheimer, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Nemaura Medical (NMRD), Kineta (KA) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Regeneron price target raised to $980 from $875 at Wells Fargo, source:Thefly.com, summary: No summary, Headline: Regeneron price target raised to $985 from $960 at BMO Capital, source:Thefly.com, summary: No summary, Headline: Analysts Are Bullish on These Healthcare Stocks: Supernus Pharmaceuticals (SUPN), Viatris (VTRS), source:TipRanks, summary: No summary, Headline: FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness, source:Benzinga, summary: No summary, Headline: Regeneron price target raised to $830 from $820 at RBC Capital, source:Thefly.com, summary: No summary, Headline: Regeneron shares climb after FDA approval of macular degeneration treatment, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. gained 1.4% premarket on Monday after the company said late Friday that the U.S. Food and Drug Administration had..., Headline: Regeneron upgraded to Buy from Hold at Canaccord, source:Thefly.com, summary: No summary, Headline: Regeneron upgraded to Buy at Canaccord after high dose EYLEA approved, source:Thefly.com, summary: No summary, Headline: REGENERON PHARMACEUTICALS, INC. - EYLEA HD INJECTION 8 MG APPROVED BY FDA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION, DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY, source:Finnhub, summary: TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA HD Injection 8 mg for the treatment of patients with wet age-related..., Headline: REGENERON PHARMACEUTICALS, INC. - VEOPOZ RECEIVES FDA APPROVAL AS THE FIRST TREATMENT FOR CHILDREN AND ADULTS WITH CHAPLE DISEASE, source:Finnhub, summary: TARRYTOWN - Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration has approved Veopoz for the treatment of adult and pediatric patients 1 year of age and older with..., Headline: Is Regeneron Pharmaceuticals Still a Top Growth Stock?, source:Yahoo, summary: Regeneron Pharmaceuticals (NASDAQ: REGN) is a leader in the field of therapeutic proteins, with a history of more than 30 years of innovation and excellence.  The biotech has partnered with Bayer to create a dominant eye-disease franchise, led by Eylea (aflibercept), the best-selling anti-VEGF drug in the market.  The biotech has also collaborated with Sanofi to develop cutting-edge therapies for cancer, inflammatory diseases, and lung disorders., Headline: Is Regeneron Pharmaceuticals Modestly Overvalued?, source:GuruFocus, summary: No summary, Headline: Cramer’s Stop Trading: Regeneron, source:CNBC, summary: CNBC’s Jim Cramer explains why he is keeping an eye on shares of Regeneron, Headline: This biotech name is one of Jim Cramer's favorite stocks and he thinks it can go even higher, source:CNBC, summary: ""I think it's going to be worth more,"" Jim Cramer said Monday after Regeneron got good news from the FDA on its macular degeneration treatment., Headline: Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner, source:TalkMarkets, summary: No summary, Headline: Palo Alto, Earthstone Energy rise; Napco Security, Nikola fall, Monday, 8/21/2023, source:Associated Press, The, summary: No summary, Headline: Value Stocks Outshine Growth Amidst Rising Treasury Yields: Key Sectors and Stocks Analyzed, source:Benzinga, summary: No summary, Headline: Regeneron Stock-Price Targets Rise as FDA Approves Higher Dose of Eye Drug, source:Yahoo, summary: The Food and Drug Administration approved 8-milligram doses of Eylea, a treatment for wet age-related macular degeneration., Headline: Is Merck's Long-Term Investment Brilliance Unshaken By COVID-19 Drug Sales Slump?, source:SeekingAlpha, summary: On August 1, Merck released its financial report for the second quarter of 2023, which showed excellent results. Read more about MRK stock here., Headline: Regeneron (REGN) Gets FDA Nod for Higher Dose of Eylea, source:Yahoo, summary: Regeneron (REGN) obtains FDA approval for a higher dose of aflibercept injection under the brand name Eylea HD for various ophthalmology indications. The regulatory body also approves Veopoz., Headline: Regeneron Pharmaceuticals Inc: A Deep Dive into Its Financial Metrics and Competitive Strengths, source:Yahoo, summary: Unpacking the Growth and Competitive Edges of Regeneron Pharmaceuticals Inc, Headline: Regeneron Hits The High End Of Its Buy Zone On The Approval That 'Could Not Come Soon Enough', source:Yahoo, summary: Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer., Headline: FDA Approves Regeneron's Drug For Ultra Rare Immune Disorder, source:Yahoo, summary: The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Veopoz (pozelimab-bbfg) for adult and pediatric patients one year of age and older with CHAPLE disease, known as CD55-deficient protein-losing enteropathy. Veopoz is the first and only treatment indicated specifically for CHAPLE. CHAPLE is an ultra-rare and life-threatening hereditary immune disease driven by an overactivation of the complement system. In healthy individuals, the complement system is a mechanism for destroying micro, Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. rallied 3.94% to $844.37 Monday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough', source:Yahoo, summary: Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer., Headline: Regeneron awarded $326M from U.S. for next-generation COVID antibody, source:Thefly.com, summary: No summary, Headline: Regeneron confirms $326M BARDA funding for Covid antibody therapy, source:Thefly.com, summary: No summary, Headline: Regeneron, J&J receive millions to develop new COVID therapies, source:Seeking Alpha, summary: No summary, Headline: Canaccord ups Regeneron to buy, sees high-dose Eylea re-igniting sales, source:Seeking Alpha, summary: No summary, Headline: Barclays Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan, Headline: Canaccord Genuity Upgrades Regeneron Pharmaceuticals (REGN), source:Fintel, summary: nan, Headline: BMO Capital Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation, source:Fintel, summary: nan, Headline: RBC Capital Maintains Regeneron Pharmaceuticals (REGN) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Wells Fargo Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation, source:Fintel, summary: nan, Headline: Truist Securities Reiterates Regeneron Pharmaceuticals (REGN) Buy Recommendation, source:Fintel, summary: nan, Headline: Oppenheimer Maintains Regeneron Pharmaceuticals (REGN) Outperform Recommendation, source:Fintel, summary: nan",REGN
288,2023-08-22,"Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX), source:TipRanks, summary: No summary, Headline: GLOBAL BROKER RATINGS: Metzler reinitiates SAP at 'buy', source:Alliance News, summary: No summary, Headline: Apogee Therapeutics: Potential To Target Autoimmune Disorders With Less Frequent Dosing, source:SeekingAlpha, summary: Apogee Therapeutics has the ability to capture large target market indications if it can ultimately achieve a specific outcome. Find out why APGE stock is a Hold., Headline: Peering Into Regeneron Pharmaceuticals's Recent Short Interest, source:Benzinga, summary: No summary, Headline: Regeneron enters $326 mln pact with US to develop new COVID therapy, source:Finnhub, summary: Regeneron Pharmaceuticals onTuesday said it had entered into a contract worth $326 millionwith a U.S. government agency for the development ofnext-generation antibody therapy for COVID-19..., Headline: Regeneron gets federal funding for next-generation COVID treatment, source:MarketWatch, summary: Regeneron Pharmaceuticals Inc. said Tuesday that the Biomedical Advanced Research and Development Authority has agreed to support the development,..., Headline: Regeneron Pharmaceuticals inks new Covid contract with BARDA, source:Alliance News, summary: No summary, Headline: US govt awards $1.4 bln for development of new COVID therapies, vaccines, source:Finnhub, summary: The U.S. government said on Tuesdayit had awarded $1.4 billion for the development of new therapiesand vaccines against COVID-19, including a $326 million contractwith Regeneron Pharmaceuticals for..., Headline: Regeneron Pharmaceuticals Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.44% to $840.63 Tuesday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: Regeneron Announces Agreement with BARDA Supporting Development of Next-Generation Antibody Therapy for COVID-19 Prevention, source:Yahoo, summary: Program is part of U.S. Government’s ‘Project NextGen’ and provides partial funding for clinical development of a novel monoclonal antibody therapyTARRYTOWN, N.Y., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has entered into an agreement with Regeneron to support clinical development, clinical manufacturing and the regulatory licensure process of a next-generation COVID-19, Headline: UPDATE 1-US govt awards $1.4 bln for development of new COVID therapies, vaccines, source:Yahoo, summary: The U.S. government said on Tuesday it had awarded $1.4 billion for the development of new therapies and vaccines against COVID-19, including a $326 million contract with Regeneron Pharmaceuticals for a next-generation antibody therapy for prevention of infections.  The funding to Regeneron is a part of a $5 billion initiative dubbed ""Project NextGen"" by the U.S. Department of Health and Human Services (HHS)., Headline: Regeneron VP Stahl sells $9.8M in company shares, source:Thefly.com, summary: No summary",REGN
289,2023-08-23,"Headline: Top 5 Health Care Stocks That May Fall Off A Cliff, source:Benzinga, summary: No summary, Headline: GLOBAL BROKER RATINGS: Redburn cuts Adyen; Morgan Stanley lifts SocGen, source:Alliance News, summary: No summary, Headline: Are Robust Financials Driving The Recent Rally In Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Stock?, source:Yahoo, summary: Most readers would already be aware that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased significantly by 14..., Headline: Samsung Bioepis Files IPR Petition Challenging Regeneron Aflibercept Patent, source:Finnhub, summary: On August 18, Samsung Bioepis Co., Ltd. , filed a petition for Inter Partes Review, IPR2023-01312, challenging the validity of claims 1-18 of U.S. Patent No. 10,464,992, assigned to Regeneron..., Headline: Adverum: H2 2023 Data Readouts For Wet-AMD Gene Therapy, source:SeekingAlpha, summary: Adverum is expecting two data readouts of Ixo-vec for the treatment of patients with Wet age-related macular degeneration in 2023. Read why ADVM is a strong buy., Headline: Health Care Roundup: Market Talk, source:Yahoo, summary: Find insight on Roche, Regeneron and Emergent BioSolutions in the latest Market Talks covering the Health Care sector., Headline: Regeneron Pharmaceuticals Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.02% higher to $840.81 Wednesday, on what proved to be an all-around favorable trading session for the stock..., Headline: Regeneron Announces Investor Conference Presentations, source:Yahoo, summary: TARRYTOWN, N.Y., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: • 2023 Wells Fargo Healthcare Conference at 8:45 a.m. ET on Wednesday, September 6, 2023 • Morgan Stanley 21st Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, September 11, 2023 The sessions may be accessed from the ""Investors & Media"" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of th",REGN
290,2023-08-24,"Headline: Agilent receives European IVDR certification for companion diagnostic assay, source:Thefly.com, summary: No summary, Headline: Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More, source:Yahoo, summary: Regulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector., Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slipped 1.14% to $831.21 Thursday, on what proved to be an all-around dismal trading session for the stock market,..., Headline: Check Out What Whales Are Doing With REGN, source:Benzinga, summary: No summary",REGN
291,2023-08-25,"Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: Merck starts phase 3 program for oral PCSK9 inhibitor to lower cholesterol, source:Seeking Alpha, summary: No summary, Headline: The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics, source:Yahoo, summary: Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog., Headline: Is Regeneron Stock a Buy Now?, source:Yahoo, summary: There's a lot going on with biotech giant Regeneron (NASDAQ: REGN) that may be of interest to investors.  The company could soon face biosimilar competition from one of its key growth drivers, Eylea, while it recently received an important regulatory approval from the U.S. Food and Drug Administration (FDA).  With that said, let's dig deeper into what's happening with Regeneron and figure out whether it is worth investing in the drugmaker., Headline: Regeneron Pharmaceuticals Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 0.10% to $830.35 Friday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: These Are the ONLY 7 Penny Stocks to Consider in August 2023, source:InvestorPlace, summary: No summary",REGN
292,2023-08-27,"Headline: Regeneron Pharmaceuticals (NASDAQ:REGN) Seems To Use Debt Quite Sensibly, source:Yahoo, summary: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says..., Headline: Regeneron treatment of myasthenia gravis granted FDA orphan status, source:Thefly.com, summary: No summary",REGN
293,2023-08-28,"Headline: Regeneron Pharmaceuticals Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.07% higher to $830.89 Monday, on what proved to be an all-around positive trading session for the stock...",REGN
294,2023-08-29,"Headline: Tuesday’s Top Wall Street Analyst Upgrades and Downgrades: Boston Scientific, Ciena, CrowdStrike, Emerson Electric, Kimco Realty, Nike and More, source:247WallSt, summary: No summary, Headline: Celularity enters Research Collaboration Services Agreement with Regeneron, source:Thefly.com, summary: No summary, Headline: Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. slumped 0.08% to $830.19 Tuesday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: Looking At Regeneron Pharmaceuticals's Recent Unusual Options Activity, source:Benzinga, summary: No summary",REGN
295,2023-08-30,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.57% higher to $834.95 Wednesday, on what proved to be an all-around favorable trading session for the stock...",REGN
296,2023-08-31,"Headline: Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. shed 1.01% to $826.49 Thursday, on what proved to be an all-around rough trading session for the stock market, with..., Headline: It’s Still Tech’s Year. These Stocks Led the Market in August., source:MarketWatch, summary: For much of Thursday, it looked drug stocks would be August's biggest gainers in the Dow, S&P 500 and Nasdaq 100, but tech firms took the top spots., Headline: Regeneron (REGN) Gains 13% in 1 Month on FDA Nod For Eylea HD, source:Yahoo, summary: Regeneron (REGN) gains 13% in a month on the FDA's approval of a higher dose of Eylea and other positive updates.",REGN
297,2023-09-01,"Headline: Regeneron Pharmaceuticals Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Regeneron Pharmaceuticals Inc. inched 0.62% higher to $831.63 Friday, on what proved to be an all-around positive trading session for the stock...",REGN
